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“You will be more disappointed 
by the things you did not do 
than by the ones you did do. 
So throw off the bowlines, 
sail away from the safe harbour. 
Catch the trade winds in your sails. 
Explore. Dream. Discover.” 
Mark Twain 
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SCOPE OF THE THESIS
Coeliac disease (CD) is a major health care issue world wide, affecting genetically susceptible 
individuals of all ages. Currently, the diagnostic work-up and follow-up comprises serological 
analysis of CD associated antibodies as well as histopathological evaluation of duodenal 
biopsies obtained by a gastro-duodenal endoscopy. In a substantial number of CD patients 
diagnosed at an adult age, mucosal recovery is slow and incomplete despite adherence 
to a gluten-free diet (GFD) with subsequent normalised serology and disappearance of 
symptoms. Moreover, in particular the adult-onset coeliac patients are prone for developing 
complications, including refractory coeliac disease (RCD) and/or enteropathy associated 
T-cell lymphoma (EATL). In contrast to the slow responders, RCD is characterised by a 
primary or secondary lack of clinical and histological response upon strict adherence to 
a GFD for more than 12 months with normalised CD associated antibodies. This syndrome 
can be subdivided into type I and type II, with immunophenotypically normal and aberrant 
(cytoplasmicCD3+, surfaceCD3-, CD4-, CD7+, CD8-, TCR-, CD103+) intraepithelial T-cells 
(IELs) in the small intestinal mucosa, respectively. Aberrant IELs are considered to be a 
premalignant cell population from which aggressive EATL can evolve, which is observed 
in approximately half of the RCD II patients. The origin of these cells, however, is not 
fully clarified so far. Furthermore, easy applicable serological tests to identify and monitor 
patients that suffer from complicated forms of CD are lacking. Although the prognosis of 
RCD I is much more favourable than that of RCD II, as reflected in 5-year survival rates 
of around 90% and 44-58%, respectively, treatment is of utmost importance to prevent 
complications of longstanding malabsorption. Apart from a GFD and nutritional support, 
immunosuppressive therapy is the mainstay of treatment, yet there is no standardised 
treatment for both types of RCD. EATL is one of the main causes of death in patients with 
long-lasting untreated CD or RCD, due to its aggressive nature and unresponsiveness to 
currently available therapies. Within the spectrum of CD, this thesis aims to evaluate new 
diagnostic aspects, gain more insight in the underlying pathophysiological differences and 
explore novel therapeutic options.
Part I, the introduction, chapter 1, provides an overview of clinical aspects and treatment 
options of uncomplicated as well as complicated forms of CD. 
Part II includes two studies investigating novel serum parameters beyond standard antibody 
testing in the spectrum of CD. Chapter 2 describes the severity and course of enterocyte 
destruction in uncomplicated adult coeliac patients using serum intestinal fatty acid 
binding protein (I-FABP) levels at time of diagnosis and upon a GFD. Chapter 3 sets out to 
investigate the potential use of novel serum parameters in the spectrum of CD, in order 
to discriminate between complicated and uncomplicated CD. Furthermore, part II includes 
two studies in which aberrant IELs and EATL are further investigated on the cellular and 
molecular level. Chapter 4 investigates the origin of aberrant IELs by molecular analysis of 
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the T-cell receptor (TCR) rearrangements and by flow cytometric analysis of small intestinal 
biopsies. In addition, chapter 5 reveals an extended phenotypic and genomic analysis of an 
exceptional case of EATL primarily presenting as ascites.
Part III evaluates new therapeutic alternatives for uncomplicated and complicated CD. 
Chapter 6 assesses the safety and efficacy of Aspergillus niger-derived prolyl-specific 
endoprotease (AN-PEP) to mitigate the immunogenic effects of gluten in uncomplicated 
coeliac patients in a randomised double-blind placebo-controlled pilot study. Chapter 7 
evaluates safety and efficacy of the non-conventional thiopurine derivative tioguanine 
in RCD I. Chapter 8 and 9 describe a relatively large cohort of RCD II patients treated 
with cladribine and in case of unresponsiveness autologous haematopoietic stem-cell 
transplantation (au-SCT) after conditioning with high dose chemotherapy, respectively. 
Finally, chapter 10 reports two cases diagnosed with EATL that were treated with allogenic 
stem-cell transplantation (allo-SCT).
Part IV, the general discussion, summarizes the main findings of this thesis, points out future 
challenges in the work-up of (R)CD and provides recommendations for further research.
PART I  
GENERAL 
INTRODUCTION

CHAPTER 1 
General introduction
The spectrum of coeliac disease: 
epidemiology, clinical aspects 
and treatment 
G.J. Tack1, W.H.M. Verbeek1, M.W.J. Schreurs2 and C.J.J. Mulder1
Departments of 1Gastroenterology & Hepatology and 
2Pathology, VU University Medical Centre, Amsterdam, The Netherlands
Partly published in Nat Rev Gastroenterol Hepatol. 2010;7(4):204-13
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ABSTRACT
Coeliac disease is a gluten-sensitive enteropathy that affects people of all ages worldwide. 
This disease has emerged a major health-care problem, as advances in diagnostic and 
screening methods have revealed its global prevalence. Environmental factors such as 
gluten introduction at childhood, infectious agents and socioeconomic features, as well 
as the presence of HLA-DQ2 and/or HLA-DQ8 haplotypes or genetic variations in several 
non-HLA genes contribute to the development of coeliac disease. Growing insight into the 
variable clinical and histopathological presentation features of this disease has opened 
new perspectives for future research. A strict life-long gluten-free diet is the only safe 
and efficient available treatment, yet it results in a social burden. Alternative treatment 
modalities focus on modification of dietary components, enzymatic degradation of gluten, 
inhibition of intestinal permeability and modulation of the immune response. A small group 
of patients with coeliac disease (2–5%), however, fails to improve clinically and histologically 
upon elimination of dietary gluten. This complication is referred to as refractory coeliac 
disease, and imposes a serious risk of developing a virtually lethal enteropathy associated 
T-cell lymphoma.  
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InTRODuCTIOn
Coeliac disease (CD) is the most common food intolerance in the Western population, and 
currently represents a major health-care issue. CD has an ancient history, first described 
in the 1st and 2nd century AD. In 1887, Samuel Gee described typical symptoms of CD in 
children, including irritability, chronic diarrhoea and failure to thrive, and cure by means 
of a diet was suggested for the first time.1 Since then, insight into CD has undergone a 
revolutionary development regarding epidemiology, diagnostics and treatment. 
Coeliac disease is a chronic, small intestinal enteropathy, which is triggered by gluten 
proteins from wheat, barley and rye. It is characterised by an autoimmune response in 
genetically susceptible individuals resulting in small intestinal mucosal injury. As a 
consequence, malabsorption develops which results in malnutrion-related problems 
including anaemia, vitamin deficiencies, osteoporosis and neurological disorders. Withdrawal 
of dietary gluten usually leads to prompt healing of the damaged small intestinal mucosa 
and improvement of nutrient absorption. A gluten-free diet (GFD) is sufficient to treat the 
overwhelming majority of patients with CD and clinical improvement is usually evident 
within a few weeks.2 
A small percentage (2–5%) of patients with adult-onset CD, especially those diagnosed 
above the age of 50, does not respond to a GFD and is seen as suffering from refractory 
coeliac disease (RCD). The occurrence of an enteropathy associated T-cell lymphoma (EATL) 
is the major complication associated with RCD and is the main cause of death in this patient 
group.3, 4 Early identification of patients with RCD enables early intervention, which results 
in reduction in morbidity and mortality.4, 5 
This review gives an overview of the latest trends in epidemiology, clinical presentation, 
diagnosis, treatment and complications with respect to the spectrum of CD. 
EPIDEMIOlOGY
Global population trends 
Until the 1970s the estimated global prevalence of CD in the general population was 0.03%.6 
The currently estimated prevalence is 1%, with a statistical range of probability of 0.5–1.26% 
in the general population in Europe and the USA.7 Even taking into account that the actual 
occurrence rate of CD has been underestimated for many decades, the prevalence of this 
disease is increasing. Advances in diagnostic methods and improvement in screening have 
played a part in this increase observed, but environmental factors have also been important.
Trends in diagnosis and screening
The introduction of gastro-intestinal endoscopic techniques in the 1970s, which provided 
the opportunity to take routine biopsy samples, opened new horizons in CD case-finding and 
diagnosis. In addition, identification of human leukocyte antigen (HLA) molecules typically 
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associated with CD, HLA-DQ2 and HLA-DQ8, in the late 1980s and early 1990s, respectively,8 
and development of highly sensitive and specific serologic tests have also been important. 
Furthermore, the implementation since the late 1980s of screening programs for detecting 
CD has contributed to a more realistic estimate of the actual disease prevalence.9 The 
recognition that atypical, minor or extra-intestinal complaints can be associated with CD in 
patients of all ages and the detection of a range of histological abnormalities in the small 
intestine of patients with the disease have also contributed to improved diagnosis.10-12
Despite the advances in screening for CD, it remains underdiagnosed.13 In the general 
population, the ratio between patients with CD who received an accurate diagnosis and 
those who were never diagnosed as having the disease was reported to range from 1:5.513 
up to 1:1014. Since the 1980s, a trend towards earlier diagnosis of CD has been observed.15 
Unawareness of CD by physicians probably still underlies misdiagnosis and diagnostic delay.
Environmental risk factors
A Finnish population-based study has shown that the almost doubled prevalence of CD 
observed from 1980 (1.03%) to 2001 (1.99%) could not be ascribed only to screening and 
improved diagnostics, but was rather most probably attributable to environmental changes.6, 16 
Infant feeding 
The role of infant feeding on the development of CD has been intensely debated since the 
late 1980s, which has resulted in recommendation by the European Society for Paediatric 
Gastroenterology, Hepatology and Nutrition (ESPGHAN) committee.17 This committee 
currently recommends that small amounts of gluten are gradually introduced between four 
and seven months of age during breastfeeding.17 This recommendation is strongly supported 
by a meta-analysis18 and, moreover, by lessons learned from the Swedish epidemic of CD 
(1984–1996), which arose as a consequence of changes in infant feeding19. In this birth 
cohort, gluten was mainly introduced abruptly after discontinuing breastfeeding at 6 months 
of age. At the same time, the gluten content of commercial infant food was increased. The 
prevalence of CD was almost threefold higher in this birth cohort compared with that in 
infants born after the epidemic, in whom gluten was introduced gradually while continuing 
breastfeeding.19 Although dietary gluten exposure in children under the age of two seems 
more important with respect to CD risk when compared with exposure in older children19, 
whether breastfeeding only delays clinical onset or whether it leads to permanent 
protection against CD remains to be elucidated. Interestingly, one study has suggested that 
breastfeeding during gluten introduction, which slightly delays onset of CD, also influences 
clinical appearance as well. Among children who develop CD during gluten introduction, 
those who were breastfed at time can present the typical (49%) or atypical (51%) form of 
disease, whereas the ones in which gluten introduction occurred after breastfeeding was 
stopped more frequently develop typical gastro-intestinal symptoms (90%).20
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Infections 
Infections after birth have been proposed to contribute to the development of CD. Whereas 
the role of infection with adenovirus type 12 in this process remains controversial, the 
association of hepatitis C infection and CD is well documented.21 A prospective study showed 
that frequent rotavirus infections, the most common cause of childhood gastroenteritis, 
represent an independent risk factor for CD in genetically susceptible individuals.22 Rotavirus 
infection changes the permeability of and the cytokine balance in the intestinal mucosa, 
potentially enhancing penetration of gluten peptides.22 If this is the case, worldwide 
implementation of a rotavirus vaccine might diminish the occurrence of CD. The influence 
of infections with other common intestinal micro-organisms, including Campylobacter 
jejuni, Giardia lamblia and enteroviruses has not yet been clarified.23
Socioeconomic features 
An epidemiological survey where comparisons were made between schoolchildren living in a 
prosperous area of Finland and children living in an adjacent poor region of Russia, whom in 
part shared genetic susceptibility and gluten intake, has suggested that worse socioeconomic 
conditions might protect against CD development.24 Variation in gut flora, infections and 
differences in diet, which are factors involved in the maturation of immunoregulatory 
functions, may in turn precipitate CD development.24
GEnETIC RISK FACTORS 
HlA genes
CD is a multigenic disorder, in which the most dominant genetic risk factors are the 
genotypes encoding the HLA class II molecules HLA-DQ2 (encoded by HLA-DQA1*0501 and 
HLA-DQB1*02) and HLA-DQ8 (encoded by HLA-DQA1*0301 and HLA-DQB1*0302). About 90% of 
individuals with CD carry the DQ2 heterodimer encoded either in cis or trans, and practically 
all of the remaining patients express DQ8.8 Deamidated gliadin peptides have a high binding 
affinity to HLA-DQ2 and HLA-DQ8 molecules, but not to other HLA class II molecules, which 
explains the immunogenicity of gluten in carriers of HLA-DQ2 and HLA-DQ8. A correlation 
has been found between homozygosity for the genes encoding HLA-DQ2 molecule and the 
development of serious complications of CD, in particular RCD and EATL, which implies a 
gene-dose effect.25 These HLA-encoding genes are associated with approximately 40% of the 
heritable risk of developing CD.26
non-HlA genes
Currently, several susceptibility loci not related to HLA have been identified by genome-
wide association studies, each of which is estimated to be associated with only a small risk 
of developing CD. Most of these loci contain immune-related genes, in particular genes 
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implicated in the control of the adaptive immune response. The proteins encoded by these 
genes include an integrin (encoded by ITGA4 at 2q31)27, chemokines, cytokines and their 
receptors (IL-2 and IL-21 at 4q27, IL-18RAP at 2q11-2q12, IL-12A at 3q25-3q26, the CCR1 and 
CCR3 cluster locus at 3p21), and proteins involved in several signalling pathways (RGS1 at 
1q31, SH2B3 at 12q24, ATXN2 at 12q24, TNFAIP3 at 6q23.3, REL at 2p16.1), regulating B-cell 
(RGS1) and T-cell activation (TAGAP at 6q25), and in maintaining cell adhesion and motility 
(LPP at 3q28)28, 29. However, association between the risk of CD development and CCR3 and 
IL-18RAP could not be confirmed in other studies.27, 30 The 4q27 region, which harbours the 
IL-2 and IL-21 genes, showed the strongest association.27, 29 The latter association, however, 
accounted for less than 1% of the familial risk of CD and genetic variation in all currently 
known non-HLA genes together accounts for less than 10%.27, 29 This indicates that many 
contributing polymorphisms in non-HLA genes still have to be discovered. An association 
between MYO9B polymorphisms and an increased risk for RCD and EATL has been found, 
however for uncomplicated CD this association remains controversial.31 Further research 
is needed to determine the functions of the proteins that these genes encode and their 
involvement in the pathogenesis of CD.
POPulATIOn, GEnDER AnD AGE DISTRIBuTIOn
Variety in genetic factors including the frequency of non-HLA alleles and environmental 
factors including dietary habits underlie the variations in the frequency of CD observed in 
different world regions (Table 1). The HLA-DQ2 heterodimer is frequently found in white 
populations in Western Europe (20-30%), Northern and Western Africa, the Middle East and 
Central Asia, whereas HLA-DQ8 is more prevalent in Latin America and Northern Europe.32 
Gluten consumption is widespread in Northern Africa, South America and the northern wheat-
eating parts of India. The Saharawi population of Arab-Berber origin living in Algeria has the 
highest prevalence of CD (5.6%) among all world populations.33 High levels of consanguinity, 
high frequencies of HLA-DQ2 and gluten being used as staple food in this population may 
potentially explain this finding.33 By contrast, CD seems to be rare in individuals of Japanese 
and Chinese ancestry, for whom the frequency of HLA-DQ2 is negligible.32 The occurrence 
of CD may vary within individual countries, for instance in different parts of India.34, 35 This 
variation is probably attributable to differences in dietary habits and to associations of 
specific genetic clusters and particular regions. Middle Eastern countries, including Iran, 
Turkey, Israel and Syria, seem to have similar frequency rates of CD to those of Western 
countries.36
As expected, in high-risk populations the prevalence of CD is much higher compared with 
that in the general population. A multicentre study conducted in the USA revealed that the 
prevalence of serotypes associated with risk of disease was 1:56 in individuals with clinical 
features of CD or CD associated extra-intestinal disorders.37 Furthermore, the prevalence of 
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risk associated serotypes in first-degree and second-degree relatives of these patients was 
1:22 and 1:39, respectively. In adults and children with symptoms that raise suspicion of CD, 
prevalence rates of 1:68 and 1:25, respectively, were observed.
Table 1  |  Worldwide prevalence of coeliac disease for children and adults.   
Country Adults Children
Europe
Czech Republic 0.45% 84 NA
Finland 0.55–2.00% 6, 14 1.00% 42
Germany 0.19% 85 0.20% 85
Great Britain 1.20% 86 1.00% 87
Italy 0.18% 88 0.54–0.85% 89, 90
Northern Ireland 0.82% 91 NA
Russia 0.20% 24 NA
Spain 0.26% 92 NA
Sweden 0.46–0.53% 93 1.30% 94
The Netherlands 0.35% 95 0.50% 96
north and South America
Argentina 0.60% 97 NA
Brazil 0.15% 98 NA
Mexico 2.60% 99 NA
USA 0.40–0.95% 7, 37 0.90–0.31% 7, 40
Asia
India NA 1.00% 34, 100
Iran 0.60% 101 0.60% 102
Israel 0.60% 103 0.17% 103
Kuwait NA 0.02% 104
Syria 1.60% 32 NA
Turkey 1.30% 105 0.90% 106
Africa
Algeria NA 5.60% 33
Tunisia 0.28% 107 0.64% 108
Oceania
Australia 0.40% 109 NA
New Zealand 1.20% 110 NA
Abbreviation: NA, not available. 
As with many other autoimmune diseases, CD is more common in women38, with a 
female to male ratio of between 2:1 and 3:1. Some genetic loci are gender-influenced 
and immunoregulation is subject to hormones, which might explain these differences. By 
contrast, patients over the age of 60 who are diagnosed as having CD are more frequently 
male.39
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CD can be diagnosed at any age, with a peak at early childhood and at the fourth and fifth 
decade of life for women and men, respectively. Currently, the reported global prevalence of 
CD in children ranges from 0.31% to 0.9%.7, 40 The prevalence of CD in adults is approximately 
1–2% in Europe6 and 0.4–0.95% in the USA7. Whether diagnosing CD at advanced age is the 
result of diagnostic delay or of a true late onset of the disease is still debated. Whereas 
several studies reported a diagnostic delay in the elderly population41, other reports suggest 
that CD may indeed develop later in life.12, 16
ClInICAl PRESEnTATIOn 
Coeliac disease has long been considered a paediatric syndrome, in which classical intestinal 
symptoms, including diarrhoea, steatorrhoea and weight loss, predominate. However, the 
disease has been increasingly diagnosed in older children and adults and has emerged 
to encompass a broad spectrum of clinical manifestations (Box 1), which are associated 
with a large variety of changes in the mucosa of the small intestine.10, 11 About 50% of 
patients with CD present with atypical symptoms, such as anaemia, osteoporosis, dermatitis 
herpetiformis, neurological problems and dental enamel hypoplasia.15, 42, 43 The variable 
clinical picture of CD is thought to have both genetic and immunological bases. Age of 
onset, extent of mucosal injury and dietary habits, but also gender44, seem to affect the 
clinical manifestation of the disease. 
The spectrum of CD currently encompasses four different types of which clinicians 
should be aware.45 The classical form, which is mainly diagnosed between 6 and 18 months 
of age, is characterised by villous atrophy and typical symptoms of intestinal malabsorption. 
The atypical form is characterised by architectural abnormalities of the small intestinal 
mucosa and minor intestinal symptoms. Patients with this form present predominantly with 
various extra-intestinal signs and symptoms, such as osteoporosis, peripheral neuropathy, 
anaemia and infertility. The latent form is defined by presence of HLA-DQ2 and/or HLA-
DQ8 molecules, normal architecture of the intestinal mucosa and possibly positive serology. 
Extra-intestinal signs and symptoms may or may not occur. In this form of disease the 
gluten-dependant changes appear later in life. The silent form is marked by small intestinal 
mucosal abnormalities and in most cases by positive CD associated serology, but is apparently 
asymptomatic. 
Patients with the non-classical forms of the disease are usually detected by screening of 
high-risk populations or during upper-endoscopic analysis for other reasons. After starting 
a GFD, the majority of patients, irrespective of the clinical presentation, will notice 
improvement of their physical and psychological condition.46 This improvement indicates 
that these asymptomatic, apparently healthy individuals are indeed affected by minor, 
unrecognised illness features such as lack of appetite, behavioural abnormalities and 
fatigue, which are most likely to be consequences of the presence of the disease for years. 
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The prevalence of several autoimmune diseases, predominantly organ-specific diseases, is 
higher in patients with CD than in the general population (Box 1).47 First-degree relatives 
of and patients with Down, Turner or Williams syndrome are also at increased risk for the 
development of CD.48 
Box 1  |  Clinical presentation of coeliac disease.
Typical signs and symptoms Atypical signs and symptoms Some associated diseases
Abdominal distension Alopecia areata Addison disease
Abdominal pain Anaemia (iron deficiency) Atrophic gastritis
Anorexia Aphthous stomatitis Autoimmune hepatitis
Bulky, sticky and pale stools Arthritis Autoimmune pituitaritis
Diarrhoea Behavioural changes Autoimmune thyroiditis
Flatulence Cerebellar ataxia Behçet disease
Failure to thrive Chronic fatigue Dermatomyositis
Muscle wasting Constipation Inflammatory arthritis
Steatorrhoea Dental enamel hypoplasia Myasthenia gravis
Vomiting Dermatitis herpetiformis Primary biliary cirrhosis
Weight loss Epilepsy Primary sclerosing cholangitis
Oesophageal reflux Psoriasis
Hepatic steatosis Sjögren disease
Infertility, recurrent abortions Type 1 diabetes mellitus
Isolated hypertransaminasemia Vitiligo
Late-onset puberty
Myelopathy
Obesity 
Osteoporosis/osteopenia
Peripheral neuropathy
Recurrent abdominal pain
Short stature
DIAGnOSIS 
Given the broad clinical spectrum of CD, accurate histological and serological testing is 
essential for correct diagnosis. The diagnosis algorithm of CD currently follows the revised 
ESPGHAN criteria, published in 1990.49 Briefly, a positive diagnosis is made when the 
following features are both present: typical small intestinal histopathological abnormalities 
defined as hyperplastic villous atrophy, and clinical remission on a strict GFD with relief 
of symptoms within weeks. In asymptomatic individuals a second biopsy is required to 
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verify mucosal recovery after withdrawal of dietary gluten. The presence of circulating CD 
associated antibodies at time of diagnosis and their normalisation after a GFD support a 
diagnosis of CD. As a consequence of the increased appreciation of the variable clinical and 
histological manifestations of the disease and improvement of serological and genetic tests, 
further revision of the ESPGHAN criteria that takes into account the results of multicentre 
studies has been repeatedly advocated.10, 50 
Appropriate diagnosis of CD is extremely important to avoid life-long unnecessary 
commitment to a GFD in patients with other gastro-intestinal diseases and to enable rapid 
treatment of patients with CD, which decreases the risk of complications. 
Histopathological analysis
Histopathological analysis of small intestinal biopsy samples of individuals with CD is 
characterised by typical architectural abnormalities. These are classified according to the 
modified Marsh classification51: normal mucosa (Marsh 0), intraepithelial lymphocytosis 
(Marsh I), intraepithelial lymphocytosis and crypt hyperplasia (Marsh II), and intraepithelial 
lymphocytosis, crypt hyperplasia and villous atrophy (Marsh III). Mucosal villous atrophy has 
long been considered the hallmark of CD and remains the gold standard in CD diagnosis. False-
positive and false-negative diagnosis, however, may occur as a consequence of interobserver 
variability, patchy mucosal damage, low-grade histopathological abnormalities and technical 
limitations.52 For example, patients with low-grade histopathological abnormalities 
(Marsh I or Marsh II) can present with gluten-dependent symptoms or disorders before 
overt villous atrophy occurs. Furthermore, several patients with isolated intraepithelial 
lymphocytosis (Marsh I), who are not clinically suspected of having CD, develop CD during 
follow-up.50 Although the mucosal changes in CD are thought to develop gradually, whether 
minor mucosal lesions in asymptomatic patients indicate CD in an early stage is not yet clear.53 
In case of strong clinical suspicion of CD, duodenal biopsy must be performed regardless of 
serological analysis54; in cases of low suspicion of disease or screening, duodenal biopsy only 
needs to be performed in seropositive patients (Figure 1). 
Serological and genetic analysis 
At present the most sensitive and specific serological tests for diagnosis of CD are assessments 
of the presence of IgA autoantibodies against the endomysium of connective tissue (IgA-EMA) 
and against tissue transglutaminase (IgA-tTG).51 Tests for antibodies against deamidated 
gliadin peptides (which are part of gluten) have also become available and are promising 
diagnostic tools.55 At diagnosis stage, at least anti-tTG antibodies should be measured and, 
if detected, the diagnosis of CD should be preferably verified with assessment of anti-
EMA antibodies. Assessment of gliadin antibodies is a less specific and sensitive test than 
anti-tTG and anti-EMA testing, except in children younger than two years of age, in whom 
measurement of antibodies to gliadin is a more sensitive test.56 An important pitfall in 
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serological testing for CD is the increased prevalence of IgA-deficiency observed in patients 
with the disease compared with that in healthy individuals.57
In order to avoid false-negative serological results in cases of IgA-deficiency, simultaneous 
monitoring of serum IgA levels is required. In case of IgA-deficiency, screening for IgG 
antibodies (either to tTG or to EMA) should be performed.58
Although HLA-DQ2 and/or HLA-DQ8 positivity is not an absolute requirement for diagnosis, 
as 40% of the healthy Western population also carry genotypes for these molecules8, CD is 
highly unlikely in case both of them are absent. As a consequence of this high negative 
predictive value for developing CD, HLA-genotyping was proposed as a contributing element 
in diagnosis, in particular in the absence of villous atrophy.59 Case-finding of patients with 
low-grade histopathological features of CD needs to be extended so that clinical studies 
that investigate the precise role of genotyping as a first-line examination in the diagnostic 
work-up can be started.
Figure 1  |  Algorithm for diagnosis of uncomplicated coeliac disease. 





  
  
 
 



Abbreviations: IgA-EMA, endomysial antibodies; IgA-tTG, tissue transglutaminase antibodies. 
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Furthermore, as negative serological testing does not exclude the development of CD later 
in life, HLA-genotyping has also been suggested as a powerful screening tool.60 Nevertheless, 
this screening strategy does not seem cost-saving compared with first-line serological 
screening, although it might prevent unnecessary anti-tTG and anti-EMA diagnostic testing.61 
The Dutch Medical Coeliac Disease Society recommends serological testing in genetically 
susceptible patients for at least IgA antibodies against tTG every 2 and 5 years in adults and 
children, respectively.62
TREATMEnT
The only currently available treatment for CD consists in dietary exclusion of grains 
containing gluten and supportive nutritional care in case of iron, calcium and vitamin 
deficiencies.63 A life-long GFD is a well tolerated therapy that improves health and quality 
of life in the vast majority of patients with CD, even in those with minimal symptoms.64 This 
treatment is, however, difficult to sustain, owing to small levels of gluten contamination 
in food products, high costs and restricted availability of gluten-free food alternatives and 
cultural practices leading to a substantial social burden.65 Therefore, in the past decade 
researchers have become increasingly interested in therapeutic alternatives for continuous 
or intermittent use in patients with CD. Implementation of these is extremely challenging, 
as their potential adverse effects will always be difficult to accept as an alternative to a 
safe GFD.
Newly developed treatment modalities for CD are aimed at reducing the need for a 
strict GFD and are based on currently available insights into the pathogenesis of the disease 
(Table 2). These therapies focus on alteration of dietary food products, decrease of gluten 
exposure by rapid enzymatic degradation, inhibition of small intestinal permeability or 
modulation of the immune response.66 Clinical trials for some of these therapies are still 
ongoing. For the time being, strict adherence to a GFD should be advised for all patients 
with CD, as it remains the only effective and safe therapy, which also seems to reduce the 
risk of complications.67, 68 
COMPlICATIOnS 
The long-term consequences of CD are a matter of debate, particularly since the recognition 
of its broad clinical spectrum. The influence of non-compliance to a GFD and the substantial 
number of patients being undiagnosed are of greatest concern, as these factors could 
possibly contribute to the refractory form of CD and to the development of malignancies.
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Table 2  |  Treatment of uncomplicated coeliac disease.
Therapeutic aims and approaches Therapies
Decrease gluten exposure
   Manipulation or selection of dietary components Cereal modification111, 112
 Polymeric gliadin binders and neutralizers113
Enzymatic degradation of gluten
Aspergillus-niger derived prolyl endopeptidase114
ALV003 enzyme cocktail115, 116
Probiotics (VSL#3)117
Inhibit intestinal permeability
   Zonulin inhibition Larazotide acetate118
Modulate the immune response
   Decrease adaptive immune activity Blockers of tissue transglutaminase antibodies119
Blockers of antigen presentation by HLA-DQ2 and 
HLA-DQ8120
Gluten peptide vaccine121
Infection with the hookworm Necator americanus122
   Reduce inflammation Interleukin-10123
Refractory coeliac disease
Some patients with adult-onset CD, especially among those diagnosed above the age of 
50, show a lack of response to a GFD. They are diagnosed as having RCD when clinical and 
histological symptoms persist or recur after a former good response to a strict GFD and 
despite strict adherence to the diet for more than twelve months, unless earlier intervention 
is necessary.4 The prevalence of RCD is currently unknown, but we believe that it might 
affect approximately 5% of patients with CD. According to the European Coeliac Disease 
working group, RCD can be subdivided into types I and II, with phenotypically normal and 
aberrant intraepithelial T-lymphocytes in the small intestinal mucosa, respectively.69 
Intraepithelial T-lymphocytes (IELs) are considered aberrant when expressing cytoplasmic 
CD3, but lacking surface expression of the T-cell markers CD3, CD4, CD84 and the T-cell 
receptor70. To discriminate between RCD I and RCD II, a clinically validated cut-off value 
of 20% aberrant IELs, determined by analysis of small intestinal biopsy samples by flow 
cytometry, is used (Figure 2).70 As flow cytometric analysis can not be performed in all 
medical centres, immunohistochemistry for CD3 and CD8 as a first-line screening, before 
performing flow cytometric analysis, in all patients diagnosed as having CD and who are 
above 50 years of age would also probably be helpful in identifying patients with RCD II, but 
proper studies are lacking. 
Patients with RCD I have a less dismal prognosis compared with those diagnosed as 
having RCD II: the 5-year survival rates are 80-96% and 44-58%, respectively.3, 71, 72 The reason 
for this difference is the higher risk of developing lymphoma in RCD II, as a consequence 
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of clonal expansion and further transformation of aberrant IELs into EATL.3, 4 EATL occurs 
in more than half of the RCD II patients within 4–6 years after RCD II diagnosis and is the 
main cause of death in this group of patients.3, 71 Development of EATL was also observed 
in patients with RCD I in a single-centre study, albeit less frequently than in patients with 
RCD II (14%).72 Furthermore, whereas RCD I can be treated effectively with prednisone 
with or without azathioprine in most cases71, 73, 74, no standardised approach has yet been 
developed for RCD II, apart from nutritional support and strict adherence to a GFD.72, 75 In 
the past decade several conventional and more experimental therapies have been evaluated 
to treat RCD II (Box 2), however this condition is usually resistant to any known therapy 
and transition into EATL could not be prevented successfully. Cladribine therapy76 and 
autologous haematopoietic stem-cell transplantation5 might be successful, but long-term 
results are awaited. Interleukin-15-blocking antibodies, which have been successfully used 
in the treatment of rheumatoid arthritis, might be a promising new therapeutic alternative, 
as this cytokine has a key role in the pathogenesis of RCD.77
Malignancies 
CD is thought to be associated with an increased risk of malignancies, in particular 
lymphomas, but the risk currently estimated for this association, 1.3-fold greater than that 
of the general population78, is much lower than that recorded in the 1970s and 1980s79. 
Earlier detection and treatment of CD in the past two decades may have contributed to 
this decline. Whether continued gluten exposure is associated with the higher incidence of 
malignancies in patients with CD is widely debated, as many patients are not recognised as 
having the disease and are, therefore, untreated. A Finnish cohort study showed no additional 
risk for malignancies among adult patients with CD who were diagnosed exclusively by 
serologic screening and followed for almost 20 years.79 
The principal malignancy associated with CD is EATL, which has an annual incidence 
of only 0.5-1.0 cases per million people in Western countries.80 Unexplained weight loss, 
abdominal pain, fever and night sweating should alarm physicians of the presence of an 
overt EATL. EATL can involve all areas of the small intestine, stomach and colon, being 
particularly frequent in the proximal jejunum. In some patients with CD, EATL may even 
occur outside the gastro-intestinal tract, for example in the lungs, ribs and spleen, without 
abdominal pain.81 EATL is one of the main causes of death in patients with adult-onset CD, 
with 2-year and 5-year overall survival rates of 15–20% and 8–20%, respectively.3, 82 This poor 
prognosis is mainly due to incomplete response to currently available therapies (Box 2), high 
rates of life-threatening complications such as perforation of the gut, and poor nutritional 
conditions.75, 83 
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Figure 2  |  Algorithm for diagnosis of complicated coeliac disease. 






 

 
 
 
 
 







 
 
  
 




  

Abbreviations: EATL, enteropathy associated T-cell lymphoma; IgA-EMA, endomysial antibodies; GFD, 
gluten-free diet; IEL, intra-epithelial lymphocyte; RCD, refractory coeliac disease; TCR-γ, T-cell 
receptor, γ-chain; IgA-tTG, tissue transglutaminase antibodies.
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Box 2  |  Treatment of complicated coeliac disease.
RCD I RCD II EATl
Azathioprine74 Alemtuzumab126 Allogenic stem-cell transplantation133
Azathioprine and prednisone73 Autologous stem-cell transplantation5 Autologous stem-cell transplantation82, 134
Budesonide124 Azathioprine and prednisone73, 74 CHOP83
Infliximab125 Budesonide124 Alemtuzumab and CHOP135
Cladribine76
Cyclosporine127,128
Interleukin-10129
Pentostatine130
Mesenchymal stem-cell infusion131
Antibodies against interleukin-15132
Abbreviations: CHOP, cyclophosphamide doxorubine vincristine prednisone; EATL, enteropathy 
associated T-cell lymphoma; RCD, refractory coeliac disease.
COnCluSIOn 
Many factors have contributed to the increased prevalence of CD, which has emerged as a 
common food intolerance worldwide that can be diagnosed at all ages. Growing insight into 
the clinical presentation of CD has resulted in novel diagnostic, prognostic and therapeutic 
dilemmas and highlights the importance of considering the current diagnostic criteria of 
CD and its complications, as well as the evaluation and development of new treatment 
modalities. 
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Serum I-FABP as marker for 
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and its relation to villous atrophy 
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ABSTRACT
Objectives: Enterocyte damage is the hallmark of coeliac disease (CD) resulting in 
malabsorption. Little is known about the recovery phase of enterocyte damage and its 
clinical consequences. This study evaluates the severity of enterocyte destruction in 
adult CD patients and its time-related changes upon a gluten-free diet (GFD), using serum 
intestinal fatty acid binding protein (I-FABP) as marker. Furthermore, the correlation 
between enterocyte damage, CD autoantibodies and small intestinal mucosal abnormalities 
during the course of disease is studied.
Methods: Serum I-FABP levels were determined in 96 biopsy-proven adult CD patients 
and in 69 CD patients repeatedly upon a GFD. 141 individuals with normal anti-tissue 
transglutaminase antibody levels (IgA-tTG) served as controls. I-FABP levels were related to 
the degree of villous atrophy (Marsh grade) and IgA-tTG.
Results: I-FABP levels were significantly higher in untreated CD compared to controls, and 
correlated with Marsh grade and IgA-tTG. Upon a GFD serum levels decreased significantly, 
however, not within the range observed in controls, despite normalisation of IgA-tTG levels 
in most of the patients. High I-FABP levels not responding to treatment were found in 
patients with persistent histological abnormalities. 
Conclusion: Enterocyte damage assessed by serum I-FABP correlates with the degree of 
villous atrophy and improves after initiation of a GFD. However, we now show that significant 
enterocyte damage persists upon a GFD despite absence of villous atrophy and low IgA-tTG 
levels in the majority of cases. Moreover, a lack of decrease in I-FABP levels during treatment 
is indicative of histological abnormalities and warrants further evaluation of patients.
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InTRODuCTIOn
Coeliac disease (CD) is a common T-cell mediated enteropathy triggered by dietary gluten 
in genetically susceptible individuals of all ages worldwide.1, 2 The disease is characterised 
by villous atrophy which is suggested to result from increased enterocyte apoptosis.3, 4 
However, a detailed understanding of the cellular behaviour of enterocytes in the intestine 
is lacking, particularly into the recovery of the small intestinal mucosa after initiation of 
a gluten-free diet (GFD). Nevertheless, mucosal damage in adult-onset CD is thought to 
recover slow and incomplete, and certain nutrient deficiencies are described to persist in 
a subgroup of patients despite treatment with a GFD.5-8 As enterocytes are the anatomical 
and functional unit of the intestinal villi responsible for nutrient absorption and barrier 
function, insight in the course of enterocyte destruction in CD is of utmost importance in 
the pathogenesis of CD.
The limited knowledge of enterocyte damage in the course of CD is mainly caused 
by the absence of a reliable non-invasive tool for evaluation of intestinal damage. The 
CD associated antibodies anti-tissue transglutaminase (IgA-tTG), anti-endomysium (IgA-
EMA) and anti-deamidated gliadin (IgA-DGA), which are used for monitoring disease 
activity, represent the immune response rather than intestinal damage or even repair.9-13 
Consequently, duodenal biopsies, taken through the invasive procedure of upper gastro-
intestinal endoscopy, are required for the assessment of small intestinal disease activity, yet 
not providing information about damage at a cellular level.
Intestinal fatty acid binding protein (I-FABP), a small (15 kD) cytosolic protein abundantly 
present in enterocytes, has proven to be a sensitive marker for damage to the intestinal 
epithelium.14-17 The expression of I-FABP is primarily limited to fully differentiated epithelial 
cells of the small intestine.18, 19 Upon cellular damage of the enterocyte I-FABP is readily 
released into the systemic circulation. Our previous studies showed that in CD patients 
serum I-FABP levels represent small intestinal mucosal damage.18, 20
This study aims to evaluate the severity of enterocyte damage in untreated adult CD 
patients, and the time-related changes of enterocyte damage after initiation of a GFD by 
assessing serum I-FABP levels. In addition, the interplay between serum I-FABP levels as 
marker for enterocyte damage and CD autoantibodies as well as small intestinal villous 
atrophy was studied.
MATERIAlS AnD METHODS
Subjects
The study group included 96 adults with biopsy-proven CD evaluated at the Maastricht 
University Medical Centre (MUMC) or VU University Medical Centre Amsterdam (VUMC), 
The Netherlands, between 1996 and 2010. CD diagnosis was based on the combination of 
positive antibodies for IgA-tTG and/or IgA-EMA, and histological abnormalities grade III 
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according to the modified Marsh classification consisting of intra-epithelial lymphocytosis, 
crypt hyperplasia and some degree of villous atrophy.21-23 All CD patients started a GFD. 
Patients with diagnosed and treated refractory coeliac disease (RCD), defined as persisting 
or recurring symptoms and mucosal villous atrophy despite strict adherence to a GFD for 
more than 12 months (assessed by a dietitian and negative IgA-tTG and IgA-EMA), and 
patients with enteropathy associated T-cell lymphoma (EATL) were excluded.24, 25 Serum 
samples at time of diagnosis were available in 80 CD patients. Furthermore, serum samples 
of 69 CD patients were analysed at six months, one year, two years and/or three years 
after initiation of a GFD. Due to the retrospective study design, follow-up samples were not 
available of all patients at all moments of follow-up.
The control group consisted of 141 adults with a clinical suspicion of CD, yet with 
negative IgA-tTG and IgA-EMA levels included retrospectively at both academic centres. IgA-
deficiency was not observed in the control group. Individuals recognised with autoimmune 
disorders were excluded from the control group.
All serum samples and biopsy specimens were obtained for diagnostic purposes and the 
procedures adhered to guidelines set by the institutional ethical committee.
Coeliac disease autoantibodies
In both CD patients and controls serum IgA-EMA was determined by means of a commercial 
indirect immunofluorescence test (Scimedx, Densvill, New Jersey, USA)26 or by an in-
house indirect immunofluorescence test according to Lerner using monkey oesophagus 
as substrate27. Serum IgA-tTG was determined by means of fluorescent-enzyme immuno-
assay (FEIA, Thermo Fisher Scientific, Freiburg, Germany, cut-off value 10 U/ml) or with 
a standard enzyme-linked immunosorbent assay (ELISA) using recombinant human tTG 
(Diarect AG, Freiburg, Germany, cut-off value 6 U/ml). IgA-deficiency was excluded to avoid 
false-negative serology. Only patients evaluated with the ELISA technique for IgA-tTG were 
analysed to study the correlation with serum I-FABP levels.
Histology
Small intestinal biopsies of both untreated and treated patients were taken from the distal 
duodenum during endoscopy. Mucosal damage was graded according to the modified Marsh 
classification; Marsh 0 normal biopsy, Marsh I intraepithelial lymphocytosis (IEL), Marsh II 
crypt hyperplasia, Marsh IIIA partial villous atrophy, Marsh IIIB subtotal villous atrophy and 
Marsh IIIC total villous atrophy.22, 23 The most severe grade of damage was reported. Small 
intestinal biopsies were not determined in the control group.
Intestinal fatty acid binding protein (I-FABP)
Serum of patients was stored at -20°C. Serum samples of the untreated patients were 
collected at a maximum of three months before CD was confirmed by small intestinal biopsy. 
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Serum I-FABP levels were determined in duplicate using a highly specific in-house ELISA that 
selectively detects human I-FABP (standard: 12.5-800 pg/ml). The optimal cut-off value for 
CD of the I-FABP ELISA was determined at 382 pg/ml. Storage time of the serum samples did 
not significantly influence levels of I-FABP.
Statistical analysis
Statistical analyses were performed using SPSS, version 19.0 for Windows (SPSS Inc, Chicago, 
Illinois, USA). For descriptive purposes, serum I-FABP levels (right-skewed distribution) are 
presented as median and interquartile range. 
In order to find the cut-off point of serum I-FABP levels that most accurately discriminates 
patients with CD from patients without CD, a receiver operating characteristic (ROC) 
curve was drawn by plotting sensitivity against 1-specificity for all possible serum I-FABP 
thresholds. The overall accuracy of serum I-FABP for detecting CD was summarized using the 
area under the curve (AUC).
Log transformed (ln) baseline serum I-FABP levels were compared between CD patients 
and controls with a linear regression model adjusting for age. Patients with CD were 
stratified for Marsh grade, and compared with serum I-FABP levels also using the Kruskal 
Wallis test. Spearman’s correlation coefficient test was used for identifying a correlation 
between serum I-FABP levels and both Marsh grades and IgA-tTG levels. A p-value below 0.05 
was considered statistically significant.
Table 1  |  Baseline characteristics of untreated coeliac disease patients 
and controls.
coeliac disease control group p-value
n=80 n=141
Mean age in years (±SD) 47.1   (±17.0)    41.3     (±16.0) 0.015
Gender  
  Male 31 (38.8%) 68 (48.2%) 0.174
  Female 49 (61.3%) 73 (51.8%)
IgA-EMA
  Positive 77 (96.3%) - -
  Negative 1 (1.3%) 141 (100%)
  ND 2 (2.5%) - -
IgA-tTG  
  Positive 71 (88.8%) - -
  Negative 1 (1.3%) 141 (100%)
  N.D. 8 (10.0%) - -
Marsh grade  
  IIIA 32 (40.0%) 
  ND  IIIB 23 (28.8%)
  IIC 25 (31.3%)
Abbreviation: ND, not determined.
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RESulTS
In total, 96 adult biopsy-proven CD patients with elevated levels of IgA-tTG and/or IgA-
EMA were included. 81 CD patients were analysed at time of diagnosis (Table 1). A total of 
32 (40.0%) biopsies were classified as Marsh IIIA, 23 (28.8%) as Marsh IIIB and 25 (31.3%) as 
Marsh IIIC. Serum IgA-tTG and intestinal histology were available in 69 and 51 CD patients, 
respectively, during follow-up. The control group comprised 141 individuals with negative 
CD autoantibody levels.
Enterocyte damage assessed by serum I-FABP in untreated CD patients are associated 
with IgA-tTG levels and severity of villous atrophy 
Serum I-FABP levels were significantly elevated in patients with untreated CD (median 
691 pg/ml, interquartile range 447-1266 pg/ml) as compared to the levels in the control group 
(median 178 pg/ml, interquartile range 126-286 pg/ml; p<0.001; Figure 1A). With proper 
adjustment for age, the magnitude of the difference in serum I-FABP levels turned out to be 
much higher for older than younger subjects. Significant interaction with log transformed 
mean difference at the age of 30 and 60 years being 0.885 and 1.571, respectively (both 
p<0.001). The ROC curve for serum I-FABP yielded a high AUC of 0.88 (95% CI: 0.83–0.93; 
p<0.001) with an optimal cut-off value of 382 pg/ml and a sensitivity and specificity of 80% 
and 87.2%, respectively. The positive predictive value (PPV) and negative predictive value 
(NPV) were 78.0% and 88.5%, respectively. As depicted in Figure 1B, significantly elevated 
I-FABP levels account for each separate category of the Marsh classification; Marsh grade 
IIIA (median 530 pg/ml, interquartile range 384-836 pg/ml), Marsh IIIB (median 755 pg/ml, 
interquartile range 475-1248 pg/ml) as well as Marsh IIIC (median 860 pg/ml, interquartile 
range 556-1620 pg/ml). In addition, I-FABP levels correlated significantly with Marsh grade 
(r=0.265, p<0.05, n=80). Furthermore, serum levels of I-FABP correlated with IgA-tTG levels 
at time of diagnosis (r=0.403, p<0.01, n=65).
Incomplete normalisation of serum I-FABP levels in CD patients upon gluten elimination
I-FABP levels were investigated during dietary treatment in 69 patients. Six months after 
dietary exclusion of gluten an evident decline of I-FABP levels was shown (p<0.01; Figure 2). 
Serum I-FABP levels decreased further between six months and one year of adherence to a 
GFD, but did not reach significance (p=0.071, pair-wise comparison). Although I-FABP levels 
decreased during follow-up in CD, these levels seem to reach a plateau after 1-2 years of 
adherence to a GFD. The values did not decline towards the normal range observed in the 
control group, even despite the improvement of histological findings to Marsh 0 and or I 
(p<0.05) as shown in Figure 3. IgA-tTG levels normalised in 77% of the patients within two 
years of follow-up.
Six patients did not demonstrate a decrease in I-FABP levels upon a GFD for 1-2 years. 
Duodenal biopsies were available for five of these patients; with a mean diet time of 19 
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
I-FABP in adult CD  |  49
months (Table 2), showing crypt hyperplasia (n=4) and/or villous atrophy (n=1). In addition, 
IgA-tTG levels normalised in two patients with Marsh II. The positive and negative predictive 
values of serum I-FABP for intestinal damage in all CD patients on a GFD were 78,3% and 
65,4%, respectively.
Figure 1  |  Serum I-FABP levels in untreated coeliac disease patients compared to control 
subjects (A) and stratified for the degree of villous atrophy (B). 
Serum I-FABP levels are expressed as medians with interquartile range. 
Controls were defined as IgA-tTG negative, no biopsies were taken. 
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Figure 3 illustrates the significant correlation between serum I-FABP levels and villous 
atrophy in all CD patients upon a GFD (r=0.405, p<0.001, n=49). Otherwise, serum I-FABP 
levels did not correlate with IgA-tTG levels in CD patients upon a GFD (r=0.159, p=0.50).
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Table 2  |  Characteristics of coeliac disease patients with persisting elevated serum I-FABP 
levels upon a gluten-free diet for 1-2 years.
Gender Age  
(yr)
Duration of 
GFD (mo)
Marsh 
grade
IgA-EMA IgA-tTG
(u/ml)
I-FABP 
(pg/ml)
1 M 40 20 Marsh II negative negative 587
(under detection limit)
2 F 68 23 Marsh IIIA negative positive 2992
(55 U/ml)
3 M 64 16 Marsh II borderline borderline 632
(8 U/ml)
4 M 63 18 Marsh II positive positive 581
(> 80 U/ml)
5 M 56 24 ND borderline negative 765
(under detection limit)
6 M 75 12 Marsh II negative negative 853
(under detection limit)
Abbreviations: M, male; F, female; ND, not determined; GFD, gluten-free diet.
Figure 2  |  Serum I-FABP levels and time-related changes after initiation of a gluten-free 
diet. Serum I-FABP levels were log transformed, the line displays estimated mean values 
during follow-up, according to the random intercept model.
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Figure 3  |  Correlation between serum I-FABP levels and Marsh grade in coeliac disease 
patients on a gluten-free diet. 
Serum I-FABP levels were expressed as medians with interquartile range. 
Controls were defined as IgA-tTG negative, no biopsies were taken. 
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DISCuSSIOn
The findings of the present study, which is the first to directly evaluate enterocyte damage 
in adult CD patients, provide new information about two fundamental aspects of CD. First, 
serum I-FABP as disease independent marker for enterocyte damage is abundantly present 
in untreated CD and correlates with both the degree of villous atrophy and IgA-tTG levels. 
Second, significant enterocyte damage persists in treated CD patients after an initial decline 
of enterocyte damage in the first year after initiation of a GFD, despite absence of villous 
atrophy and low levels of IgA-tTG in the majority of cases.
Excessive enterocyte apoptosis has been proposed as one of the responsible mechanisms 
for the loss of absorptive villi in CD and correlates with the degree of villous atrophy.3, 4, 28 
The subsequent enhanced proliferative state does not compensate for the excessive loss of 
enterocytes, ultimately leading to villous atrophy.28 After short-term adherence to a GFD 
apoptotic rate is suggested to fall to a normal level.3 Besides apoptosis markers, different 
parameters have been investigated as evidence for intestinal epithelial damage in CD, 
including markers of intestinal paracellular permeability and absorptive surface area and 
function (plasma citrulline levels, C-sucrose breath test).29, 30 However, these parameters 
do not represent enterocyte damage directly. As the enterocytes are the main target in CD 
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and the leading cause of the clinical features, direct insight in mucosal damage at a cellular 
level is mandatory.
This report showed significantly elevated levels of serum I-FABP at time of CD diagnosis 
as compared to control subjects. These levels correlate with the degree of villous atrophy 
and level of IgA-tTG. The latter implies an association between an activated immune 
response (IgA-tTG) and enterocyte damage (I-FABP). In agreement with previous studies on 
enterocyte apoptosis, this study revealed a correlation between serum I-FABP levels and 
villous atrophy in untreated CD patients, in line with the hypothesis that villous atrophy 
occurs as a consequence of enterocyte damage.3, 4
Furthermore, serum I-FABP levels decreased during the first year of follow-up after 
initiation of a GFD. However, I-FABP levels did not decline towards the normal range 
observed in the control group in a subgroup of patients despite treatment with a GFD 
up to three years, suggesting ongoing enterocyte damage. These findings are consistent 
with other reports showing slow and incomplete recovery of the small intestinal mucosa 
by histopathological assessment in adult-onset CD. Only 35-65% of these patients show 
histological remission within 2 years, despite apparent strict adherence to a GFD and 
remission of symptoms.5-7, 31 Serum I-FABP levels correlate with villous atrophy in CD patients 
upon a GFD as well, yet persisting increased levels in a lower range were not related to 
villous atrophy. This discrepancy between persisting enterocyte destruction and absence 
of intestinal mucosal abnormalities is in line with recent studies. These reports show that 
morphometric indices including villous area and crypt length, improve upon a GFD in adult 
CD, however, rarely return to values observed in control subjects, even when the Marsh 
grade normalised.32 Villous area was found to stabilise after one year of apparent adherence 
to a GFD and improved less than 50% after long-term treatment. In addition, electron 
microscopy revealed persisting enterocyte damage, despite a normalisation of the intestinal 
mucosa by routine histological assessment.33, 34 Therefore, it is tempting to speculate that 
there are subtle alterations of the enterocyte integrity that persist for a long period after 
the start of a GFD in adult CD patients that can explain the significantly increased levels of 
I-FABP found in this study. 
In contrast to the described results in adult CD patients, our previous study on serum 
I-FABP levels in children diagnosed with CD, showed a rapid decrease and normalisation of 
I-FABP levels after initiation of a GFD, which is faster than the decline of CD autoantibodies.20 
In line with these findings, mucosal recovery in children is thought to progress faster and 
more complete as compared to patients diagnosed at an adult age.6, 35
Although serum I-FABP levels in untreated CD patients correlated with IgA-tTG levels 
implying that the activated immune response is responsible for this enterocyte damage, 
our results showed that enterocyte damage assessed by serum I-FABP levels persists in CD 
patients upon a GFD despite low IgA-tTG levels. This suggests that enterocyte damage is 
independent of autoantibody production or at least from circulating autoantibodies. It has 
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been shown that serum autoantibody levels decline faster than the intensity of mucosal 
autoantibody deposits during dietary treatment and moreover the presence of deposits can 
persist for more than two years.36
The cause for the ongoing enterocyte damage in adult CD patients on a GFD remains to 
be revealed. Gluten ingestion might be one explanation. Despite the diet, all CD patients 
ingest at least minute amounts of gluten, and it is reported that up to 60% of CD patients are 
partially non-adherent.10, 37-39 Dietary compliance is suggested to be related to the severity 
of symptoms of malabsorption before treatment. Individuals with adult-onset CD have 
mostly mild symptoms, whereas children often present with classic symptoms, which might 
contribute to age-dependent differences in mucosal recovery.37, 39 In addition, prolonged 
gluten exposure in adult CD patients before final diagnosis may result in severe damage and 
consequently slow recovery of the mucosa, whereas early diagnosis in children might be 
related to mild intestinal damage and fast recovery.7, 40 Furthermore, it has been suggested 
that the immune response to gliadin may persist even upon a GFD.1, 7, 36, 41 However, in this 
study in most of the long-term treated patients circulating IgA-tTG autoantibodies were not 
detectable.
Currently, it is unknown whether the observed enterocyte damage in CD patients on a GFD 
influences nutrient absorption. Nevertheless, it is suggested that ongoing intestinal damage 
in CD patients is based on several mechanisms such as increased intestinal permeability 
and production of cytokines that may contribute to systemic symptoms, and associated 
with long-term complications of autoimmune and malignant disorders.42, 43 For daily clinical 
practice, our findings suggest that serum I-FABP might be a potential marker for follow-up, 
but a prospective study is mandatory.
A limitation of this study is related to drop-out linked to the retrospective nature of the 
study design. It is possible that missing data biased our results; some patients may have 
undergone follow-up CD autoantibody tests and duodenal biopsy on account of their clinical 
deterioration. If so, drop-out was not at random (as assumed by the model), meaning 
that we could be missing complete histological responders potentially biasing our data. 
Otherwise, incompliant patients might have withdrawn from medical care. Our follow-up 
at three years on a GFD data included only 15% of the CD patients. Moreover, no intestinal 
biopsies were taken in the control group. Although the sensitivity of IgA-tTG tests is high, 
there might be hidden seronegative CD patients in this control group. As we expect that 
these patients could be responsible for the highest serum I-FABP levels in the control group, 
this will only emphasize the difference between enterocyte damage in CD patients (on 
a GFD) and controls. Although our data fit with the results of different studies reporting 
slow and incomplete recovery of the intestinal mucosa in adult-onset CD patients5-7, 31, 32, a 
prospective study is indicated.
In conclusion, this study provides direct insight in damage to the small intestinal 
epithelium at enterocyte level during the course of CD in adult patients. We demonstrated 
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evident elevated levels of I-FABP associated with villous atrophy and IgA-tTG levels in 
untreated CD patients and improvement of this mucosal damage after initiation of a GFD in 
the majority of patients. Interestingly, significant enterocyte damage persists in CD patients 
despite apparent long-term adherence to a GFD. Serum I-FABP levels might be useful in daily 
practice in identifying non-compliance and unintentionally gluten intake, evaluating new 
therapeutic options, and might provide us with a minimal-invasive marker for detection of 
ongoing mucosal architectural abnormalities without the need of endoscopy. 
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Serum parameters in the spectrum of 
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ABSTRACT
Objectives: Invasive techniques are still required to distinguish between uncomplicated and 
complicated forms of coeliac disease (CD).
Methods: We set out to investigate the potential use of novel serum parameters, including 
IL-6, IL-8, IL-17, IL-22, sCD25, sCD27, granzyme-B, sMICA and sCTLA-4 in patients diagnosed 
with active CD (ACD), CD on a gluten-free diet (GFD), refractory coeliac disease (RCD) type 
I and II, and enteropathy associated T-cell lymphoma (EATL).
Results: In both active CD and RCD I-II elevated levels of the pro-inflammatory IL-8, IL-17 
and sCD25 were observed. In addition, RCD II patients displayed higher serum levels of 
soluble granzyme-B and IL-6 in comparison to ACD patients. In contrast, no differences 
between RCD I and ACD or RCD II were observed. Furthermore, EATL patients displayed 
higher levels of IL-6 as compared to all other groups.
Conclusion: A series of novel serum parameters reveal distinctive immunological 
characteristics of RCD II and EATL in comparison to uncomplicated CD and RCD I. 
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InTRODuCTIOn
Coeliac disease (CD) is a chronic immune-mediated inflammation of the small intestine 
caused by a permanent state of intolerance to ingested gluten proteins affecting genetically 
susceptible individuals. Its hallmarks, lymphocytic infiltration of the lamina propria, 
expansion of the intraepithelial lymphocyte (IEL) population, hyperplasia of the crypts and 
atrophy of the villi are mediated by the interplay between an innate and adaptive immune 
response against gluten.1 The complex of deamidated gliadin peptide interacting with the 
HLA-DQ2 and/or –DQ8 heterodimers on antigen presenting cells, is capable of activating the 
lamina propria T-helper lymphocytes, thereby initiating antibody production and a gluten-
specific pro-inflammatory type 1 T-cell response (Th1).1 Th1-cells play an important role 
in the pathogenesis of CD by secreting IL-2 that induces proliferation of T-lymphocytes 
and, in particular, by secreting the pro-inflammatory cytokine interferon-gamma (IFN-γ).2 
Furthermore, recent evidence has indicated that Th17-cells play a pathogenic role in CD.3-5 
In addition, IL-15 activates a cytotoxic response of intra-epithelial lymphocytes through 
IFN-y release and up regulation of NKG2D. In combination with epithelial stress, the NKG2D 
ligand MHC Class I chain-related A (MICA) is up regulated by enterocytes.6, 7 The interaction 
of MICA and NKG2D induces enterocyte destruction by intraepithelial lymphocytes (IELs). 
A gluten-free diet (GFD) results in mucosal recovery in the majority of patients, who 
are referred to as uncomplicated CD-patients. However, a small subset of adult-onset 
CD patients fails to regain intestinal homeostasis after elimination of dietary gluten, or 
symptoms recur after initial response.8 After careful evaluation of dietary compliance 
and exclusion of other possible disease-entities causing villous atrophy, these patients are 
diagnosed to suffer from refractory coeliac disease (RCD).9 RCD is considered a complicated 
form of CD, and is divided into type I (RCD I), when patients lack an aberrant IEL population, 
or type II (RCD II) in which a substantial (>20%) aberrant IEL population is found in the small 
intestinal mucosa.10, 11 An aggressive type of lymphoma which carries a dismal prognosis, the 
enteropathy associated T-cell lymphoma (EATL), is thought to arise from this aberrant IEL 
population. An interesting observation is that both aberrant IELs as well as EATL cells display 
a cytotoxic phenotype and contain high levels of granzyme-B12 13, which could therefore 
serve as a marker for complicated CD. 
In consequence of a good response to immunosuppressive therapy, RCD I patients have 
a better prognosis than RCD II patients.14-17 Therefore, early identification of CD patients 
developing RCD II and/or EATL enables early intervention, which will likely reduce morbidity 
and mortality.
Currently, antibodies against tissue transglutaminase (IgA-tTG), endomysium of 
connective tissue (IgA-EMA) and deamidated gliadin peptides (DGP) provide valuable and 
generally accepted serological parameters for the diagnosis and follow-up of uncomplicated 
CD. However, these antibodies are of no use in predicting and monitoring RCD I-II and EATL, 
implying that histological and flow cytometric analysis of duodenal biopsies are still required 
R2
R4
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
60  |  Chapter 3
to distinguish between the uncomplicated and complicated forms of CD. Additional serum 
markers could potentially provide us with a minimal-invasive, easy applicable test without 
the need to perform a gastro-duodenal endoscopy. In addition, immunological markers in 
the peripheral blood could provide more insight in the similarities and differences of the 
pathophysiology underlying the CD spectrum. 
Therefore, in the present study we evaluated several immunological and biochemical 
parameters in sera from the five stages of CD, including ACD, CD on GFD, RCD I-II and 
EATL, for their ability to differentiate between complicated and uncomplicated forms, and 
secondly, to gain insight in the pathophysiological relations between these disease entities. 
For this purpose, we analysed serum levels of the inflammatory cytokines IL-6, IL-8, IL-17 
and IL-22, the T-cell activation factors soluble (s)CD25 (IL-2R-alpha) and sCD27, the T-cell 
dysregulation factor sCTLA-4, shown previously to be up-regulated in different autoimmune 
diseases, the cytotoxic T-cell parameter granzyme-B, and sMICA, previously shown to be 
associated with the presence of epithelial stress and malignancies.
MATERIAlS AnD METHODS
A retrospective cohort study was conducted at a tertiary referral centre for CD in The 
Netherlands. Patients previously diagnosed with (complicated) CD in the VU medical centre 
were identified and included in our study when stored serum samples at time of diagnosis 
were available. Overall, 92 blood samples collected for diagnostic purposes between 1997 
and 2010 were included. Serum levels of a substantial number of immunological markers were 
determined in the five different subsets of CD. In addition, results from several biochemical 
parameters of this cohort at time of diagnosis were collected from the electronic patient 
file in our centre.
Patients
CD diagnosis was based on the ESPGHAN guidelines.18 All patients included in the active 
CD group had positive IgA-EMA and/or IgA-tTG, and histological abnormalities grade III 
according to the modified Marsh classification consisting of intra-epithelial lymphocytosis, 
crypt-hyperplasia and some degree of villous atrophy.19 Furthermore, serum samples of 
these patients at time of an inactive phase of CD were collected. Remission of disease (GFD 
group) was defined by the disappearance of one or both CD antibodies upon a GFD, and if 
a gastro-duodenal endoscopy with subsequent collection of biopsies was performed during 
follow-up, normalisation of mucosal abnormalities (Marsh 0 or I) was required. Patients 
included in the RCD group had persisting or recurring symptoms and small intestinal villous 
atrophy, despite strict adherence to a GFD for at least one year (assessed by a dietitian and 
negative IgA-tTG / IgA-EMA). The clinically validated cut-off value of more than 20% of the 
IELs expressing an aberrant phenotype (surface CD3-, but cytoplasmic CD3+) as detected by 
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flow cytometric analysis was used to distinguish RCD type I and II.11 All procedures were in 
accordance with the regulations of the medical ethics committee, and all patients declared 
their informed consent to store and use their blood samples collected for regular diagnostics 
for further research. 
In total, 26 paired serum samples of CD patients at time of disease activity (ACD group) 
and after serological normalisation on a GFD (GFD group), and of an additional 40 patients 
with complicated CD at time of diagnosis were included. The latter group consisted of 12 
RCD I, 16 RCD II and 12 EATL patients.
Serum parameters: enzyme linked immunosorbent assay (ElISA)
Levels of cytokines IL-6, IL-8, IL-17 and IL-22 were determined in serum using commercial 
ELISA kits (Pelikine-compactTM ,Sanquin, Amsterdam, The Netherlands), according to the 
manufacturer’s instructions. Levels of soluble CD25 (sCD25), soluble CD27 (sCD27), soluble 
CTLA-4 (sCTLA-4), soluble MICA (sMICA) and granzyme-B were determined in serum using 
a specific commercial ELISA kit (Diaclone, Besancon, Cedex, France), according to the 
manufacturer’s instructions. 
Biochemical parameters
The concentration of C-reactive protein (CRP; g/L), erythrocyte sedimentation rate (ESR; 
mm per 1h), leukocyte count (WBC; 10E9/L), albumin (g/L) and haemoglobin (Hb; mmol/L) 
were extracted from the hospital patient file for all patients included at time of diagnosis.
Statistical analysis
Data were analysed and plotted using SPSS software (SPSS Inc. Chicago, Illinois, USA), 
using non-parametric tests as most variables examined in this study did not appear to be 
normally distributed. A Wilcoxon signed-rank test was used for pair wise comparison of the 
variability of immunological and biochemical parameters among the active CD and GFD 
group. The latter groups were individually compared to the complicated forms of CD by 
using the Kruskal-Wallis non-parametric test to identify possible serological and biochemical 
differences in the spectrum of CD. A receiver operating characteristic (ROC) curve was 
made of all significantly different parameters to represent the trade off between the false 
negative and false positive rates. As a considerable number of markers were determined, 
the level of significance was set at highly significant (p<0.001) and moderately significant 
(0.001< p <0.05).
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RESulTS
Table 1 shows the characteristics of the five subsets of CD. Serum samples of 26 ACD patients 
at time of diagnosis and after remission of disease on a GFD were included. In all patients 
CD associated antibodies reverted to negative upon a GFD, and in 62% (16/26) a biopsy 
was taken which revealed mucosal healing (Marsh 0/I) in all those evaluated. Overall, 12 
RCD I, 16 RCD II and 12 EATL patients were included. Significant differences were found 
for cytokine profiles between the five subsets of CD, as described in more detail below 
(Figure 1A-I). 
ACD versus GFD 
Serum levels of the inflammatory chemokine IL-8 (p=0.00) and the T-cell activation factor 
sCD25 were higher in active CD patients than in patients in remission on a GFD (p=0.00, 
highly significant) as well as the Th-17 lineage-defined cytokine IL-17 levels (p=0.011, 
moderately significant). Serum levels of IL-6, IL-22, sCD27, sMICA, granzyme-B and sCTLA-4 
were not significantly elevated in the ACD group. In addition, levels of CRP, ESR, albumin 
and WBC were similar (data not shown). 
uncomplicated CD versus RCD I-II
The serum levels of IL-8, IL-17 and sCD25 in RCD type I and type II were comparable to 
those in the ACD group, however, significantly lower levels were observed in the GFD 
group. Moreover, in comparison to both ACD and GFD patients, RCD II patients showed 
increased levels of granzyme-B (p=0.020; p=0.016, both moderately significant) and IL-6 
(p=0.018; p=0.024, both moderately significant), respectively. Furthermore, serum levels of 
soluble CTLA-4 were lower in RCD II patients than those in remission upon a GFD (p=0.003, 
moderately significant). Similar IL-22 serum levels were found in uncomplicated CD and RCD 
I-II. 
Comparison of the inflammatory parameters CRP, ESR and WBC did not reveal significant 
differences between uncomplicated CD and RCD I-II. The concentration of albumin was 
lower in both RCD subsets when compared to ACD (p=0.003, moderately significant) and GFD 
(p=0.000, highly significant) (Figure 2). 
The RCD complex
None of the markers tested was able to distinguish RCD II from RCD I. Moreover, no 
significant differences in levels of albumin or inflammatory parameters CRP, ESR and WBC 
were observed.
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Table 1  |  Characteristics of the different groups in the spectrum of coeliac disease.
SPECTRuM OF CD
ACD GFD RCD I RCD II EATl
n=26 n=26 n=12 n=16 n=12
Age at CD (yr), 
median (SD; range)
42.5 
(16; 21-76)
45 
(15; 21-77)
50.5 
(16; 19-69)
61.5 
(13; 27-74)
61.5 
(7; 48-66)
Age at RCD (yr), 
median (SD; range)
- - 59 
(11; 35-74)
65 
(10; 47-77)
64 
(8; 51-72)
Age at EATl (yr), 
median (SD; range)
- - - - 65 
(6; 51-74)
HlA-staus
  DQ2 heterozygous 10 7 8 7 3
  DQ8 heterozygous 9 13 - - 3
  DQ2/8 heterozygous 3 2 1 3 2
  DQ2 homozygous 4 4 3 6 4
Marsh
  0 - 12 - - 2
  I - 4 - - -
  II - - - - 1
  IIIA 11 - 8 9 5
  IIIB 5 - 3 4 3
  IIIC 10 - 1 3 1
  ND - 10 - - -
IgA-EMA
  Negative (-) - 26 12 15 7
  Dubious (+/-) - - - 1 2
  Weak positive (+) 3 - - - -
  Positive (++) 11 - - - -
  Strongly positive (+++) 11 - - - 2
  ND 1 - - - 1
IgA-tTG
  Negative - 7       1 2 14 6
  Dubious - - - 2 2
  Weak positive 8 - - - 1
  Positive 6 - - - 1
  Strongly positive 9 - - - 1
  ND 3 19 - - 1
Aberrant IEls (%), 
median (SD; range)
- - 4 
(6; 2-19)
64 
(23; 20-96)
7 
(32; 1-87)
EATl type
  Primary - - - - 4
  Secondary - - - - 8
Abrreviations: GFD, coeliac disease patients on a gluten-free diet; RCD I and II, refractory coeliac disease 
type I and II; EATL, enteropathy associated T-cell lymphoma; IgA-EMA; endomysial antibodies; IgA-tTG, tissue 
transglutaminase antibodies; IELs, intra-epithelial lymphocytes; ND, not determined.
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Figure 1A-I  |  Concentration of serum parameters in the different subsets of the 
coeliac disease spectrum: IL-6 (A); IL-8 (B); IL-17 (C); IL-22 (D); sCD25 (E); sCD27 (F); 
sMICA (G); sCTLA-4 (H); granzyme-B (I). 
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EATl versus ACD and RCD I-II
The highest serum levels of IL-6 were observed in the EATL group, which were higher 
(p=0.000, highly significant) as compared tot the active CD and GFD groups, as well as 
higher (p=0.002, p=0.007, moderately significant) than RCD I-II, respectively. Moreover, 
serum levels of IL-6 were clearly elevated in EATL over RCD II with an AUC of 0.82 (95% CI: 
0.649-0.971). IL-6 levels in EATL patients tended to correlate (0.45, p=0.08) with CRP levels, 
but not with IL-17 levels. Furthermore, serum levels of sCD27 were decreased (moderately 
significant) in EATL patients as compared to all other groups, except RCD II in which (highly) 
significant (p=0.000) differences were found. Nevertheless, ROC analysis resulted in a very 
low AUC. In addition, similar levels of sMICA, granzyme-B and sCD25 were measured in 
EATL and RCD I-II. However, the serum albumin concentration in EATL patients was lower 
(moderately significant) than in ACD and both types of RCD (Figure 2).
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Figure 2  |  Concentration of albumin in the 
different subsets of the coeliac disease spectrum. 
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DISCuSSIOn
Currently, physicians are unable to predict who will develop complicated CD. As invasive 
techniques are still required to differentiate between uncomplicated and complicated 
forms of CD, the purpose of the present analysis was to evaluate the ability of markers 
in peripheral blood to distinguish the various CD subsets. By doing so, it may also provide 
insight in the potential differences in underlying immunopathomechanisms of these disease 
subsets. The results could be biased by cytokine production from different cellular sources 
in the peripheral blood, and therefore may not exactly mimic the intestinal inflammation.20 
However, other investigators have previously shown that blood cytokine profiles do reflect 
intestinal mRNA expression in active CD patients.2, 21-23  Care must be taken in case our 
findings are extrapolated to other age groups, as it can not be excluded that normal values 
vary over age.
ACD versus GFD
These results are in keeping with previous studies showing up regulation of IL-820, 24, a 
chemokine produced by macrophages, epithelial as well as endothelial cells that attracts 
leukocytes to a site of inflammation, as well as elevated levels of sCD25 that is cleaved 
off from the membranous CD25 (IL-2R-alpha) during T-cell activation.25-27 Furthermore, 
the increased levels of the pro-inflammatory cytokine IL-17 observed in the current study, 
supports the view that Th17-cells that produce this particular cytokine are involved in several 
autoimmune diseases and are suggested to have a pathogenic role in CD.3-5 In contrast to the 
(pro-) inflammatory environmental characteristics observed in this analysis and to previous 
The concentration of albumin is significantly 
higher in both the ACD (p=0.003) and the GFD 
(p=0.000) subset compared to the complicated 
forms of CD. In EATL patients clearly lower 
albumin concentrations compared to both 
RCD I and II (p=0.003 and p=0.037, 
respectively) were observed.
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reports20, 26, 28, the levels of IL-6, illustrative of an acute phase response and a potent inducer 
of the Th17 pathway29, were low and similar in both uncomplicated CD subsets. A clear 
explanation for these findings is lacking, especially as strongly increased levels were found 
in RCD II and EATL patients. Another cytokine involved in gut inflammation is IL-22 that 
is produced by Th17 and/or Th22 cells, where it is currently believed to exert regulatory 
functions.30, 31 Elevated levels of IL-22 have been found in the mucosa of Crohn’s disease32, 
but its role in CD is yet unclear3, 33. Nevertheless results failed to reveal a correlation 
between serum IL-22 levels and disease activity or disease entity. 
sCD27 serum levels are increased in T-cell mediated diseases, including some auto-
immune disorders.34, 35 However, the sCD27 levels were normal in ACD. This in contrast 
to the previously reported increased production of another lymphocyte activation marker 
sCD25. This dissimilarity is remarkable as in SLE patients sCD25 and sCD27 levels are strongly 
correlated during the whole disease course.36 
The RCD complex
Although, by general consent, RCD type I and II are considered two related disease 
entities within the spectrum of CD, it remains unclear whether both diseases share a 
similar pathogenesis responsible for the gluten-independent inflammation. In keeping 
with the current opinion, our results showed in both types of RCD similar inflammatory 
characteristics and T-cell activation based on serum levels of IL-8, IL-17, IL-22 and sCD25, 
respectively. On the other hand, a transition from RCD I to RCD II has only been reported 
sporadically.16 Theoretically, granzyme-B is a suited parameter to differentiate between 
RCD type I and II, since aberrant IELs are clearly cytotoxic and express high amounts of 
intracellular granzyme-B.12 Although increased levels of soluble granzyme-B were observed 
in RCD II patients, these were not significantly higher than in RCD I patients.
RCD I-II versus uncomplicated CD 
Currently, it is unknown to what extent the gluten-independent inflammation as generally 
observed in RCD evolved from and/or differs from the gluten induced inflammation in active 
CD. In this study, the pro-inflammatory T-cell response, including IL-8, IL-17, sCD25, in both 
types of RCD and ACD patients shows resemblance, with exception of evidently increased 
IL-6 levels in RCD II over ACD. This finding suggests a higher inflammatory state in RCD II 
than in ACD, however, similar levels of the inflammatory parameters CRP, ESR and WBC were 
observed. In line with the lack of intestinal inflammation in patients adhering to a GFD, the 
pro-inflammatory response was significantly lower as compared to the complicated forms 
of CD. Interestingly, in comparison to ACD patients, RCD II patients displayed a distinctive 
cytotoxic T-cell activation profile based on elevated serum levels of granzyme-B. The levels 
of these parameters observed in RCD I patients did not differ from either ACD or RCD II 
patients. 
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Monitoring EATl development
RCD II patients carry a high risk to develop an EATL, yet, so far no serological parameters for 
EATL development have been identified, including efforts in the present analysis. Based on 
the fact that EATL cells contain large amounts of granzyme-B13, these levels were measured 
in the peripheral blood, but EATL patients did not contain higher levels than ACD or RCD 
patients. Furthermore, elevated levels of sCD2737 and sCD2538 have been suggested to be 
associated with tumour burden in some lymphoid neoplasia. Neoplastic lymphoid cells in 
non-Hodgkin lymphoma express CD27 and are considered responsible for the increased sCD27 
production.37 The current analysis failed to show increased sCD27 levels in EATL patients and 
thereby suggests that EATL regards a distinct type of lymphoma and does not aid in the 
identification of this particular lymphoma. In line with a previous study showing elevated 
sCD25 levels in EATL39, we found comparable levels of sCD25 in EATL, RCD and active CD. 
Another potential marker evaluated in this study is sMICA, that is cleaved from membranous 
MICA and has been shown to impair NKG2D mediated tumor surveillance in epithelial 
tumors41, as well as it has shown potential as a prognostic parameter in haematopoietic 
malignancies since increased levels of sMICA were found in leukemia patients41. The only 
marker that distinguished EATL from all other groups was IL-6 and its levels correlated 
with CRP levels, indicating a more severe acute inflammatory response in EATL patients. In 
accordance with our data, an association with IL-6 levels and survival in Hodgkin lymphoma 
has been recognized almost twenty years ago.42 
                                 
Clinical implication and potential application
Taken together, for daily clinical practice the results of this analysis suggest that apart from 
detection of CD associated antibodies and duodenal biopsies, other variables including IL-8, 
sCD25 and possibly IL-17, might be helpful in monitoring inflammatory disease status and 
differentiating between patients on a strict GFD and those diagnosed as having RCD. In case 
CD-specific antibodies remain mildly elevated, which is not rare in RCD patients, serum 
levels of granzyme B could possibly serve as an additional marker to distinguish active CD 
from RCD II, and will enable early intervention. However, the currently accepted diagnostic 
work-up of RCD remains required, pending prospective serological studies including larger 
series of patients. 
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Conclusion
In conclusion, both types of RCD are characterised by an ongoing and/or recurring 
inflammatory disease status showing great resemblance to that observed in ACD despite 
strict adherence to a GFD, yet differentiates itself by elevated serum IL-6 concentrations in 
RCD II. Furthermore, in addition to this increased pro-inflammatory profile, RCD II reveals a 
distinctive cytotoxic T-cell activation profile as compared to ACD based on elevated levels 
of granzyme B, whereas RCD I does not. Although no EATL-specific or -associated variables 
were found in this study, our ongoing efforts may identify relevant markers. Further research 
will also address the prospective and diagnostic value of the serum variables identified in 
this study in order to expand the clinical application of (R)CD serology beyond standard 
autoantibody testing.
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ABSTRACT
Objectives: Aberrant intraepithelial lymphocytes (IELs) are the hallmark of refractory 
coeliac disease (RCD) type II and considered a premalignant cell population from which 
aggressive enteropathy associated T-cell lymphoma (EATL) can evolve. The aim of this study 
was to gain further insight in the origin and characteristics of aberrant IELs by analysing 
T-cell receptor (TCR) rearrangements, and by immunophenotypic analysis of aberrant IELs.
Methods: Duodenal biopsies from 18 RCD II patients and three RCD II cell lines were analysed 
for the presence of TCR delta, gamma, and beta rearrangements. In addition, IELs isolated 
from biopsies derived from RCD II patients were phenotypically analysed. 
Results: Aberrant IELs showed an up regulated expression of granzyme-B and a decreased 
expression of PCNA. TCR rearrangements in the aberrant IEL population in biopsies of 
RCD II patients were heterogenic, which is most likely due to a variation in maturity. 
Similarly, RCD II cell lines displayed a heterogenic TCR rearrangement pattern.
Conclusion: Aberrant IELs originate from deranged immature T-lymphocytes and display 
clear differentiation to a cytotoxic phenotype. Aberrant IELs displayed different stages of 
maturity between RCD II patients, of which only the patients harbouring the most mature 
aberrant IEL population developed an EATL.  
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InTRODuCTIOn
Coeliac disease (CD) is a common small intestinal enteropathy induced by dietary gluten 
proteins as well as other undefined environmental factors, affecting genetically predisposed 
individuals of all ages. A permanent state of intolerance to gluten-containing food leads to 
a chronic autoimmune mediated inflammatory response with subsequent remodelling of the 
proximal small bowel mucosa and nutrient malabsorption.1 Withdrawal of dietary gluten 
usually leads to prompt healing of the damaged small intestinal mucosa and improvement of 
nutrient absorption. Although a substantial group of adult-onset CD patients lacks histological 
recovery after two years on a gluten-free diet (GFD) only a small subgroup of patients2, 3, 
especially those diagnosed above the age of 50 years, develop primary or secondary 
resistance to a GFD with intestinal villous atrophy and persisting or recurring symptoms 
of malabsorption.4 After evaluation of diet-compliance by a dietitian and exclusion of 
other underlying diseases known to cause villous atrophy, subjects are considered to suffer 
from refractory coeliac disease (RCD).5 Based on the immunophenotype of intraepithelial 
lymphocytes (IELs), RCD can be subdivided into type I lacking a substantial aberrant IEL 
population (CD3-, CD45+, CD103+, CD7+, CD4-, CD8-, cytCD3+ cells) and type II in which 
an aberrant IEL population is present.6 The distinction between RCD I and II is defined by a 
clinically validated cut-off of 20% aberrant IELs.7
As a consequence of a generally good response to immunosuppressive therapy, 
RCD I has a less dismal prognosis compared to patients suffering from RCD II, reflected in 
a 5-year survival rate of approximately 90% and 44-58%, respectively.5, 8-10 More importantly 
approximately 40-50% of all RCD II patients develop an aggressive enteropathy associated 
T-cell lymphoma (EATL), which is considered to arise from the clonal expansion of the 
premalignant aberrant IEL population.11-13 EATL is one of the main causes of death in 
RCD II patients, due to its aggressive nature and unresponsiveness to currently available 
therapies.5, 8-10 Despite standardised treatment, one half of the RCD II patients develops an 
EATL whereas the other half does not, which could indicate that aberrant IEL populations 
between patients are heterogeneous and might be accompanied with a variable risk to 
develop an EATL. Even though RCD II and EATL patients are associated with HLA-DQ2 
homozygosity14, currently no histopathological or immunophenotypic features have been 
identified that have a prognostic value in the evolution of aberrant IELs into an EATL. 
Therefore it is of utmost importance to gain more insight in the origin and characteristics 
of aberrant IELs in RCD II, which will enable a better identification of high risk patients and 
the development of new therapeutic options.
Recently, elegant work addressing the expansion and function of aberrant IELs has been 
performed15, 16, nevertheless, the exact role of aberrant IELs in the mucosa of the small 
intestine still remains unclear. Furthermore, the cells from which monoclonal aberrant IELs 
originate is currently under debate. Although aberrant IELs found in RCD II do not express 
the T-cell lineage-specific surface CD3-TCR complex, these cells do contain cytoplasmatic 
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CD3 antigen and display T-cell receptor (TCR) rearrangements, indicative of T-cell lineage 
commitment. It has been suggested that the TCR-CD3 complex is internalised due to 
overstimulation of IELs, implying that aberrant IELs originate from mature TCR+ IELs.11 More 
specifically, it is hypothesised that these cells derive from gamma-delta T-lymphocytes 
based on the observed inversed correlation between aberrant IELs and gamma-delta cells 
in RCD II.17, 18 Alternatively, a small, unique CD3-CD7+ population considered to be NK/
T-cell precursors, which is found in the intestine of healthy individuals, is suggested to 
represent the physiological counterpart of aberrant IELs.19-21 The presence of an immature 
lymphoid precursor population in the gut mucosa, which could hypothetically serve as origin 
for aberrant IELs, is emphasised by the ongoing extrathymic maturation of T-cells in the 
intestinal mucosa throughout life.22 
Therefore, in this study we isolated lymphocytes from duodenal biopsies collected from 
RCD II patients and compared the expression of markers representing activation, proliferation, 
DNA-repair and lymphocyte development on aberrant lymphocytes to the expression on 
normal lymphocytes within the same patient. To elucidate the origin of aberrant IELs, we 
assessed these biopsies for the presence of TCR delta (TCR-δ), gamma (TCR-γ) and beta 
(TCR-β) rearrangements. In addition, extensive analysis of TCR rearrangements in RCD II 
cell lines was performed.  
MATERIAlS AnD METHODS 
Patients
RCD II patients included in this study visited the out-patient department of gastroenterology 
at the VU University Medical Centre, Amsterdam, The Netherlands for diagnostic work-up 
or regular follow-up. The diagnosis of RCD II was based on persisting or recurring symptoms 
and small intestinal villous atrophy after a former good response despite strict adherence 
to a GFD for at least one year. Furthermore, the clinically validated cut-off value of 20% 
aberrant IELs as detected by flow cytometry was predominantly used to distinguish RCD 
type I and type II.7 A lower percentage of aberrant T-cells was allowed in the presence of 
ulcerative jejunitis. 
Small intestinal biopsies
During upper gastro-intestinal endoscopy multiple large spike forceps biopsies were 
taken from the second part of the duodenum. For TCR rearrangement analysis, 1-2 biopsy 
specimens were stored in liquid nitrogen until analysis. For flow cytometric evaluation, six 
biopsy specimens were collected from various locations in the duodenum, from which IELs 
were isolated and pooled before immediate analysis. All biopsy specimens were obtained 
for diagnostic purposes and the procedures were in accordance with the ethical guidelines 
of our institution.
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Cell lines and cell culture
RCD cell lines P1, P2 and P3 were isolated from duodenal biopsies of RCD II patients as 
previously described.23 In short: biopsy specimens were treated with 1mM dithiothreitol 
(Fluka, Buchs, Switzerland) and 0.75 mM ethylenediaminetetraacetic acid (EDTA, Merck, 
Darmstadt, Germany) after which the biopsy was cultured in Iscove’s modified Dulbecco’s 
medium (IMDM, Lonza, Verviers, Belgium) supplemented with 10% normal human serum (NHS) 
and 10 ng/ml IL-15 (R&D systems Europe, Abingdon, UK). Released cells were propagated 
on IMDM containing 10% NHS and 10ng/ml IL-15 and restimulated approximately every four 
to five weeks with 1 μg/ml phytohemagglutinin, 10 ng/ml IL-15 and 1 x 106/ml irradiated 
allogenous peripheral blood mononuclear cells as feeder cells. A TCR-,CD3+,CD4+ T-cell 
clone isolated from a duodenal biopsy of a CD patient was maintained in IMDM containing 
10% NHS supplemented with 10 ng/ml IL-15 and 20 Cetus units/ml IL-2 (Proleukin, Chiron 
corporation, Emeryville, California, USA) and restimulated every two weeks.
Flow cytometric analysis
Multiparameter flow cytometric immunophenotyping was performed on IEL suspensions, 
isolated as previously described.7 Briefly, biopsies were vigorously shaken at 37°C for 60 
minutes in PBS supplemented with 1 mM DTT (Fluka, Buchs, Switzerland) and 1 mM EDTA 
(Merck, Darmstadt, Germany). The released IELs were washed twice with PBS supplemented 
with 0.1% BSA (Roche Diagnostics) and subsequently stained for 30 min on ice, with 
fluorescein isothiocyanate (FITC), phycoerythrin (PE), peridinin chlorophyll protein (PerCP) 
and allophycocyanin (APC)-labeled monoclonal antibodies directed against CD3, CD4, CD5, 
CD7, CD8, CD16+56, CD19, CD25, CD30, CD34, CD45, CD45RA, granzyme-B, HLA-DR, Ki-67, 
NKG2D, PCNA (all from BD Biosciences, San Jose, California, USA), CD52 (Serotec, Düsseldorf, 
Germany), terminal deoxynucleotidyl transferase (TdT) and CD1a (Glostrup, Denmark), 
CD103 (IQ products, Groningen, The Netherlands), and IL-15R-alpha (eBioscience, Hatfield, 
United Kingdom). Cytoplasmic staining of CD3 was performed after cell permeabilisation 
by Cytofix/CytoPerm Plus (BD Biosciences), according to the manufacturer’s instructions. 
Nuclear staining of Ki-67 and PCNA was performed after cell permeabilisation by eBioscience 
Cell Fixation/Permeabilisation (eBioscience), according to the manufacturer’s instructions. 
Stained cells were washed with PBS containing 0.1% bovine serum albumin (BSA, Sigma) and 
analysed on a standard four-color flowcytometer (FACSCalibur, BD Biosciences). The data 
were analysed using Cellquest software (BD Biosciences). Care was taken to analyse only 
viable cellular events based on light scatter properties.  
Both aberrant IELs (sCD3-, CD45+, cytCD3+) and normal IELs (sCD3+, CD45+, cytCD3+) 
were reported as percentage of the total number of CD45+ (lymphocytic) cells. The 
expression level of the aforementioned markers on aberrant lymphocytes was compared 
to that of IELs with a normal immunophenotype within each individual and reported in 
percentage and/or mean fluorescent intensity (MFI) index. For all markers corresponding 
isotype controls were used. 
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PCR-based analysis of TCR-δ, TCR-γ and TCR-β gene rearrangements
TCR-δ, TCR-γ and TCR-β gene rearrangements were assessed by multiplex PCR as previously 
described and resulting PCR products were further evaluated by GeneScan analysis.24
 
Southern blot
Southern blot analysis of TCR-β and TCR-δ genes was performed according to earlier 
published protocols, using TCR- δJ1, TCR-βJ1 and TCR-βJ2 probes.25, 26 
Statistical analysis
Data were analysed in SPSS software (SPSS Inc. Chicago, Illinois, USA). Flow cytometric 
data were analysed with the non-parametric Mann-Whitney test to test for differences 
between aberrant lymphocytes and its normal counterpart. A p-value ≤0.05 was considered 
significant.
RESulTS
Flow cytometric analysis
An extensive panel of surface- and intracellularly expressed markers was evaluated by 
multiparameter flow cytometry. Overall, immunophenotyping of duodenal biopsies was 
performed during follow-up in 16 RCD II patients characterised by a median aberrant IEL 
percentage of 58.5% (range 21% - 97%; Table 1). All patients except one were treated with 
cladribine and three were subsequently treated with high dose chemotherapy followed 
by autologous haematopoietic stem-cell transplantation as previously described.27, 28 
In addition, six patients visited the department for follow-up more than once. In these 
patients, repetitive flow cytometric analysis showed almost identical results regarding the 
immunophenotype of aberrant and normal IELs (data not shown), indicating stability of the 
observed aberrant IEL phenotype. Table 2 shows an overview of all markers analysed and 
their respective expression by both aberrant and normal IELs. 
All IELs showed strong expression of CD45 and low to intermediate forward and sideward 
scatter, indicating a relatively homogeneous population of lymphocytic cells (Figure 1A). 
In keeping with the generally accepted aberrant IEL immunophenotype found in RCD II 
patients, this population expressed cytoplasmic CD3 but lacked expression of surface CD3 
(Figure 1B). In addition, these cells expressed CD7 (Figure 2A). Expression of the early 
T-cell development-associated markers terminal deoxynucleotide transferase (TdT), CD1a 
and CD34 was not detected (data not shown). Aberrant IELs did not show expression of 
CD5 (Figure 2B). Interestingly, 30% of the normal IEL population lacked CD5 expression, in 
contrast to the uniform expression of CD5 by peripheral T-cells. 
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Table 2  |  Immunophenotype of aberrant and normal IELs determined by flow cytometric 
analysis.
Aberrant T-cells
(median; range)
normal T-cells
(median; range)
Mann-
Whitney
Mann-
Whitney
   % MFI-index
n     % MFI-index   % MFI-index    p    p
CD45RA 10   55.5  (20-99) 4.5  (1.4-17.4) 45.0  (20-97) 4.2  (1.8-15.9)    NS    NS
Il-15R-alpha 14    3.2  (0.2-59.8) 1.0  (1-3.4)   9.6  (1.8-55.4) 1.3  (1-3.6)    0.056    NS
Ki-67 15    8.8  (3.4-44.7) 1.9  (1.3-5.6)   6.2  (2.8-23.2) 2.1  (1.1-6.1)    NS    NS
PCnA 11  17.6  (2-70) 1.9  (1-3.8) 49.9  (7.5-75.8) 2.8  (2-4.7)    0.047    0.007
nKG2D  8  34.0  (5-67.2) 2.4  (1.3-3.4) 29.2  (15-74.8) 2.6  (1.4-3.2)    NS    NS
HlA-DR  8  34.5  (7.2-82) 5.8  (2.4-16.6) 53.3  (15.5-76.5) 7.7  (5.2-30)    NS    NS
granzyme-B  8  78.7  (48.7-96) 8.2  (3.8-92.4) 38.7  (29-69.3) 6.1  (2.1-16.5)    0.03    NS
Abbreviation: NS, not significant.
Figure 1  |  Gating strategy to identify aberrant and normal IELs. Cells with a 
strong CD45 expression and low to intermediate forward and sideward scatter 
were selected (A), after which IELs expressing intracellular CD3 expression 
were used for further studies (B). 
Abbreviations: Ab IEL, aberrant IEL population (sCD3-, cytCD3+); NL IEL, normal IEL 
population (sCD3+, cytCD3+).
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Figure 2  |  Surface expression of CD7 (A), CD5 (B), HLA-DR 
(C) and IL-15R-alpha (D) on aberrant IELs and normal IELs 
derived from case 5, case 19, case 13 and case 5 (Table 1).
Significantly more aberrant lymphocytes than normal IELs expressed intracellular granzyme-B, 
illustrating a cytotoxic phenotype (p<0.05; Figure 3A-C; Table 2). No expression of CD30, 
or its ligand CD153 was observed on aberrant T-cells, thereby confirming the absence of 
an EATL.29 However, we did find expression of CD45RA on both normal and aberrant IELs, 
which is known to be associated with cytotoxic activity in antigen experienced T-cells. 
Furthermore, natural killer (NK) associated receptor NKG2D was similarly expressed on 
aberrant IELs as on normal IELs (Table 2). Moreover, no differences in expression of the 
T-cell activation marker HLA-DR and IL-15R-alpha were found on both cell types (Figure 2C 
and D; Table 2). 
Analysis of cell cycle activity of the intestinal IELs using nuclear staining of proliferating 
cell nuclear antigen (PCNA) revealed a significantly lower MFI expression in aberrant IELs 
compared to the immunophenotypically normal IELs (p<0.01; Figure 3G-I; Table 2). Even 
though only limited PCNA expression was observed in IELs, in all 11 patients tested PCNA 
levels were lower in the aberrant IEL population than in the normal IEL population. In 
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contrast, the expression of the proliferation marker Ki-67 was similar on both cell types 
(Figure 3D-F; Table 2). Both markers were tested simultaneously but no correlation between 
the two was observed. 
Figure 3  |  Intracellular expression of granzyme-B (B), Ki67(E) and PCNA (H) in aberrant 
IELs (Ab IEL) and normal IELs (NL IEL) derived from case 9, case 5 and case 13 (Table 1), 
with corresponding isotype controls (A, D and G). Depending on distribution, expression 
of granzyme-B (D) and Ki67 (F) was reported as percentage positive cells, while MFI was 
used to report PCNA expression which was correlated to the MFI of the isotype control (I). 
Aberrant populations revealed significant (p<0.05) higher granzyme-B expression (C) and 
significantly lower PCNA expression (p<0.01) as compared to normal IELs (I). 
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TCR rearrangement analysis
Detailed TCR rearrangement analysis was performed on duodenal biopsies of 18 well-
defined RCD II patients: 15 at time of diagnosis, two following cladribine therapy and one 
after cladribine with subsequent autologous stem-cell transplantation (au-SCT). The patient 
characteristics are shown in Table 1. 
Aberrant IEL populations in RCD II patients revealed a heterogeneous pattern of TCR 
rearrangements (Table 3). In one sample the DNA quality was probably inadequate (patient 1) 
as no amplification was found. The other cases could be subdivided into four groups. In 
the first group (patients 2-5) a polyclonal signal was detected. The second group (patients 
6-8) revealed a monoclonal TCR-δ and/or TCR-γ gene rearrangement. The majority of 
the patients was present in the third group (patients 9-15) and all contained monoclonal 
TCR-δ and/or TCR-γ as well as incomplete TCR-β gene rearrangements. The last group 
(patients 16-18) showed monoclonal TCR-δ and/or TCR-γ gene rearrangements, while a 
complete, monoclonal TCR-β gene rearrangement was observed as well. Remarkably, all 
three patients in the last group, but none in the other groups, developed an EATL. No 
correlation between the above described groups and expression of any of the phenotypical 
markers was observed. Furthermore, in two patients (6 and 12) no clonal TCR-γ gene 
rearrangements were found, whereas the TCR-β and TCR-δ gene rearrangements clearly 
revealed a monoclonal population. 
Table 3  |  Rearrangement analysis of the TCR-delta, gamma and beta chains in small 
intestinal biopsies.  
Patient TCR-delta TCR- gamma TCR-beta Interpretation
  1 No amplification
  2 NC
  3 NC
  4 NC
  5 NC
  6 C NC NC
  7 C C NC
  8 C C NC
  9 NC C NC V-J beta loss
10 NC C NC V-J beta loss
11 NC C NC V-J beta loss
12 C NC C V-J beta loss; TCR beta incomplete
13 C C C V-J beta loss; TCR beta incomplete
14 C C C V-J beta loss; TCR beta incomplete
15 NC C C V-J beta loss; TCR beta incomplete
16 NC C C Complete TCR beta
17 NC C C Complete TCR beta
18 C C C Complete TCR beta
Abbreviations: TCR, T-cell receptor; NC, no clonality; C, monoclonal.
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In addition, the presence of TCR gene rearrangements in RCD cell line P1, P2 and P3 was 
assessed with multiplex PCR analysis and Southern blot analysis. PCR-based analysis indicated 
that in RCD cell line P1 TCR-δ gene rearrangements were absent while rearrangement of the 
TCR-γ gene and TCR-β gene were, respectively, non-functional and incomplete (Table 4). 
Southern blot analysis of the TCR-δ gene and TCR-β gene rearrangements confirmed these 
data as bi-allelic loss of the TCR-δ gene and incomplete rearrangement of the TCR-β gene 
were found. Bi-allelic loss of the TCR-δ gene could point to rearrangement of both TCR-
alpha (TCR-α) alleles in RCD cell line P1. RCD cell line P2 displayed incomplete TCR-δ gene 
rearrangement, non-functional TCR-γ gene re- arrangement and no rearrangement of the 
TCR-β gene (Table 4) Southern blot analysis indicated that one allele of the TCR-δ gene was 
lost while rearrangement of the other was incomplete (data not shown). Furthermore, the 
TCR-β gene was in germline configuration indicating that no rearrangements of the TCR-β 
gene were made in RCD cell line P2 (data not shown). In contrast to RCD cell line P1 and P2, 
no TCR gene rearrangements were found with multiplex PCR for RCD cell line P3 (Table 4) 
and with Southern blot analysis of this cell line only germ line configuration of the TCR 
genes was found (data not shown). These data indicate that RCD cell lines can display a 
diverse phenotype regarding the TCR gene rearrangements, characterised by incomplete, 
non-functional or even total absence of TCR gene rearrangements (Table 4).
Table 4  |  Rearrangement analysis of the TCR-delta, gamma, and beta chains in three 
RCD II cell lines.
Cell line TCR-delta TCR-beta Interpretation
P1 NC C TCR-delta: D-J rearrangement
TCR-gamma: non-functional V
P2 C NC TCR-delta: incomplete
TCR-gamma: 1 out of frame, 1 non-functional V
P3 No rearrangements
CD4+, TCR- 
alphabeta+
NC C Rearrangements fitting with TCR alpha-beta phenotype
Abbreviations: TCR, T-cell receptor; NC, no clonality; C, monoclonal.
DISCuSSIOn
Although it is generally accepted that EATL in RCD II patients originates from a clonal 
expansion of aberrant T-lymphocytic population located in the small intestine that tends to 
disseminate to the blood and the entire gastro-intestinal epithelium30, it is unclear for what 
reason this has been observed in only half of the cases. Therefore, this study aimed to gain 
insight in the immunophenotypic characteristics and origin of aberrant IELs. 
In this study, flow cytometric analysis revealed an increased granzyme-B expression 
on aberrant IELs over its normal counterpart, indicating a differentiation towards a 
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
Aberrant IEL in RCD II  |  85
more cytotoxic phenotype, possibly in consequence of a continuous pro-inflammatory 
environment. In uncomplicated CD normal CD3+ IELs are thought to be reprogrammed 
into cytotoxic NK-like T-cells31, and data is emerging that aberrant IELs also differentiated 
towards a cytotoxic NK-like phenotype with up regulation of KIRS, granzyme-H and NKG2D 
(Tjon et al. manuscript in preparation). Due to their cytotoxic phenotype aberrant IELs 
may be involved in the gluten-independent destruction of enterocytes in RCD II. However, 
since aberrant IELs lack a TCR, a TCR-independent mechanism is required in this process. 
Recently, it was shown that aberrant IELs, in a subset of RCD II patients, can acquire the 
ability to lyse epithelial cells via DNAM-1.32 Nevertheless, a TCR independent mechanism 
is known to be involved in uncomplicated CD as well, since NKG2D expressed by cytotoxic 
T-lymphocytes is able to bind to its ligand MICA that is expressed on enterocytes, and 
subsequently induces apoptosis of these enterocytes.33, 34 Therefore, NKG2D expression on 
aberrant IELs was evaluated, which revealed a similar NKG2D expression on aberrant IELs 
compared to normal IELs. 
IL-15 has an anti-apoptotic effect on aberrant IELs and by doing so it plays an important 
role in the expansion of the aberrant IEL population.15 Given the observation that the IL-15 
threshold for IEL expansion in CD patients appears to be linked to an increased expression 
of IL-15R-alpha on these IELs, in combination with the report that a substantial number of 
EATL-cells expressed IL-15R-alpha, we compared IL-15R-alpha expression on aberrant and 
normal IELs, but did not find any difference in expression.35, 36 It must be noted that although 
IL-15R-alpha has the highest affinity for IL-15, recently it became clear that IL-15R-alpha 
is not necessary for IL-15 induction since most IL-15 transduction is directed by the beta/
gamma chain.37
In contrast to Malamut and colleagues15 who observed low Ki-67 expression in aberrant 
IELs, our flow cytometric analysis showed a substantial percentage of the aberrant IELs 
expressing intracellular Ki-67, yet comparable to that in normal IELs. This suggests that 
aberrant IELs do proliferate to a similar extent as normal IELs, and together with the 
anti-apoptotic effect of IL-15 specifically on aberrant IELs, may provide the aberrant IEL 
population with a survival benefit with subsequent expansion in the intestinal mucosa. 
Furthermore, our results revealed a significant decrease of PCNA expression in aberrant 
IELs, with a concomitant non-different Ki-67 expression. Ki-67 and PCNA are both considered 
proliferation markers, whereas the latter has been implicated in the process of DNA-
mismatch repair as well.38 Therefore, the decreased PCNA expression found in aberrant IELs 
compared to its normal counterpart is unlikely the result of a lower proliferation and might 
rather indicate an impaired DNA-mismatch repair system in these cells. These findings are 
in line with previously reported chromosomal damage in aberrant IELs, and may facilitate 
further transformation of aberrant IELs into EATL.39 Our findings might be influenced by 
previous treatment with cladribine, that was administered to all but one patient studied. 
Nonetheless, we recently reported that cladribine induces only a limited reduction of the 
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percentage of aberrant IEL in 40% of cases, while the majority still harbours a substantial 
aberrant IEL population after cladribine treatment.28 This suggests that cladribine exerts 
a similar effect on aberrant and normal IELs, and therefore we feel that the comparison 
of the phenotype of both cell types provides useful information regarding their respective 
characteristics.
Currently it remains unclear whether this aberrant population originates from 
dedifferentiating mature IELs, or that it regards a monoclonal expansion of a unique, 
physiological subpopulation.20, 21 In this study, a heterogeneous TCR gene rearrangement 
pattern in duodenal biopsies of a relatively large series of RCD II patients was observed, 
and confirmed in three RCD II cell lines. Based on TCR gene rearrangements four groups 
could be distinguished. First, a small group of RCD II patients showed no clonal TCR gene 
rearrangements indicating either a NK-cell origin, clonal T-cells in an early stage of their 
development prior to TCR rearrangements, or simply a polyclonal T-cell population. The 
second group contained clonal TCR-δ and TCR-γ gene rearrangements, but no TCR-β 
gene rearrangements, suggesting either a gamma-delta T-cell origin or a deranged early 
developing T-cell. The latter results were in agreement with findings by Cerf-Bensussan 
and colleagues18, who reported clonal TCRD-δ/TCR-γ gene rearrangements in several RCD II 
patients. The fourth group displayed complete, monoclonal TCR-β gene rearrangements. It 
must be noted however, that mature alpha-beta T-cells not only contain a complete beta 
chain, but subsequently also rearrange an alpha chain. TCR-α gene rearrangements were 
not determined in this study due to lack of RNA, so from these results it cannot be concluded 
that these monoclonal populations are derived from fully mature T-cells. Strikingly, all three 
patients in the fourth group developed an EATL in a later stage, possibly indicating that 
secondary EATL evolve from T-cells that have reached a certain stage of maturity. These 
findings are in agreement with the current WHO-classification which classifies EATL as a 
mature T-cell neoplasm.40 It could be hypothesised that these more mature cell populations 
are less responsive to currently available therapies.
Furthermore, the phenotype of RCD cell line P1 is closest to that of a mature T-cell as 
analysis of TCR gene rearrangements suggest functional rearrangement of the TCR-α gene 
but demonstrate incomplete rearrangement of the TCR-β gene. This is also in line with 
the previous report describing that replacement of the TCR-β chain restores TCR alpha-
beta expression in this cell line.23 RCD cell line P2 could represent an immature T-cell as 
TCR rearrangements were initiated in this cell line. The absence of TCR rearrangements 
in RCD cell line P3 could indicate that this cell line represents an even earlier stage in 
T-cell or NK cell development. Taken together, the TCR rearrangement analysis strongly 
suggests that the majority of the aberrant IEL populations in RCD II patients originates from 
a monoclonal expansion of immature T-cells, that deranged in their development before 
reaching full maturity. The latter finding is supported by the lack of expression of the 
early T-cell development-associated markers TdT, CD1-alpha and CD34 by aberrant IELs. 
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Furthermore, evolvement into an EATL was only observed in patients harbouring the most 
mature TCR rearrangement pattern. Although this patients series is small, this might be, 
at least in part, an explanation for the clinical observation that half of the RCD II patients 
eventually develops an EATL, but further research addressing the cause of this abnormal 
development is warranted. 
For daily clinical practise it is relevant that two RCD II patients with a phenotypically 
aberrant IEL population revealed clonal TCR-β or TCR-δ rearrangements however displayed 
polyclonal TCR-γ rearrangements. This can be explained by the fact that TCR-γ gene 
rearrangements are present in most, but not all alpha-beta T-cells.24 Moreover, these 
results confirmed our previous findings that clonality analysis of only the TCR-γ gene 
rearrangement, as often used in the workup of RCD, misses at risk monoclonal populations, 
and that phenotypical identification of an aberrant population is a superior predictor of EATL 
development.7 Therefore, TCR-β gene rearrangement analysis in addition to phenotypical 
identification of aberrant IELs could be useful to identify an at risk aberrant IEL population. 
Further prospective studies are needed.
In conclusion, this study showed that aberrant IELs originate from deranged developing 
precursor T-lymphocytes and display clear differentiation to a cytotoxic phenotype. Aberrant 
IEL populations between RCD II patients displayed different stages of maturity, of which only 
the patients harbouring the most mature aberrant IEL populations developed an EATL. 
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ABSTRACT
Approximately 2–5% of coeliac disease patients develops refractory coeliac disease (RCD), 
associated with the development of an aggressive enteropathy associated T-cell lymphoma 
(EATL). We report on immunophenotypic and genomic analysis of an exceptional case of 
type 1 EATL presenting as leukemic ascites. Our results, obtained by flow cytometry and 
karyotyping /comparative genomic hybridisation, indicate immunophenotypic and genomic 
aberrations previously reported for type 1 EATL. In addition, we found a substantial number 
of aberrations not reported so far and not included in the current WHO classification of 
lymphoid malignancies. The case described appears to represent an evolved form of type 
1 EATL. 
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InTRODuCTIOn
Approximately half (30-50%) of all extra-nodal non-Hodgkin lymphomas arises from the 
gastro-intestinal tract1 with more frequent localisation in the stomach compared to other 
intestinal sites.2 Among them, the fast majority originate from B-cells3, 4, whereas peripheral 
T-cell lymphomas (PTCL), although frequently manifested in the skin and upper airway, 
seldomly develop in the gastro-intestinal tract at initial presentation. Those PTCL that do 
primarily affect the digestive tract are most commonly located in the small intestine.3 PTCL 
associated with coeliac disease (CD) are classified as (type 1) enteropathy associated T-cell 
lymphoma (EATL) according to the current WHO classification.5 With an annual incidence 
rate of 0.5-1 per million people in the Western countries, this type of EATL accounts for less 
than 0.5% of all non-Hodgkin’s lymphomas and covers approximately 35% of all small bowel 
lymphomas.6
EATL is a highly aggressive pleiomorphic form of high-grade T-cell lymphoma that can 
involve all areas of the small intestine, stomach and colon, with a particular preference for 
the proximal jejunum.7, 8 Two thirds of EATL cases is initially limited to the gastro-intestinal 
tract and lymph nodes.6 Dissemination is seen in many organs, including liver, spleen and 
skin.6 Although ascites is commonly due to peritoneal metastasis, malignant lymphoma 
primarily presenting as ascites is very rare. Vakar-Lopez et al.9 described in a review on 
initial presentation of lymphomas in ascites only two cases of T-cell origin neither of which 
represented EATL.
EATL shows a striking association with adult-onset CD, of which 2–5% develops refractory 
coeliac disease (RCD).10, 11 In contrast to RCD type I, RCD type II is characterised by the 
presence of a population of aberrant intraepithelial T-lymphocytes (IELs) expressing 
cytoplasmic CD3 but lacking surface expression of CD3, CD4 and CD8.12-14 About half of 
the RCD type II patients develops EATL, most probably originating from aberrant IELs upon 
clonal expansion and malignant transformation.14, 15 EATL is more prevalent in males and has 
a peak incidence in the 7th decade in The Netherlands.7 Despite its rare occurrence EATL 
is one of the main causes of death in patients with RCD II, with 1-, 2- and 5-year overall 
survival rates of respectively 31-39%, 15-20% and 8-20%.15, 16 The poor prognosis is mainly 
due to incomplete response to currently available therapies, high rates of life-threatening 
complications such as perforation of the gut and poor nutritional conditions.17, 18
The immunophenotype of EATL plays an important role in its diagnostic work-up. EATL 
expresses CD3, CD7 and CD103, but lacks expression of CD4, CD5 and CD8 in the majority 
of cases. Furthermore, EATL usually exhibits a cytotoxic immunophenotype, characterised 
by expression of CD30 and the presence of cytotoxic granules recognised by the TIA-1 
antibody.2, 5, 19 
Current knowledge of EATL immunophenotype is almost exclusively based on 
immunohistochemistry. Although this technique has proven to be instrumental in the 
diagnostic work-up of EATL, it has limitations. In contrast to immunohistochemistry, flow 
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cytometric analysis allows simultaneous multiparameter immunophenotyping, analysis of 
expression levels and distinction between intra- and extracellular antigen expression. To 
the best of our knowledge, no extensive flow cytometric analysis of EATL cells primarily 
presenting as leukemic ascites has been performed to date. We report such analysis and show 
an immunophenotype that is in agreement with the known immunohistochemical features 
of EATL, expanded with antigens not previously analysed on EATL cells. Interestingly, we 
found several significant differences between the immunophenotype of EATL and aberrant 
intestinal T-cells associated with RCD type II. In addition, the leukemic presentation 
and resulting availability of single EATL cells provided the opportunity to perform both 
karyotype and array comparative genomic hybridisation (CGH) analysis in search of potential 
chromosomal abnormalities.
CASE HISTORY
A 62-year-old woman was diagnosed with CD by serology and small intestinal histology 
(Marsh IIIB) and subsequently treated with a gluten-free diet (GFD). Human Leukocyte 
Antigen typing showed a DQ2 heterozygous genotype. Seven months after diagnosis she was 
referred to our hospital with persisting diarrhoea, steatorrhoea, abdominal tenderness and 
distension, flatulence, regurgitation, night sweat, morning nausea and 10 kg of weight loss. 
Apart from CD, her medical history was unremarkable. Physical examination revealed a 
pale woman with a BMI of 23.5 kg/m2, no fever and she had a distended and slightly painful 
abdomen. Neither hepatomegaly nor lymphadenopathy was noted. Laboratory evaluation 
showed anaemia, elevated CRP, hypocalcaemia, hypomagnesaemia, hypoalbuminaemia and 
deficiency of zinc, folic acid, vitamin B12 and vitamin B6. Malnutrition was treated with 
total parenteral nutrition and all trace elements and vitamins were supplied. Nonetheless, 
the anaemia persisted and inflammatory markers, liver enzymes and lactate dehydrogenase 
further increased. Coeliac specific serology, including endomysial antibodies (IgA-EMA) 
and tissue transglutaminase antibodies (IgA-tTG), was still positive at the time of referral 
but substantially decreased in the following two months. A dietary inquiry performed by a 
skilled dietitian in CD showed strict adherence to the GFD. 
At time of referral duodenal biopsies were classified as Marsh IIIB lesions based on 
intraepithelial lymphocytosis, crypt hyperplasia and subtotal villous atrophy, however without 
signs of malignancy. Immunohistochemical staining of the duodenal biopsies suggested the 
presence of an immunophenotypically aberrant IEL population, expressing CD3 but lacking 
expression of CD8. In order to confirm the presence as well as the precise quantity of 
aberrant IELs, intestinal lymphocytes were isolated from duodenal biopsies and analysed by 
flow cytometry as previously described.13, 20 Within the IEL compartment, 66% of lymphoctes 
showed the aberrant immunophenotype CD3-, CD4-, CD8-, CD7+, cytoplasmicCD3+, 
indicating RCD type II associated aberrant IELs.13 In addition, 22% of lymphocytes within 
the lamina propria compartment (LPL) showed a similar aberrant immunophenotype. Based 
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on the presence of >20% aberrant IELs, her clinical condition and persisting villous atrophy 
for which no other cause could be identified, she was diagnosed with RCD type II. Other 
investigations included abdominal ultrasound, CT- and PET-scan, showing slight dilatation 
of the pancreatic and common bile duct, a few slightly enlarged mesenteric lymph nodes 
with a maximum of 13 mm in diameter, hepatomegaly and steatosis hepatis. Cladribine, a 
purine analogue inducing T-cell depletion, was subsequently given intravenously for five 
days aiming to eradicate the aberrant intestinal T-cells. 
After two months, no clinical and histological response was attained. Duodenal biopsies 
still showed subtotal villous atrophy in agreement with a Marsh IIIB lesion, however, no 
intraepithelial lymphocytosis was observed. In our experience the latter phenomenon 
is often observed upon cladribine treatment. In contrast to the persisting histological 
abnormalities, the relative percentage of aberrant IELs and LPLs decreased to 44% and 18%, 
respectively, after cladribine treatment. Subsequent CT-scan, video capsule endoscopy and 
MRI-enteroclysis showed abnormalities suspicious for lymphoma, including jejunal ulcers, 
multiple enlarged mesenterial lymph nodes, diffuse wall thickening of the jejunal-ileal 
border up to 12 mm, marked ascites and peritoneal lesions. Bone marrow analysis showed no 
abnormalities. Cytological analysis of the ascitic fluid showed many small to medium sized 
atypical lymphocytic cells most likely associated with lymphoma development. Importantly, 
an identical clonal TCR-γ gene rearrangement was found in the ascitic fluid derived cells as 
compared to duodenal biopsy derived lymphocytes, thereby supporting both the diagnosis 
EATL and the intestinal origin of this malignancy. Due to clinical deterioration no further 
treatment was possible and our patient deceased within three weeks after the diagnosis of 
this rare ascitic presentation of EATL.  
MATERIAlS AnD METHODS
Cytological analysis
Ascitic fluid was obtained by peritoneal puncture and cells from this fluid were obtained 
by centrifugation at 530 g. Cells were either analysed directly or stored in liquid nitrogen. 
The ascites supernatant was stored at -80°C. Cytospins were generated and stained with 
May-Grünwald-Giemsa staining solution (Merck, Darmstadt, Germany) using standard 
procedures. Immunocytochemistry was performed with peroxidase labelled monoclonal 
antibodies directed against CD3, CD4, CD5, CD8, CD15, CD20, CD30, CD45 and CD79a (Dako, 
Glostrup, Denmark), using standard procedures. 
Flow cytometric analysis
Multiparameter flow cytometric immunophenotyping was performed by staining cells for 
30 minutes on ice with fluorescein isothiocyanate (FITC), phycoerythrin (PE), peridinin 
chlorophyll protein (PerCP) and allophycocyanin (APC)-labelled monoclonal antibodies 
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directed against CD2, CD3, CD4, CD5, CD7, CD8, CD11a, CD14, CD16+56, CD18, CD19, CD25, 
CD30, CD45, CD45RA, CD45RO, CD54, CD69, CD95, CCR7, granzyme-B, HLA-DR, IL-2, IL-4, 
IL-10, IL-13, IFN-γ, Ki-67, NKG2D, PCNA, TCR-γδ (all from BD Biosciences, San Jose, 
California, USA), against CD52 (Serotec, Düsseldorf, Germany), against CD103 (IQ products, 
Groningen, The Netherlands) and against IL-15R-alpha (eBioscience, Hatfield, United 
Kingdom). Cytoplasmic staining of CD3, IL-2, IL-4, IL-10, IL-13 and IFN-γ was performed 
after cell permeabilisation by Cytofix/CytoPerm Plus (BD Biosciences), according to the 
manufacturer’s instructions. Intracellular cytokine staining was proceeded by a four hour 
stimulation of the ascitic cells with 1 µg/ml PMA (Sigma, Zwijndrecht, The Netherlands) 
and 1 µM ionomycin (Sigma), in the presence of GolgiStop (BD Bioscience, according to 
instructions). Nuclear staining of Ki-67 and PCNA was performed after cell permeabilisation 
by eBioscience Cell Fixation/Permeabilisation (eBioscience), according to the manufacturer’s 
instructions. Appropriate isotype controls were included. Stained cells were washed with 
PBS containing 0,1% bovine serum albumin (BSA, Sigma) and analysed on a standard four-
colour flowcytometer (FACSCalibur, BD Biosciences). The data were analysed using Cell 
quest software (BD Biosciences). Care was taken to analyse only viable cellular events based 
on light scatter properties. 
Enzyme linked immunosorbent assay (ElISA)
Levels of soluble CD25 (sCD25) were determined in the ascites supernatant using a commercial 
ELISA kit (Diaclone, Besancon, Cedex, France), according to the manufacturer’s instructions. 
Levels of cytokines IL-1β, IL-4, IL-6, IL-10, IL-13, TNF-α and IFN-γ were determined in the 
ascites supernatant using commercial ELISA kits (Pelikine-compactTM , Sanquin, Amsterdam, 
The Netherlands), according to the manufacturer’s instructions.
Karyotype analysis
Metaphase chromosome preparations were obtained from EATL cells derived from ascites. 
The cells were cultured in RPMI 1640 with 10% fetal calf serum (both from Lonza, Verviers, 
Belgium) and incubated for 24 and 48 hours at 37ºC. The cultures were synchronized using 
FdU (0.03 µg/ml, Sigma) for 22 hours and Thymidin (3.3 µg/ml, Sigma) for 5-6 hours. Before 
harvesting the cells were treated with colcemid (0.21µg/ml, Sigma) for the last 10 minutes. 
After a hypotonic treatment at 37ºC with KCL (0.075M, Merck) the cells were fixated three 
times with methanol/acetic acid (first step 1:9 and two times 1:3, Merck). Slide preparation 
was performed according to the conventional method. Chromosome analysis was performed 
on GTG-banded metaphases and 14 cells were analysed. 
Array comparative genomic hybridization (CGH ) 
DNA was isolated from fresh frozen ascitic EATL cells, using the QIAamp DNA mini kit (Qiagen, 
Leusden, The Netherlands) and QIAamp microkit (Qiagen). The sample contained at least 
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95% tumour cells. Labeling and hybridization procedures were performed according to 
Buffart et al.21 Briefly, 500 ng genomic DNA was labeled using a Genomic DNA Labeling kit and 
according to the manufacturer’s protocols (Enzo Life Sciences BVBA Zandhoven, Belgium). 
Cy3 label was used for the patient sample and Cy5 label was used for the reference which 
consisted of DNA isolated from blood obtained from 18 healthy females. Hybridizations 
were performed on custom designed Agilent Sure print arrays (Agilent Technologies, Palo 
Alto, California, USA) containing about 180.000 probes, designated 180K-CC. This design 
encompasses 169.793 probes distributed over the genome at 17kb intervals and is enriched 
with 4548 additional probes on 238 of the genes in the Cancer Census list22 in addition to 
standard control probes. The exact design is available in the Gene Expression Omnibus 
(GEO) platform GSE17715 http://www.ncbi.nlm.nih.gov/geo/. Images of the arrays were 
acquired using a micro array scanner G2505C (Agilent Technologies) at 2mm resolution and 
image analysis was performed using feature extraction software (version 10.1.1.1; Agilent 
Technologies). Aberrations were subsequently called used CGHcall.23 Raw and processed 
data are available under GEO accession number GSE17715 http://www.ncbi.nlm.nih.gov/
geo/.
RESulTS
Cytological analysis
Cytological analysis of the leukemic ascites showed lymforeticular cells with hyperchromatic 
nuclei, some of which were multinuclear and Reed-Sternberg-like (Figure 1A). 
Immunocytochemical staining of these cells showed expression of CD3, CD30 and CD45, in 
agreement with a mature malignancy of T-cell origin, including EATL (Figure 1B and 1C). No 
expression of the T-cell associated markers CD4, CD5 and CD8 was detected. Additionally, 
neither expression of the myeloid marker CD15, nor of the B-cell markers CD20 and CD79a 
was observed (data not shown). 
Figure 1  |  Morphology and immunohistochemical analysis of the ascitic fluid EATL cells.
(See page 214 for colour figure)
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Flow cytometric analysis
An extensive panel of surface and intracellularly expressed markers was evaluated by 
multiparameter flow cytometry. Table 1 shows an overview of all markers analysed and 
their respective expression by the ascitic cells, both EATL and normal lymphocytes. All 
cells in the ascitic fluid showed strong positive expression of CD45 and low to intermediate 
sideward scatter, indicating a relatively homogeneous population of lymphocytic cells 
(Figure 2A). Analysis of CD3 expression showed that approximately 95% of these cells had 
lost surface expression of CD3, but remained positive for cytoplasmic CD3, in agreement 
with the previously described immunophenotypically aberrant intestinal T-cells (Figure 2C). 
The remaining 6% of cells displays surface CD3 expression and represent phenotypically 
normal T-cells. In keeping with the generally accepted aberrant immunophenotype found 
in the intestinal T-cells in RCD patients, the aberrant ascitic fluid cells lacked surface CD4 
and CD8 expression in addition to CD3. Furthermore, CD5 expression was not detected, 
however is not expressed by aberrant intestinal T-cells either (unpublished results by 
MWJS and BMEvB). In contrast to aberrant intestinal T-cells, the 95% EATL cells had lost 
expression of CD2, CD7 (Figure 2B), CD52 and CD103 (Figure 2D), illustrating progression 
towards an “elevated level” of immunophenotypic aberrancy. Expression of the beta-2-
integrin adhesion molecule CD11a/CD18 (LFA-1) was also undetectable, whereas its ligand 
CD54 (ICAM-1) was still expressed. 
Consistent with the usual immunophenotype of EATL, expression of CD30 was readily 
observed on all ascitic EATL cells (Figure 2E). Interestingly, we observed a positive correlation 
between the CD30 expression level and sideward scatter, showing the highest CD30 expression 
on the cells with the highest cytoplasmic granularity and/or nuclear anomaly (not shown). 
In addition to CD30, granzyme-B is usually expressed by EATL, illustrating its cytotoxic 
phenotype. In contrast to the normal ascitic T-cells however, granzyme-B expression was 
not detected in the current EATL presentation. We did find expression of CD45RA on all 
cells, but not CD45RO, which is known to be associated with cytotoxic activity in (antigen 
experienced) T-cells. In agreement with the recognised role of IL-15 in the pathogenesis of 
RCD, and presumably in the development of EATL in RCD II patients, we found IL-15R-alpha 
expression on one-third of the EATL cells (Figure 2F). 
Analysis of cell cycle activity of the leukemic cells using nuclear staining of Ki-67 and 
proliferating cell nuclear antigen (PCNA) revealed the majority of these cells being positive 
(Figure 2G and H). The latter indicates highly active cell cycle progression and proliferative 
activity, consistent with the large amount of tumour cells present in the ascitic fluid.
Intracellular IFN-γ expression in PMA/ionomycin stimulated EATL cells was detected by 
flow cytometric analysis, be it in a small percentage (6,5%) of the cells. A quarter of the 
EATL cells showed intracellular IL-4 expression. Intracellular IL-2, IL-10 and IL-13 was not 
observed. In the supernatant of the leukemic ascitic fluid high levels of sCD25, IL-6, IL-10 
and IFN-γ, and intermediate levels of IL-13 were detected by ELISA, but not IL-1β, IL-4 and 
TNF-α (data not shown).
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Table 1  |  Immunophenotype of the ascitic fluid EATL and normal T-cells determined by 
flow cytometric analysis.
EATl-cells normal T-cells EATl- cells normal T- cells
(~94%) (~6%) (~94%) (~6%)
CD2 - + CD45RO - -
CD3 - + CD52 - +
cytCD3 + + CD54 + (99%) +
CD4 - + CD95 + (100%) -
CD5 - + CD103 - +
CD7 - + Il-15R-alpha + (30%) -
CD8 - + Ki-67 + (88%) -
CD11a - + PCnA + (70%) -
CD14 - - nKG2D - -
CD16 - - HlA-DR - +
CD18 - + granzyme-B - +
CD19 - - Il-2 - NA
CD25 + (40%)1 - Il-4 + (25%) NA
CD30 + (90%) - Il-10 - NA
CD45 + + Il-13 - NA
CD45RA + (90%) + IFN-γ +/- (6.5%) NA
Abbreviation: NA, not analysed.
1 Percentages indicate the relative fraction of the ascitic EATL cells. 
Genomic analysis
Chromosome analysis of the ascitic fluid cells revealed the following karyotype: 46-48, -X, 
add(X)(q2?6), +1, i(1)(q10), der(1;15)(p10;q10), 3, add(3)(q2?7), del(3)(q21), add(4)(q2?1), 
del(6)(q13q21), qdp(7)(q22q32), add(9)(p24), del(10)(p11.2), -11, ?ins(11)(q13q13q14), -13, 
del(13)(q14q21), -15, -17, add(18)(q23), 3-4 mar[cp14]. 
Because of its complexity, this karyotype is reported as a composite karyotype [cp], 
which means that all clonal abnormalities are mentioned in the karyotype, but not all 
abnormalities are present in all cells. Subsequently, these multiple genetic aberrations 
were analysed in more detail by a high resolution (180 K) array CGH. In agreement with the 
karyotype described above, multiple chromosomal gains and losses with sizes up to 37 Mb 
were identified by array CGH (Figure 3; Table 2). The major corresponding results included 
a loss of chromosome X, a gain of chromosome 1q, a gain and a loss within chromosome 3, 
an additional part to chromosome 9 and a deletion of part of chromosome 13. In contrast, 
the karyotype showed trisomy of chromosome 6, a deletion of chromosome 10, insertion in 
chromosome 11 and an additional part to chromosomes 4 and 7 whereas the array CGH did 
not show these aberrations. 
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Figure 2  |  Flow cytometric analysis of the ascitic fluid cells. 
Almost all cells express CD45 (A). About 6% has a normal immunophenotype expressing CD3, 
CD7 (B) and CD103 (D) and 94% an aberrant immunophenotype lacking CD3, CD7 (B) and 
CD103 (D) but expressing cytCD3 (C), CD30 (E), IL-15R-alpha (F), Ki-67 (G) and PCNA (H).
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In this case, an array CGH of non-tumour cells of our patient for DNA matching could not be 
performed due to lack of blood samples. Therefore all identified regions of chromosomal 
alteration were compared to well-known naturally occurring copy number variants (CNV) 
in the human genome described in the reference database of genomic variants [available 
at: http://projects.tcag.ca/cgi-bin/variation/gbrowse/hg18/]. Consequently, regions of 
alteration were excluded when identical to a known CNV currently present in this genome 
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database. In total, 43 CNV were ruled out, 37 losses with a mean size of 0,18Mb (range 0,01-
1,35) and 16 gains with a mean size of 0,125 (range 0,01-0,76). 
As described for EATL in the current WHO classification of tumours of haematopoietic 
and lymphoid tissues5, our results did show a gain of the 9q (9q31.3-q34.3) chromosome 
region, but not a loss of 16q12.1, which both are described to be important in the 
oncogenesis of EATL. The MYC oncogene locus at 8q24 showed a gain, as reported for almost 
30% of CD associated (type 1) EATL. Although reported for 80% of type 1 EATL, a gain of the 
5q34-q35.2 region was not found. In keeping with the majority of type 1 EATL, a 1q gain 
was detected at region 1q32.1-q41 in the leukemic cells. As compared to other previously 
reported chromosomal aberrations of EATL cells, our case shows both similarities as well 
as discrepancies. Whereas some chromosomal regions were amplified in our case as well 
(gains of 1q23.1-q23.3, 1q23.3-q31.2, 7q21.3-31.1) other aberrations described by De 
Leeuw et al.24 were not detected. Interestingly, a substantial number of novel chromosomal 
aberrations were identified in the current case, as listed in Table 2. In Table 2, only the 
chromosomal gains and losses larger than 1Mb are shown. All data are available under GEO 
accession number GSE17715 at http://www.ncbi.nlm.nih.gov/geo/.
Figure 3  |  Array CGH of the ascitic fluid EATL cells showing multiple 
chromosomal gains and losses.   
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Table 2  |  Chromosomal gains and losses (>1 Mb) of the ascitic fluid EATL cells detected by 
array CGH.
Chromosome     Start      End Clones Gain Loss Cytoband Size (Mb)
1 114177461 119445721 327 Loss 1p13.2-p12 5.27
1 187482775 188627699 66 Gain 1q31.1-q31.2 1.14
1 239527839 241285152 113 Gain 1q44 1.76
1 153299745 155287847 167 Gain 1q22-q23.1 1.99
1 242308966 246659020 278 Gain 1q44 4.35
1 155591301 160148729 315 Gain 1q23.1-q23.3 4.56
1 7133719 15251130 358 Gain 1p36.23-p36.21 8.12
1 142684203 153211435 556 Gain 1q21.1-1q22 10.53
1 188817376 200074269 673 Gain 1q31.2-q32.1 11.26
1 160659687 187034587 1702 Gain 1q23.3-q31.1 26.37
1 200265176 237873835 2269 Gain 1q32.1-q43 37.61
3 153615576 169368050 952 Loss 3q25.2-q26.2 15.75
3 189514724 192067160 209 Gain 3q28 2.55
3 186142831 189471639 228 Gain 3q27.2-q27.3 3.33
3 169954218 180811404 796 Gain 3q26.2-q26.33 10.86
4 118768823 123758682 305 Loss 4q26-q27 4.99
4 80274266 85861549 333 Loss 4q21.21-q21.23 5.59
5 10839633 11998259 69 Loss 5p15.2 1.16
6 94237970 103827105 557 Loss 6q16.1-q16.3 9.59
6 103873584 115825594 713 Loss 6q16.3-q22.1 11.95
7 97406212 112063267 922 Gain 7q21.3-q31.1 14.66
7 76442283 97338051 1354 Gain 7q11.23-q21.3 20.90
8 137147912 146272353 578 Gain 8q24.23-q24.3 9.12
9 36679951 38526827 150 Gain 9p13.2 1.85
9 33809009 36522241 183 Gain 9p13.3-p13.2 2.71
9 194193 2952674 169 Gain 9p24.3-p24.2 2.76
9 89578197 94690454 326 Gain 9q22.2-q22.32 5.11
9 3173242 33767785 1903 Gain 9p24.2-p13.3 30.59
9 109307305 140241876 2057 Gain 9q31.3-q34.3 30.93
10 32785560 34728920 115 Loss 10p11.21-p22 1.94
10 30748387 32748105 120 Loss 10p11.22-p23 2.00
10 22035743 30660372 538 Loss 10p12.31-p11.23 8.62
11 68093207 69711909 97 Loss 11q13.2-q13.3 1.62
11 69730962 70937887 77 Gain 11q13.3-q13.4 1.21
11 71304306 90873318 1234 Gain 11q13.4-q14.3 19.57
13 47707348 63242326 971 Loss 13q14.2-q21.31 15.53
15 41985456 43037392 69 Loss 15q15.3-q21.1 1.05
19 35592894 36890614 75 Gain 19q12 1.30
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DISCuSSIOn
Classical type 1 EATL is a non-Hodgkin T-cell lymphoma of the gastro-intestinal tract and, in 
contrast to the monomorphic type 2 EATL, strongly associated with CD.5 In spite of its low 
prevalence, EATL is one of the main causes of death in patients with long-lasting untreated CD 
or RCD, due to its aggressive nature and unresponsiveness to currently available therapies.15, 18 
Therefore it is of utmost importance to gain more insight into the pathogenesis of RCD and 
EATL in order to develop new therapeutic options. We report on an evolved type 1 EATL with 
an exceptional presentation as leukemic ascites, and on the unique opportunity to perform 
an in depth flow cytometric analysis of the immunophenotype and analysis of genomic 
alterations of these cells.
In agreement with the highly aggressive nature of EATL, our patient showed a very 
prompt deterioration of her clinical course and subsequently died within a few weeks. 
Although coeliac serology was still positive, yet decreasing on a GFD for seven months, she 
was already diagnosed with and treated for RCD. This phenomenon is seen in a minority of 
RCD patients.25 In addition, clonal expansion of intestinal aberrant IELs, which is causative 
for EATL, was readily detected. Importantly, an identical clonal TCR-γ gene rearrangement 
was detected in the ascitic fluid cells as compared to the duodenal biopsies, proving the 
intestinal origin of this apparently evolved type 1 EATL.
Flow cytometric analysis showed that the immunophenotype of this EATL is substantially 
different from the corresponding aberrant T-lymphocytes in the small intestine, most 
probably as a consequence of further transformation. Whereas aberrant IELs found in RCD 
patients have lost some but not all (intestinal) T-cell lineage associated markers and generally 
still do express CD2, CD7, CD52 and CD103,2, 5, 19 these markers could not be detected on the 
leukemic ascitic fluid derived EATL cells. Importantly, lack of CD7 and CD103 expression on 
EATL has not been reported so far and is not included in the current WHO classification of 
haematological malignancies.5 Absence of CD103, an αEβ7 integrin contributing to tissue-
specific retention of lymphocytes within the intestinal epithelial layer by binding its ligand 
E-cadherin expressed on all epithelial cells26, may have contributed to migration of EATL 
cells away from the gastro-intestinal tract. The lack of LFA-1 expression observed on the 
same EATL may play a role in this as well. Although gastro-intestinal localisation of EATL 
has not been confirmed by histological examination in this case, MRI-enteroclysis did show 
diffuse wall thickening of the jejunal-ileal border, suggesting infiltration of tumour cells 
into the intestinal wall towards the peritoneum. 
In contrast to most EATL cases exhibiting a cytotoxic immunophenotype5, 19 the current 
EATL presentation showed absence of granzyme-B expression. Yet, the observed expression 
of CD45RA is associated with cytolytic effector cell activity.27 The lack of CD45RO positive 
EATL cells is in contrast to other studies which showed that EATL often expresses this T-cell 
memory associated surface marker.28, 29 The EATL cells showed extensive proliferative activity 
indicated by high expression levels of Ki-67 and PCNA. Similar to CD30 expression30, 31, 
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high proliferative activity of EATL cells is supposed to be an adverse prognostic factor32 
which is in agreement with the clinical outcome of our patient.
The high levels of IL-2R-alpha (sCD25) and cytokines IL-4, IL-10, IL-13 and IFN-γ detected 
in the supernatant of the leukemic ascites indicate local T-lymphocyte activation. Since 
only IL-4 and IFN-γ expression was detected in the EATL cells themselves, other cytokines 
detected may have been produced by the reactive normal T-cells shown to be present in 
the ascites as well. Indeed, the latter population showed clear expression of the T-cell 
activation marker HLA-DR, not expressed by the EATL cells. Expression of CD25 was 
detected on EATL cells, in agreement with previous work indicating that sCD25 is a sensitive 
marker for tumour burden in some lymphomas.33 Illustrative for the local pro-inflammatory 
environment, IL-6 was clearly detected in the ascites, explaining the B-symptoms fever and 
night sweats in our patient. 
Over expression of IL-15 by enterocytes and resulting up regulation of natural killer (NK) 
associated receptor NKG2D by IELs are both assumed to be involved in the pathogenesis of 
(R)CD.34, 35 Since IL-15 promotes the clonal expansion and activation of IELs36, it may even 
have the potential to induce further transformation of aberrant IELs towards EATL upon 
continued over expression. Our results show that approximately one-third of the ascitic EATL 
cells expressed the IL-15R-alpha, which indeed suggests a role for IL-15 in the pathogenesis 
of the current EATL. Interestingly, up regulation of NKG2D expression was not detected. 
The cytogenetic analysis identified multiple chromosomal alterations not included in the 
current WHO classification, which might be a contributing factor to the observed extensively 
aberrant immunophenotype of this EATL and its exceptional clinical presentation as leukemic 
ascites. It should be pointed out that the use in this study of the currently most sensitive, 
180 K, array CGH may contribute to the many chromosomal aberrations found. Limited 
studies about the karyotype of aberrant IELs in RCD patients suggested a partial trisomy 
of the long arm of chromosome 1 as an early marker of EATL transformation and a gain in 
chromosome 9q as a late event in such a malignant transformation.37 In agreement with this, 
we also observed a gain in the 9q region as well as a trisomy of chromosome 1. De Leeuw et 
al.24 postulated a stepwise genetic model for the whole spectrum of CD including a 9q gain or 
a 16q loss responsible for inducing transition from RCD into EATL, and gains of 1q/5q and 8q 
distinguishing between most cases of type 1 and 2 EATL, respectively. The aforementioned 
genomic alterations are included in the current WHO classification.5 We found both 1q and 8q 
gains, suggesting an increased level of chromosomal instability. Interestingly, the observed 
lower expression of PCNA as compared to Ki-67 appears to be in agreement with the latter, 
since PCNA is a known factor involved in DNA repair.38 The described immunophenotypical 
aberrations of the current EATL cells do not fully correspond to the observed chromosomal 
gains and losses, except for the lack of CD2 expression corresponding to loss of chromosome 
1p12-1p13.2 and the high expression of CD30 in line with a gain of 1p36.21-23. Although 
CD7 was not expressed on the EATL cells, a gain of chromosome 7q25.5, harbouring the CD7 
gene, was found (http://www.ncbi.nlm.nih.gov). 
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We report on a unique type 1 EATL case, primarily presenting as ascites and displaying a 
significantly elevated level of immunophenotypic and genomic aberrancy as compared to the 
current WHO classification. The combined abundant absence of T-cell lineage-, activation- 
and cytotoxicity-associated markers, high proliferative capacity, as well as substantial level 
of chromosomal instability of the current EATL may explain the clinical behaviour of this 
apparently evolved malignancy. Further insight into the mechanisms responsible for the 
development of these characteristics may be further elucidated in future research and will 
contribute to a better understanding of the pathogenesis of EATL and may aid in predicting 
its prognosis. In addition, functional and expression profiling could be supportive in the 
search for new, more sensitive markers to predict the EATL occurrence in an early stage, in 
order to improve prognosis and development of new treatment approaches.
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ABSTRACT
Objectives: To assess the safety and efficacy of AN-PEP to mitigate the immunogenic effects 
of gluten in coeliac patients. Aspergillus niger prolyl endoprotease (AN-PEP) effectively 
degrades gluten in vitro. 
Methods: In a randomised double-blind placebo-controlled pilot-study, 16 patients consumed 
toast (~7 g/d gluten) with AN-PEP for two weeks (safety phase). After a two-week washout 
period, 14 patients were randomised to gluten intake with either AN-PEP or placebo 
for two weeks. Measurements included complaints, quality-of-life, serum antibodies, 
immunophenotyping of T-cells and duodenal mucosa immunohistology (primary endpoint).
Results: During the safety phase, 14 patients remained stable on gluten and subsequently 
completed the efficacy phase. Only minor deteriorations from baseline were observed for 
all parameters in both AN-PEP and placebo group. However, small intestinal IgA-tTG deposits 
were observed slightly more frequent in the placebo group compared to AN-PEP. 
Conclusion: Administration of AN-PEP appears to be safe and well tolerated in coeliac 
patients. However, the primary endpoint was not achieved due to lack of clinical deterioration 
on gluten in the placebo group, impeding the identification of a possible effect of AN-PEP. 
Further studies with longer gluten challenge are warranted to support the potential of AN-
PEP in degrading gluten and reducing the patient’s burden of disease.  
The trial protocol has been registered in the Dutch Trial register (NTR1281) and the FDA 
Clinical Trial register (NCT00810654). 
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InTRODuCTIOn
Coeliac disease (CD) is a major health care issue affecting people of all ages, with a 
worldwide prevalence of approximately 1%.1 This immune-mediated small intestinal 
enteropathy is triggered by gluten proteins derived from wheat, barley and rye. CD is 
characterised by an inflammatory immune response, resulting in small intestinal mucosal 
injury and malabsorption in genetically susceptible individuals.2 Currently, the only safe and 
effective treatment is a strict gluten-free diet (GFD) combined with nutritional support, 
which improves the health and quality of life in the vast majority of patients.3 However, a 
GFD is perceived as a substantial burden, particularly due to high costs, dietary restriction, 
reduced social activity, and increasing health worries.4 
Gluten proteins are highly abundant in proline (15%) and glutamine (35%) residues, 
particularly in those regions identified as immunogenic in CD.5 The proline- and glutamine-
rich peptides in gluten are relatively resistant to proteolysis by gastric, pancreatic and 
intestinal enzymes.6, 7 Consequently, digestion-resistant proline- and glutamine-rich 
peptides can reach the intestinal epithelium intact and can trigger an immune response 
that eventually results in mucosal damage. To eliminate such proline-rich gluten peptides, 
prolyl oligopeptidases, enzymes that can cleave after a proline residue in peptides, have 
been investigated by Shan and colleagues.6 Such enzymes, derived from bacteria like 
Flavobacterium meningoseptum, Shingomonas capsulate and Myxococcus xanthus, were 
capable of breaking down toxic gluten in vitro.6, 8, 9 However these prolyl oligopeptidases 
are not stable and functional under acidic conditions of the stomach9, 10 and are unlikely to 
degrade gluten epitopes before they reach the small intestine. Alternative enzymes that 
can break down gluten are derived from germinating barley and the fungus Aspergillus 
niger. From the latter a prolyl endoprotease termed AN-PEP (Aspergillus niger-derived 
prolyl endoprotease) is derived which has distinct advantages over the bacterial prolyl 
oligopeptidase as it degrades both whole gluten and gluten peptides into non-immunogenic 
residues within minutes.11, 12 Moreover, the enzyme is active between pH 2 and pH 8, with 
an optimum activity at pH 4-5, and is therefore effective at the pH levels present in the 
stomach and beyond.11, 13 Importantly, the enzyme is not degraded by pepsin in the stomach 
and thus remains fully functional. Mitea et al.12 extended these findings by showing that AN-
PEP degraded toxic gluten proteins in a food matrix into non-immunogenic gluten fragments 
in an in vitro digestion model that mimics the human gastrointestinal tract.12 After these 
promising in vitro results, it remains to be established whether AN-PEP can reduce the 
clinical response to gluten in CD patients. The aim of this two-phase proof of concept-study 
was to demonstrate the safety of AN-PEP in the first phase and the ability of AN-PEP to 
reduce the clinical response to gluten consumption by CD patients in the second phase of 
the study. This information will be important to further develop AN-PEP as a future digestive 
aid for unintentional ingestion of gluten by CD patients. 
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MATERIAlS AnD METHODS
Patients
Sixteen adults with CD were recruited at the outpatient clinic of the department of 
Gastroenterology and Hepatology of the VU Medical Centre Amsterdam, The Netherlands. 
Inclusion criteria were an initial diagnosis of CD as confirmed by histological abnormalities on 
duodenal biopsies classified as a Marsh IIIB or IIIC lesion and supported by positive serology; 
endomysium IgA antibodies (IgA-EMA) and/or tissue transglutaminase IgA antibodies (IgA-
tTG). Patients were required to have well-controlled CD as evidenced by Marsh 0 or I, and 
normalised IgA-EMA and IgA-tTG on a strict GFD for at least one year. Women at fertile 
age were required to take adequate contraception measures. Reasons for exclusion were: 
use of any anticoagulant or immunoregulatory drug within the last six months; clinically 
suspected bleeding tendency; pregnancy or breast feeding; presence of any concurrent 
active infection; and IgA-deficiency. 
The study was approved by the Medical Ethics Committee of the VU Medical Centre 
and conducted in accordance with the guidelines of the Declaration of Helsinki. The 
trial has been registered in the Dutch Trial register (NTR1281) and the FDA Clinical Trial 
register (NCT00810654). A written informed consent was obtained from each patient before 
enrolment.
Design and intervention
The intervention was performed between May 2008 and April 2009. The intervention 
consisted of two periods, each lasting two weeks (Figure 1). The first study phase was an 
open-label period designed to assess the safety of high gluten intake with AN-PEP (safety 
phase). The second phase was a randomised, double-blind, placebo-controlled parallel-
group study to assess the effect of AN-PEP on gluten-induced clinical response (efficacy 
phase). Sixteen patients with diagnosed CD were enrolled in the safety phase. Patients 
were asked to consume five pieces of toast (in total ~7 g gluten, Bolletje®, The Netherlands) 
with AN-PEP-containing topping daily in the morning for two weeks. Patients were allowed 
to consume a glass of water (250 mL) with their toast. They were asked to continue their 
usual GFD. For ethical reasons, patients deteriorating ≥2 scales on the histological Marsh 
classification during this safety phase were not included in the efficacy phase. Between 
the study phases, a two-week washout period was introduced in which patients continued 
their usual GFD. Subsequently, 14 patients were randomised in a 1:1 ratio in blocks of 
four in a double-blind fashion to the same amount of toast with AN-PEP-containing topping 
(n=7) or placebo topping (n=7) for two weeks while remaining on their usual GFD. Patients’ 
compliance with the product intake was checked by regular telephone contact.
Before and during the study phases, the patients visited the outpatient clinic five times 
(Figure 1). During the safety phase, blood was collected one week before (baseline), and 
one and two weeks after start of gluten with AN-PEP consumption. During the efficacy phase, 
blood was collected at one and two weeks after start of gluten with AN-PEP or placebo 
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consumption. Duodenal biopsies were taken at baseline and at the end of the safety phase 
and the end of the efficacy phase. Both in the safety and efficacy phase, participants were 
asked to complete a coeliac disease-specific health-related quality of life questionnaire for 
adults14 at baseline and after two weeks of intervention. Biopsies and blood sampled at the 
end of the safety phase were used as baseline values to limit the burden for the patients. 
Figure 1  |  Study design and flow chart.
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In the safety phase, 16 coeliac patients daily consumed five pieces of toast with AN-PEP for 
two weeks while continuing their GFD. Two patients deteriorated on Marsh grades and were 
excluded. After a 2-week wash-out period with their usual GFD, the remainder of 14 patients 
were randomised to the efficacy phase to receive two weeks of toast with either AN-PEP or 
placebo while continuing their GFD.
An-PEP enzyme
The AN-PEP and placebo topping were prepared by DSM Food Specialties, Delft, The 
Netherlands. Both toppings (18.5 g) contained 8.2 wt% sucrose, 8.2 wt% saccharine solution 
(400 mg/L saccharine plus 4000 mg/L cyclamate), 0.4 wt% citric acid (Jungbunzlauer, Basel, 
Switzerland), 0.08 wt% potassium sorbate (Interland Chemie, Oosterhout, The Netherlands), 
0.31 wt% sodium benzoate (Prolabo, Leuven, Belgium), and 1.23 wt% xanthane gum Keltrol 
RD (CP Kelcko, Nijmegen, The Netherlands). The AN-PEP topping contained 81.5 wt% AN-PEP 
enzyme concentrate corresponding with 168 Proline Protease Units of enzyme activity. The 
placebo topping contained 81.5 wt% distilled water with 0.06 wt% Plantex® MDA31 (colouring 
agent, DSM Food Specialties, Delft, The Netherlands) to match for colour differences. The 
aroma, flavour and consistency of the topping with AN-PEP were identical to those with 
placebo and both toppings could not be distinguished. Microbial counts and enzyme activity 
of the AN-PEP and placebo toppings were analysed monthly. All microbial counts remained 
below 10 CFU/g and the activity of the enzyme was maintained at 9.1±0.3 PPU/g topping 
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during 12 months shelf life at 4°C. The AN-PEP and placebo toppings were identical in taste 
and appearance. They were pre-packed in containers (14 per box) by DSM and consecutively 
numbered for each patient according to the randomisation schedule (prepared by the DSM 
statistician). 
Blinding
Each patient was assigned a random order number and received from the physician the 
containers in the corresponding non-transparent pre-packed box. The allocation sequence 
was concealed from the researcher enrolling and assessing participants in sequentially 
numbered sealed non-transparent envelopes. Envelopes were opened only after completion 
of the trial and assessments. All patients, investigators, care providers, and staff assessing 
outcomes were kept blind to treatment assignment. 
Measurements
Mucosal biopsy immunohistology and immunophenotyping of lymphocytes, and serum 
antibodies were measured in the service laboratories of the VU University Medical Centre 
Amsterdam, The Netherlands. Mucosal biopsy gluten-specific T-cell lines were measured in 
the research laboratory of the Leiden University Medical Centre Leiden, The Netherlands. 
Mucosal biopsy IgA-tTG deposits were analysed at the University of Debrecen, Hungary.
Adverse event reporting
Tolerability of the gluten intake with AN-PEP or placebo was assessed by adverse event 
reporting to the physician during visits. All complaints were documented throughout the 
study. The study design did not allow for differentiation between complaints resulting from 
gluten or treatment. A difference in complaints between the AN-PEP and placebo group 
during the efficacy phase may give an indication of treatment-related effects. 
Coeliac disease quality of life
All participants were asked to complete at home the CD quality of life questionnaire, 
which was translated into Dutch. The CD quality of life questionnaire included four disease-
specific and health-related categories (emotional problems, social problems, disease-
related worries, and gastro-intestinal symptoms) with seven items each. Each question was 
weighed on a scale of 1-7 points, a high score corresponding to a high level of well-being. In 
total 196 points could be obtained, with a maximum of 49 points for each separate category. 
A change of 12 or more points on the total score or of 3 or more on the different categories 
was considered a clinically relevant change.14 
Mucosal biopsy immunohistology
Twelve duodenal mucosal spike biopsies were taken through upper gastro-intestinal 
endoscopy. Four paraffin-embedded biopsies were sectioned and hematoxylin-eosin-stained 
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for histological evaluation according to the modified Marsh classification.15 At least two 
grades increase in the Marsh scale was considered a clinically significant deterioration. Six 
fresh biopsies were used for flow cytometric analysis and two were snap frozen in liquid 
nitrogen and stored. 
Mucosal biopsy immunophenotyping of lymphocytes
Multiparameter flow cytometric immunophenotyping of mucosal intraepithelial and lamina 
propria lymphocytes was performed. These lymphocytes were isolated from six duodenal 
biopsy specimens per time point through chemical and enzymatic dissociation.16 The cells 
were stained with fluorescein isothiocyanate (FITC), phycoerythrin (PE), peridinin chlorophyll 
protein (PerCP) and allophycocyanin (APC)-labelled monoclonal antibodies directed against 
CD3, CD4, CD8, CD16/56, CD19, CD45, CD45RA, HLA-DR, NKG2D, CD25 and TCR- γδ (all 
from BD Biosciences, San Jose, California, USA), and appropriate isotype controls were 
included. Stained cells were analysed on a 4-colour flow cytometer (FACSCaliburTM, BD 
Biosciences) and the data were analysed using CellquestTM software (Becton Dickinson, San 
Jose, California, USA). Care was taken to analyse only viable cellular events based on light 
scatter properties. The mean fluorescence intensity index as compared to isotype controls 
was calculated for the markers included.
Mucosal biopsy gluten-specific T-cell lines
Gut-resident, gluten-reactive T-cells are a hallmark of CD. To demonstrate that all patients 
possessed such cells polyclonal T-cell lines were generated from small intestinal biopsies 
as described.17 The resulting T-cell lines were tested for reactivity against a pepsin/trypsin 
digest of gluten and a pepsin/trypsin digest of gluten that had been treated with tissue 
tranglutaminase in a T-cell proliferation assay as described.17 In all patients gluten reactivity 
could be demonstrated (not shown). 
Mucosal biopsy IgA-tTG deposits 
Biopsies at the end of the randomisation study phase were stained for tTG-related 
extracellular IgA deposits and, in case of positivity, baseline biopsies were stained as 
well. Twelve unfixed, 5 μm-thick frozen sections were examined per patient by double 
immunofluorescent labelling of IgA (green) and tTG (red) as previously described.18 IgA is 
normally detected only inside plasma cells and at the luminal surface, whereas in active CD, 
subepithelial deposits composed of IgA-tTG are found along the surface and crypt basement 
membranes and around mucosal vessels, corresponding to the intestinal localisation of tTG. 
The CD-type IgA deposits were graded from 0 to 3 according to their intensity along the 
basement membranes in the villous-crypt area. As this study of the small intestinal IgA-tTG 
deposits is highly subjective, it was performed by an independent specialist in this field in 
a blind manner to greatly increase its accuracy.
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Serum antibodies
Blood samples were collected by venapuncture to analyse CD associated antibodies. 
Levels of IgA-tTG, gliadin IgA antibodies (IgA-AG) and gliadin IgG antibodies (IgG-AG) 
were determined with a standard in-house enzyme-linked immunosorbent assay (ELISA), 
using recombinant human tissue transglutaminase (Diarect AG, Freiburg, Germany) and 
gliadin extract (Sigma-Aldrich, Zwijndrecht, The Netherlands) as substrates, respectively. 
IgA-EMA antibodies were determined by an in-house indirect immunofluorescence test 
according to Lerner using monkey oesophagus as substrate.19 IgA-deficiency was excluded 
to avoid false-negative serology. In addition, in retrospect a combined test for IgA and 
IgG antibodies directed against human tissue transglutaminase and deamidated gliadin-
derived peptides (IgA/G-DGP-tTG; tTG/DGP Screen ELISA, INOVA Diagnostics, San Diego, 
USA) was performed.20 References values for antibodies were categorised into negative, 
dubious, weak positive, positive, and strong positive. References values for antibodies were 
categorised into negative, dubious, weak positive, positive, and strong positive. Reference 
ranges for IgA-AG were <2.4, 2.5-3.9, 4.0-20, 20-80, and >81 U/mL, for IgG-AG, <11, 12-20, 
21-40, 41-100 U/mL, for IgA-tTG, <2.9, 3.0-5.9, 6.0-20, 21-50, >51 U/mL, and for IgA/G-DGP 
<6.9, 7.0-10.9, 11-30, 31-100 and >100 U/ml, respectively.
Statistical analysis
Data were analysed by OCS Biometric Support (Leiden, The Netherlands). Difference from 
baseline in mucosal immunohistology between the two groups after two weeks as measured 
by Marsh classification was considered the primary outcome measure. All other parameters 
were considered secondary endpoints. Power analysis revealed that for the detection of a 
two-grade difference in the Marsh score with a power of 0.80 and a one-sided a level of 
0.05, 14 patients were needed to finalise the study. Data were analysed in the SAS version 
9.1, using both parametric and non-parametric tests depending on the nature of the data. 
The quality of life data were analysed with paired t-tests to test for differences between 
data before and after the 1st (safety) and 3rd (efficacy) period of the study. Serological and 
histopathological outcome parameters were analysed with Wilcoxon signed-rank tests to 
determine differences between data before and after the 1st period and the Wilcoxon rank 
sum tests to test the treatment differences in change from baseline in the 3rd period of the 
study. In order to explore whether patients’ baseline characteristics would predict their 
response to gluten (and hence to increase the chances of success in a future trial), rank 
correlations between baseline characteristics and outcome variables were explored in the 
placebo group using the Spearman Rank Correlation Coefficient (r) of the ranked data. A 
p-value of <0.05 was considered significant.
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RESulTS
The demographic and baseline characteristics of the patients are presented in Table 1. 
In total, 16 adults on a GFD diagnosed as having CD (median age 55 year (range, 20-68)) 
were enrolled in the study. The demographic characteristics of both treatment groups were 
comparable with exception of the median age at diagnosis of CD, which was 20 year higher 
in the AN-PEP compared to the placebo group. The median time on GFD treatment was 
similar in both groups. Two patients were excluded after the safety phase because of a 
histological deterioration of two and three Marsh grades, respectively, which for one patient 
returned to normal (Marsh 0) after four weeks of exclusion. The patient that did not return 
to normal started the study with high IgA/G-DGP-tTG values. However, other CD related 
antibodies remained undetectable in these two patients. The remaining 14 patients entered 
and completed the efficacy phase. 
When correlating the patients’ baseline characteristics with their response to gluten, 
highly significant inverse relationships were found between the patients’ time since 
diagnosis or time spent on a GFD and their response to gluten as measured by IgG-AG, 
IgA-tTG and IgA/G-DGP-tTG, and Marsh grades (data not shown).
Adverse events
No serious adverse events occurred during the trial; patients reported no severe adverse 
events and no patients withdrew during the trial. Complaints that were reported during the 
safety and efficacy phase were of gastro-intestinal nature and mostly mild and transient. 
The number of reported gastro-intestinal complaints did not differ between the AN-PEP and 
placebo group (Table 2).
Table 1  |  Demographic and baseline characteristics of the safety and efficacy phase.
Safety phase Efficacy phase
Gluten + An-PEP Gluten + Placebo Gluten + An-PEP
Patients, n  16  7  7
Gender 
  Male   4  2  1
  Female  12  5  6
Median age at inclusion (yr), range    55 (20-68)  44  (20-68)  57  (30-64)
Median age at diagnosis (yr), range   44.5  ( 0-62)  29  ( 0-62)  49  (26-53)
Median time on a GFD (yr), range  7.5  ( 2-40)  9  ( 2-40)  8  ( 4-12)
HlA class, n
  DQ2/X  12  5  5
  DQ2/DQ2   2  1  1
  DQ2/DQ8   1  0  1
  Unknown   1  1  0
Marsh at inclusion, n
  Marsh 0  10  4  3
  Marsh I   6  3  4
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Table 2  |  The number of adverse events experienced during the 2-week safety phase and 
2-week efficacy phase.
Safety phase Efficacy phase
Gastro-intestinal symptoms Gluten + An-PEP 
n=16
Gluten + Placebo 
n=7
Gluten + An-PEP 
n=7
Abnormal bowel sounds 4 – 2
Abdominal pain 5 3 2
Bowel distension 5 3 1
Change of defecation 4 2 6
Constipation 3 2 –
Diarrhoea 3 1 1
Dysgeusia 1 1 –
Flatulence 6 1 2
Nausea 4 2 –
Reflux 2 – 1
Vomiting 1 1 –
Weight loss – 1 –
Total number of symptoms 38 17 15
Coeliac disease quality of life
The mean total scores of the four categories on the CDQ were relatively high (145-156 out 
of a total score of 196) in the total group and throughout both study phases. In the safety 
phase, the total CDQ score significantly (p=0.04) increased by 6 points during gluten with 
AN-PEP treatment. This increase was, however, lower than the 12 points increase that is 
considered a clinically relevant quality of life improvement.14 In the efficacy phase, the 
individual or total CDQ scores of patients consuming gluten with placebo or gluten with 
AN-PEP did not significantly deteriorate. No differences between the groups were observed. 
The mean score for the gastro-intestinal CDQ was relatively high throughout the study, 
indicating that gluten with AN-PEP was well tolerated. 
Mucosal biopsy immunohistology
In the patients receiving gluten plus AN-PEP treatment in the safety phase, several patients 
showed variability in Marsh scores but overall no significant change in degree of mucosal 
damage, as indicated by changes in the Marsh score, was observed (Table 3). Two of 16 
patients were excluded from entering the efficacy phase as their mucosa showed an increase 
of two Marsh steps while 14 patients were considered histologically stable on gluten with 
AN-PEP. Also after the efficacy phase, no significant deterioration was observed in the group 
consuming gluten with placebo compared to the group receiving AN-PEP.
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Mucosal biopsy immunophenotyping of lymphocytes
Flow cytometric analysis of intestinal lymphocyte subsets showed no significant changes 
in the expression of the T-cell lineage associated markers CD3, CD4, CD8 and TCR-gd, in 
either the intraepithelial lymphocyte or the lamina propria lymphocyte populations of both 
treatment groups during the efficacy phase. The mean fluorescence index of the activation 
markers CD25, HLA-DR, the NK receptor NKG2D as well as CD45RA, a marker for naïf T-cells, 
showed no significant change in either group. 
Mucosal biopsy IgA-tTG antibody deposits 
Mucosal tTG-related extracellular IgA deposits are hypothesised to be an early marker for 
CD activity.21 Despite a GFD, two of seven patients started with positive staining for IgA-
tTG at baseline (Table 3). Compared to baseline, IgA-tTG deposit staining increased after 
two weeks of gluten intake in four out of seven patients on placebo. In the seven patients 
receiving AN-PEP, one patient showed increased and one showed decreased IgA-tTG deposits 
(Table 3, Figure 2).
Serum antibodies
Serum CD associated antibodies (IgA-tTG, IgA-EMA, IgA-AG, IgG-AG and IgA/G-DGP-tTG) 
were not detectable in the serum of enrolled patients at baseline (Table 3) except for 
one patient in which borderline levels of IgA/G-DGP-tTG were detected, which became 
negative after two weeks of gluten with AN-PEP consumption. The IgA-tTG, IgG-AG, IgA/G-
DGP-tTG, and IgA-EMA antibody titers remained negative on gluten with AN-PEP. Three out 
of 16 patients developed detectable or borderline IgA-AG levels, while 13 patients remained 
negative during two weeks of gluten with AN-PEP (Table 3). 
During the efficacy phase, neither the placebo nor the AN-PEP group developed significant 
antibody titers (Table 3). The median antibody titers after two weeks gluten intake did not 
significantly differ between AN-PEP and placebo treatment. The IgA-EMA concentrations 
remained negative in both groups.
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DISCuSSIOn
The enzyme AN-PEP might possibly assist in digesting unintentionally ingested amounts of 
gluten in those who cannot tolerate gluten. However, demonstrating a treatment effect on 
(small) clinical deterioration induced by small amounts of gluten in the placebo group may 
be difficult. Therefore, in this proof of principle study, the enzyme was given to patients 
consuming large amounts of gluten in a relative small period of time. A 2-week safety phase 
(AN-PEP + gluten) preceded the randomisation for AN-PEP or placebo as requested by the 
medical ethical commission due to concerns about such a high dose of gluten consumption. 
Unfortunately, the primary aim of the study was not met as the placebo group did not show 
any deterioration after two weeks of gluten consumption. With hindsight, the study should 
possibly have been designed for a much longer period of time with many more patients.
The baseline characteristics were balanced between groups except for median age 
at diagnosis, which was 20 years higher in the AN-PEP compared to the placebo group. 
However, this is unlikely to have influenced the study outcome as no relationship between 
the age of diagnosis and the response to gluten was observed (data not shown). 
The safety phase showed that AN-PEP treatment, when consumed with a high dose of 
about 7 g of gluten for two weeks, was safe in patients and no severe adverse events were 
reported. The CDQ scores remained relatively high during two weeks consumption of gluten 
and AN-PEP indicating that patients’ general well-being remained high. Serum antibodies of 
the 16 patients did not increase when consuming AN-PEP with 7 g of gluten for two weeks. 
Also, histology of the biopsies of the majority of patients (14) showed no deterioration while 
two patients developed increased Marsh grades, however not accompanied by increased 
antibodies. The safety phase was subject to a so-called “ceiling effect” because patients 
entered the study on a GFD reflecting relatively healthy baseline values, limiting the ability 
to demonstrate any further improvement by AN-PEP. 
Patients in the placebo group did not show significant deterioration on any of the 
measured clinical variables after a 2-week gluten challenge, indicating that two weeks 
of gluten challenge is insufficient to induce a clear clinical response in this population of 
coeliac patients. Due to lack of response to gluten in the placebo arm, no treatment effect 
of AN-PEP could be detected. The measured serum levels of IgA-tTG, IgA-EMA, and IgA/G-
DGP-tTG antibodies are considered sensitive markers of CD and should be able to detect 
subtle immunogenic effects of gluten. Similarly, the CD specific quality of life questionnaire 
is considered a CD specific measure of quality of life and should also be able to pick up 
relevant changes in health.14 However, histological examination of small intestinal biopsies 
may be less reliable than CD associated antibodies due to heterogeneous distribution of 
lesions, low grade histopathology, and intra- and interobserver variability.22 Interestingly, 
measures of clinical response to gluten (Marsh grades, antibody titres, quality of life scores) 
did not correlate in this study, which may in part be explained by the lack of response to 
gluten. The IgA antibody reactivity to small intestinal mucosa tTG has been considered 
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to be an early marker for gluten-induced pathology in CD patients.23 It was observed that 
intestinal IgA-tTG deposits can be detected in latent CD patients in which the mucosal 
villous architecture is still intact, and that the intensity of these mucosal deposits decreased 
after adherence to a GFD and increased after gluten consumption. Although numbers were 
low, mucosal IgA-tTG deposits increased in four patients on placebo and one on AN-PEP and 
decreased in one patient on AN-PEP, compared to baseline values, suggesting that AN-PEP 
may mitigate gluten exposure. 
Some gastro-intestinal related symptoms, mostly mild and transient, were reported 
during gluten challenge, and symptoms between the two groups were comparable suggesting 
no treatment-related effects. Besides the substantial gluten intake, emotional stress as a 
consequence of having to ingest gluten might have triggered some of the reported gastro-
intestinal complaints. 
The coeliac patients consumed approximately 7 g gluten daily, which is about half of 
the average adult daily gluten intake in The Netherlands.24 Despite this high gluten dose, no 
substantial histological, serological, or symptom changes were observed on placebo after 
two weeks. In another study25 in which adult CD patients consumed approximately 3.5 g/day 
of gluten from cracker biscuits for two weeks, only few patients consuming gluten on placebo 
showed deterioration on histology, serology and symptoms. Two other studies investigating a 
gluten challenge in adult CD patients, based on either lower gluten intake (2.5 – 5.0 g/day) 
for at least three months26 or comparable gluten intake (four slices of white bread daily; 
~8 g/d)27 showed that a moderate gluten intake can be tolerated by some patients for several 
weeks-to-months without significant changes in symptoms27, serology26 and histology26, 27. 
The time to serological and mucosal relapse and recovery after gluten reintroduction and 
elimination, respectively, can be highly variable among adult CD patients from several 
weeks up to many years.27-29 Excluding two out of 16 patients that may have been more 
sensitive to gluten from the efficacy phase may, to a small extent, have caused sample bias 
by selecting patients being less sensitive to gluten. Nevertheless, the same population of 
patients that entered the efficacy phase were randomly allocated to the AN-PEP or placebo 
arm. Also attrition bias can be excluded since all patients remained in the study. The lack 
of substantial clinical response to gluten observed in this study indicates that a longer 
gluten challenge is likely necessary to induce a significant clinical response to gluten in 
the majority of patients. Moreover, unresponsiveness to gluten of patients being diagnosed 
for more than 10 years ago, suggests that future studies may benefit from selecting more 
recently diagnosed patients.
In conclusion, AN-PEP appeared to be safe in coeliac patients. More patients and gluten 
challenge for a longer period of time seem to be required to induce significant clinical 
changes and to confirm whether the tendency of AN-PEP to reduce small bowel IgA-tTG 
deposits is of clinical significance. These results together with previous in vitro evidence 
that AN-PEP efficiently degrades gluten under simulated gastro-intestinal conditions warrant 
confirmation in a larger trial. 
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Tioguanine in the treatment of 
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a single centre experience
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ABSTRACT
Objectives: Refractory coeliac disease type I (RCD I) is a complicated form of coeliac 
disease characterised by primary or secondary resistance to a gluten-free diet (GFD) with 
persisting or recurring intestinal villous atrophy and symptoms of malabsorption. Besides 
corticosteroids, azathioprine has been advocated for the treatment of RCD I. However, 
tioguanine (TG) might be better tolerated and more efficacious owing to a simpler 
metabolism towards bioactivation. We evaluate tolerability and effectiveness of the non-
conventional thiopurine derivative TG in RCD I.
Methods: RCD I patients treated with TG between June 2001 and November 2010 with a 
follow-up period of at least one year were included. Adverse events, laboratory values, 
6-thioguanine nucleotide concentrations and rates of both clinical and histological response
were evaluated at baseline and during follow-up.           
Results: Twelve adult RCD I patients were included. The median TG treatment duration was 
14 months. Ten patients tolerated TG treatment on the long-term, whereas two patients 
withdrew treatment due to adverse events. No nodular regenerative hyperplasia of the liver 
was observed. During follow-up clinical and histological response was observed in 83% and 
78%, respectively. Corticosteroid dependency decreased by 50%.
Conclusion: Tioguanine appears to be a convenient drug for the treatment of RCD I based on 
higher histological and similar clinical response rates as compared to historical conventional 
therapies.
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InTRODuCTIOn
A small percentage of the adult-onset coeliac disease (CD) patients displays a primary or 
secondary lack of clinical and histological response upon strict adherence to a gluten-free 
diet (GFD) for more than 12 months despite normalised CD associated antibodies. These 
patients are diagnosed as having refractory coeliac disease (RCD) when dietary consumption 
of gluten and other causes of malabsorption with villous atrophy are ruled out.1, 2 This 
syndrome can be subdivided into RCD type I and RCD type II, with immunophenotypically 
normal and aberrant intraepithelial T-lymphocytes (IELs) in the small intestinal mucosa, 
respectively. Aberrant IELs express cytoplasmic CD3, but lack the surface markers CD3, CD4 
and CD8. A clinically validated cut-off value of 20% aberrant IELs, detected by using flow 
cytometric analysis of small intestinal biopsies, is currently used to discriminate between 
RCD I and RCD II.3 Although the prognosis of RCD I is much more favourable than that of 
RCD II, as reflected in 5-year survival rates of around 90% and 44-58%, respectively4-6, 
treatment is believed to be important in preventing complications of longstanding 
malabsorption. The poor prognosis of RCD II is due to a high risk of clonal expansion and 
further transformation of aberrant mucosal T-lymphocytes into an aggressive enteropathy 
associated T-cell lymphoma (EATL).1, 2  
Apart from a GFD and nutritional support, corticosteroids are the mainstay of treatment 
in RCD I. However, an 80% corticosteroid dependency associated with systemic side effects 
has been reported.5 To reduce corticosteroid dependency and in case of corticosteroid 
refractoriness, the immunomodulatory purine analogue azathioprine (AZA) has been used.7, 8 
Although clinical response rates following AZA therapy were promising, histological remission 
was lagging behind.5 In addition, AZA therapy is regularly complicated and discontinued due 
to adverse events, as has been shown in the treatment of inflammatory bowel disease 
(IBD) but also in small RCD I series.7, 9 Both therapeutic failure as well as adverse events 
may be due to an unfavourable metabolism of AZA. Azathioprine is metabolized via 
mercaptopurine (MP) into the pharmacologically active 6-tioguanine nucleotides (TGN), 
and into multiple other metabolites including 6-methyl mercaptopurine (6-MMP) (Figure 1). 
Despite a weight-adjusted dosing regimen, there is a wide interindividual variety in 
TGN and 6-MMP concentrations, which reflects individual differences in the activities of 
involved enzymes.10 High concentrations of 6-MMP are associated with adverse events often 
necessitating drug withdrawal.11 In view of the aforementioned limitations of corticosteroid 
and immunosuppressive therapies, it is important to evaluate therapeutic alternatives for 
RCD I. 
The non-conventional thiopurine derivative tioguanine (TG) might be a suitable 
alternative treatment option for RCD I, either as first-line treatment, second-line treatment 
in patients unresponsive to corticosteroids or AZA, or as a steroid-sparing drug. Tioguanine 
only needs one enzymatic conversion towards the formation of the active metabolites TGN 
and when metabolized, it is not converted into 6-MMP. In addition, TG was shown to be 
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well-tolerated and efficacious in the treatment of IBD.12, 13 We report a single centre series 
concerning tolerability and effectiveness of TG in RCD I.
MATERIAlS AnD METHODS
All patients who were diagnosed with RCD I and received first or second line TG therapy 
between June 2001 and November 2010 at the gastroenterology department of a tertiary 
referral centre were identified.
Diagnosis of RCD I was based on persisting or recurring symptoms and small intestinal 
villous atrophy despite strict adherence to a GFD for at least one year ascertained by 
negative serology and a specialised dietitian.1 Furthermore, the proportion of aberrant IELs 
detected by using flow cytometric analysis of small intestinal biopsies had to be less than 20 
percent.3 In all patients EATL was excluded.14
After informed consent, TG was prescribed in a daily dose of approximately 0.3 mg/kg 
and administered as 18, 21 or 24 mg capsules (generic) or 20 mg tablets (Lanvis® 
GlaxoSmithKline, Middlesex, United Kingdom). Patients visited the outpatient clinic on a 
regular basis, usually every three to six months. Patient demographics, date of onset of 
coeliac disease, date of onset of RCD I, clinical details, HLA-DQ haplotype, history of prior 
immunosuppressive therapy, reason for and date of initiating TG therapy, and laboratory 
results were collected from medical records. In addition, where available clinical and 
histological details were also obtained after cessation of TG.
Figure 1  |  Simplified thiopurine metabolism. 
Figure 1 | Simplified thiopurine metabolism.
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Tolerability 
Adverse events that had occurred during the use of TG were reported by the treating 
physicians and described by the researchers as being certainly related, possibly related or 
not related to TG therapy. In addition, laboratory values regarding the safety of TG therapy 
that had been determined at baseline and at different time points during follow-up were 
collected. These values included hemoglobin concentrations, platelet counts, leukocyte 
counts and liver biochemistry, usually at three month interval. 
Therapeutic response
Both clinical and histological characteristics were evaluated at baseline and at different 
time points during follow-up of TG treatment. Gastro-intestinal symptoms, weight and 
laboratory values, including haemoglobin and albumin were reported. Multiple duodenal 
biopsies were taken by upper gastro-intestinal endoscopy to detect histopathological 
abnormalities. Clinical response was defined as amelioration of gastro-intestinal symptoms, 
combined with at least two out of the following parameters within their reference range 
or with an improvement of ≥1 point: body mass index (BMI), albumin and haemoglobin.15 
Complete histological response was characterised by normalisation of the architecture of 
the small intestinal mucosa, defined as a Marsh 0 or I score according to the modified Marsh 
criteria, as assessed by an experienced coeliac disease pathologist.16 A partial histological 
response was defined as an improvement of the Marsh classification of two or more steps. 
Corticosteroid dependency was arbitrarily defined as the use of prednisone or budesonide 
during follow-up (≥6 months) in a daily dose of at least 10 mg or 9 mg, respectively. The 
primary end of follow-up was set at the time of TG withdrawal. If remission was the reason 
for TG cessation, a secondary end of follow-up was set at the time of the last duodenal 
biopsy performed after TG discontinuation to evaluate ongoing remission.  
6-Tioguanine nucleotide concentration
Red blood cell (RBC) TGN concentrations obtained during follow-up were measured by 
reversed-phase high-performance liquid chromatography according to a slightly modified 
method described by Dervieux and Boulieu and expressed in pmol/8x108 RBC.17 The mean 
values of these measurements were used for comparison between patients. For comparability 
with the frequently used method of Lennard the observed values must be divided by 2.6.
 
Statistical analysis
Data are tabulated or presented descriptively. Continuous variables were expressed as 
median values with their range. Based on the skewed distribution of the included variables 
the non-parametric Mann-Whitney U-test was used for comparison between groups. 
P-values less than 0.05 were considered statistically significant. SPSS 15.0 for Windows 
(SPSS Inc, Chicago, Illinois, USA) was used for statistical analysis.
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RESulTS 
Overall, 13 RCD I patients received TG therapy between June 2001 and November 2010. 
One patient was excluded due to loss to follow-up. The remaining 12 RCD I patients, four 
males and eight females, were included in the analysis. Their median age at RCD I diagnosis 
was 58 years (range 35–68), the median time adhering to a GFD was 4.6 years (range 1-33) 
and median daily dose of TG was 19 mg (range 18-40), corresponding with 0.36 mg/kg 
(0.26–0.69). Eight patients were treated with TG as first-line treatment, whereas four 
patients received TG as second-line treatment due to intolerance or resistance to AZA or 
corticosteroid dependency. The median TG treatment duration was 14 months, ranging from 
three weeks up to almost eight years. Table 1 shows additional patient characteristics. 
Tolerability 
Three patients experienced an adverse event during TG treatment, two of which supposedly 
related to the use of TG. One patient died within four months of therapy due to progression 
of RCD I with severe diarrhoea not responding to prednisone induction therapy. Subsequently, 
severe metabolic dysregulation consisting of metabolic acidosis, hypokalemia, and 
hypoalbumenia occurred and was complicated by septic shock and multiple organ failure. 
Permission for autopsy to exclude EATL was not obtained. This serious adverse event was 
not likely to be related with TG treatment itself, supported by the fact that there was 
no myelotoxicity preceding septic shock. The second patient withdrew TG therapy only 
after three weeks due to muscle spasms without laboratory abnormalities. This patient 
was refractory to previous AZA treatment. The spasms resolved after cessation of TG 
and initiation of corticosteroids. This adverse event was classified as possibly related. 
The third patient experienced liver test abnormalities after nine months of therapy. 
Gamma glutamyltransferase, alanine aminotransferase and aspartate aminotransferase 
concentrations increased up to twice the upper limit of the normal range, yet with alkaline 
phosphatase within the normal range. Despite a dose reduction from 21 to 10 mg TG daily 
laboratory findings remained steadily elevated. In this particular patient TG was withdrawn 
after 17 months as both clinical response and complete histological remission was achieved. 
Following the complete cessation of TG the deviant laboratory values returned to within 
the normal range during follow-up. Apart from these transitory, mild non-specific elevation 
of biochemical liver tests, no other clinical clues for nodular regenerative hyperplasia were 
observed during follow-up, including a normal alkaline phosphatase level and absence of 
esophageal varices at gastro-duodenoscopy, ascites and trombopenia indicative for portal 
hypertension. As these nodular abnormalities are usually isoechoic on ultrasonography this 
investigation was not performed. Diagnosis requires a liver biopsy and might have revealed 
(early) signs of nodular regenerative hyperplasia, but was not performed owing to the low 
suspicion. This adverse event was classified as possibly related. 
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The two patients initially intolerant of AZA did tolerate TG. No episodes of trombopaenia, 
leucopaenia or anaemia were observed in any of the patients. In addition, apart from the 
one patient described above, no episodes of hepatotoxicity, as indicated by abnormal liver 
tests, occurred in any other patient. Overall, TG was tolerated in nine out of twelve patients 
(75%).
 
Therapeutic response
Prior to treatment with TG all patients had weight loss and gastro-intestinal symptoms 
including diarrhoea. One year after initiation of TG, clinical response was observed in ten 
out of all twelve patients (83%), corresponding to ten out of ten patients who tolerated 
TG (Table 1). Median weight, BMI, haemoglobin concentration and albumin concentration 
increased from 56,5 kg (46-86), 19.5 kg/m2 (16.7–27.8), 7.7 mmol/L (6,5-9.7) and 38 g/L 
(27–44) at baseline, to 65 kg (53-84), 22.4 kg/m2 (19.7– 27.1), 8.0 mmol/L (7.3 -9.9) and 
40 g/L (32-45), respectively. None of these parameters showed a statistically significant 
difference at one year of follow-up as compared to baseline.
At baseline, duodenal biopsies of all patients revealed intraepithelial lymphocytosis, 
crypt hyperplasia and villous atrophy. After one year, nine out the ten patients who tolerated 
TG had been endoscopically evaluated. Complete histological response, was observed in 
seven patients (78%). In the other two patients no histological response was observed after 
12 to 14 months of follow-up despite showing a clinical response (Table 1; Figure 2). Neither 
clinical nor histological response was related to baseline Marsh grade.
Six patients were withdrawn from TG treatment following both clinical and complete 
histological respons after a median treatment duration of 17 months (7-92). In four out of 
these patients, endoscopic evaluation was also performed during follow-up after cessation 
of TG therapy. One of them again needed TG after five months when symptoms of diarrhoea 
arose and duodenal histology revealed a Marsh II. Clinical response persisted in the remaining 
three patients, whereas an ongoing histological response was found in two patients after 
6 and 20 months, and evolvement from a Marsh I into a Marsh IIIA in one patient within six 
months of the extended follow-up.
Four out of the ten patients tolerating TG for at least six months, corticosteroids 
(prednisone ≥10mg/budesonide ≥9mg) had been using at baseline. Out of these four, two 
(50%) were corticosteroid dependent during follow-up. All of these patients showed a clinical 
response, whereas a histological response was only observed in the two corticosteroid 
dependent patients. 
 
6-Tioguanine nucleotide concentration
During follow-up, the median RBC TGN concentration was 734 pmol/8x108 RBC (378-1180). 
There was no statistically significant difference in TGN concentration between patients 
who experienced adverse events and those who did not (p=1.0), nor was there a difference 
between patients with a histological response and those without (p=0.29).
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Figure 2  |  Flow chart of RCD I patients treated with tioguanine. 
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Abbreviations: C, clinical; H, histological; CR, clinical response; HR, histological response; 
RCD, refractory coeliac disease; TG, tioguanine.
DISCuSSIOn
Refractory coeliac disease type I is a complicated form of CD characterised by primary 
or secondary resistance to a GFD with persisting or recurring intestinal villous atrophy 
and symptoms of malabsorption.1, 2 Although the prognosis is good, adequate treatment is 
believed to be important in preventing complications of longstanding malabsortion. However 
randomised trials are lacking and treatment is largely empiric, limited by case-reports, 
small observational series and a few prospective open-label studies. This study reports on 
the effectiveness of the non-conventional thiopurine derivative TG in 78% of patients with a 
well-defined diagnosis of RCD I. In addition, TG seems to have an acceptable safety profile.
Tolerability
The short-term tolerability profile of TG in this study is comparable with that reported in 
the treatment of IBD, varying between 70% and 80%.13, 18 However, almost all IBD patients 
from previous studies had proven to be intolerant of or resistant to AZA or 6-MP prior to TG 
treatment, whereas most of the RCD I patients in this study were thiopurine naïf. Importantly, 
the two patients who were intolerant to AZA did tolerate TG. The suggested advantageous 
tolerability of AZA in the treatment of RCD I in previous studies is remarkable, whereas 
around 40% of the IBD patients fail therapy due to adverse events.7, 8, 11 This difference 
might indicate disease specific adverse event profiles, although contrasting reports have 
been published in this regard19, 20, or adverse events in RCD I treatment may not have been 
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put down in writing. Although not explicitly reported in the treatment of RCD I, potential 
adverse effects including gastro-intestinal complaints, hepatotoxicity and myelotoxicity 
may hamper the use of AZA.11 The complex metabolism of AZA with production of unwanted 
and potentially toxic metabolites might play an important role in the occurrence of these 
adverse events.11 A well-known and dreaded adverse event of TG treatment is the sinusoidal 
obstruction syndrome, which may induce nodular regenerative hyperplasia of the liver, with 
in its clinical end stage portal hypertension and its complications. In this study two adverse 
events were classified as potentially or probably related to TG treatment. One patient with 
muscle spasm and another with liver test abnormalities. In the latter patient with nonspecific 
mild elevated liver biochemical tests it is unlikely to be a result of an evolving sinusoidal 
obstruction syndrome as this usually coincides with signs of portal hypertension, including 
thrombopaenia and esophageal varices, and elevated levels of alkaline phosphatase. In 
addition, after cessation of TG the biochemical liver tests normalised during follow-up, 
consequently a liver biopsy was not performed, however, this investigation is required to 
fully exclude nodular regenerative hyperplasia. Interestingly, in addition to TG treatment, 
coeliac disease itself has been associated with the occurrence of nodular regenerative 
hyperplasia21 and hypertransaminasaemia22. 
Therapeutic drug monitoring of thiopurine treatment (i.e. azathioprine and 
mercaptopurine) by measuring erythrocyte TGN concentrations is of growing interest in 
the treatment of IBD. However, routine measurement to optimise treatment cannot be 
recommended.23, 24 With regard to TGN measurement during TG therapy there is even less 
evidence of its usefulness. In this study we evaluated erythrocyte TGN concentrations 
obtained during TG treatment. As anticipated, no relation between TGN concentration and 
toxicity or efficacy was observed. 
Therapeutic response
The 83% clinical response rate observed in this study seemed to be at least as effective 
as that of previous reported therapies.5, 6, 8, 25, 26 Furthermore, we observed a histological 
response in over half of the cases, compared to 30% previously reported.5, 6 Moreover, a 50% 
reduction in corticosteroid dependency was achieved.  
Systemic corticosteroids are the mainstay of treatment in RCD I with clinical response 
in the majority (~80%) of patients5, 6, however, potentially severe side effects comprise the 
long-term use of these agents. Moreover, steroid-dependency is observed in the majority 
of cases.5 Oral budesonide is suggested to be an attractive alternative treatment option 
owing its topical effect and low systemic bioavailability. Daum and colleagues26 reported 
good tolerability and stable disease for a median time of 28 months (range 14-56) in four 
RCD I patients treated with budesonide (9-12 mg/day) after a clinical response to induction 
therapy with prednisone (median 12 months). However, three patients were eventually 
treated with AZA, suggesting that long-term use of budesonide monotherapy might not be 
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effective. In spite of clinical improvement, complete small intestinal mucosal repair was 
not observed.25, 26 Furthermore, in the light of oral budesonide lacking long-term efficacy, 
a recent open-label study investigated small intestinal release mesalamine (SIRM; 4mg/kg) 
with or without concomitant budesonide in ten RCD I patients. Overall clinical response was 
50%, hence with SIRM monotherapy a complete response was observed in three out of the 
four patients. Moreover, SIRM was generally well-tolerated.27 
The immunomodulatory agent AZA has been used for its steroid-sparing effect and in case 
of steroid-refractoriness. Goeres et al.8 demonstrated that prednisone with concomitant 
AZA (2 mg/kg) for one year is usually sufficient to gain clinical response in RCD I, however, 
histologic response rates (partial ~30%; complete ~10%) were lagging behind. Case-reports 
suggest that other immunosuppressive agents, such as cyclosporine28 and infliximab29 might 
induce prompt clinical and histological improvement as well. Although this study suffers 
from several limitations, including its retrospective design, its small sample size and the 
absence of a control group, our experience suggests that TG is effective in obtaining a 
clinical response in RCD I patients within one year. As most patients in our series were 
treated with first-line TG, it still remains to be established whether this drug might be a 
good alternative option in patients intolerant of or refractory to other immunosuppressive 
drugs as well. In addition, the optimal treatment duration of TG should be established. 
In conclusion, TG is relatively safe, potentially steroid-sparing, and efficacious in 
obtaining clinical and histological improvement in the treatment of RCD I. Although 
randomised trials are warranted, this particular agent might be an additional or alternative 
therapeutic option. 
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ABSTRACT
Objectives: This study aimed to evaluate cladribine (2-chlorodeoxyadenosine [2CdA]) 
therapy in refractory coeliac disease (RCD) II. 
Methods: An open-label cohort-study of RCD II patients treated with 2-CdA was performed 
between 2000 and 2010. Survival rate, EATL occurrence, clinical course, and histological 
and immunological response rates were evaluated. 
Results: Overall, 32 patients were included with a median follow-up of 31 months. Eighteen 
patients responded well to 2-CdA. Patients responsive to 2-CdA have a statistically significant 
increased survival compared to those who were unresponsive. The overall 3- and 5-year 
survival was 83% in the responder group and 63% and 22% in the non-responder group, 
respectively. The overall 2-year clinical, histological and immunological response rates were 
87%, 48% and 44%, respectively. Progression into EATL was reported in 17%, all of them died. 
Conclusion: Treatment of RCD II with 2-CdA holds promise, showing excellent clinical and 
histological response rates, and probably less frequent transition into EATL.
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InTRODuCTIOn
Coeliac disease (CD) is characterised by a permanent state of intolerance to dietary gluten 
leading to an inflammatory T-cell response in the small intestine with mucosal injury in 
genetically susceptible individuals.1, 2 Although reduction of this intestinal inflammatory 
activity is usually seen upon strict adherence to a gluten-free diet (GFD), a small percentage 
(2%-5%) of the adult-onset CD patients, especially those diagnosed above the age of 50 
years, displays a lack of response to such a diet. They are regarded as suffering from 
refractory coeliac disease (RCD) when clinical and histological symptoms persist or recur 
after a former good response to a strict GFD, despite strict adherence to the diet for 
more than 12 months, unless earlier intervention was necessary.3, 4 Immunologically, this 
syndrome can be subdivided into RCD I and RCD II, with immunophenotypically normal and 
aberrant intraepithelial T-lymphocytes (IELs) in the small intestinal mucosa, respectively. 
Clonal expansion of these aberrant IELs, lacking the T-cell surface markers T-cell receptor 
(TCR), CD3, CD4 and CD85, but expressing cytoplasmic CD3, is supposed to be responsible for 
the occurrence of enteropathy associated T-cell llymphoma (EATL).4-6 This type of lymphoma 
occurs in 60%-80% of the RCD II patients within 5 years and has a poor prognosis with a 
2-year survival of only 15%.7, 8 The latter is mainly due to incomplete response to currently 
available therapies, high rates of life-threatening complications such as perforation of the 
gut and poor nutritional conditions.7, 8 Therefore, it is of utmost importance to evaluate 
new treatment strategies for RCD II in order to improve clinical course and prevent or delay 
progression to overt EATL. 
Since the late 1990’s, researchers have become increasingly interested in therapeutic 
alternatives for treating RCD II, however, as far as has been published there is no standardised 
approach yet.9, 10 RCD II is, at least in part, resistant to most evaluated therapies so far.10-12 
Until 2005 RCD II, patients were initially treated in our tertiary referral centre with 
conventional immunosuppressive drugs, mainly azathioprine and prednisone, and if 
clinically and histologically unresponsive cladribine (2-chlorodeoxyadenosine [2-CdA]) was 
prescribed. Since then, a modified treatment strategy was initiated with cladribine being 
drug of first choice. 
Cladribine is a synthetic purine nucleoside homologue being equally toxic to proliferating 
as to non-dividing lymphoid cells. Because of this unique feature it is supposed to be 
especially active against low-grade malignancies, including hairy cell leukaemia. Cladribine 
is metabolised into its pharmacologically active cladribine triphosphate, which induces 
apoptosis, necrosis and inhibition of DNA/RNA synthesis (Figure 1). Clinically, 2-CdA is of 
proven value in the treatment of a number of haematological malignancies and selected 
autoimmune disorders, including multiple sclerosis.13-15 Our pilot-study showed that 2-CdA 
therapy is feasible and well tolerated in these patients.16 Survival at that time seemed 
promising, but follow-up was short. 
This analysis evaluates 2-CdA therapy in a large prospectively studied open-label cohort of 
RCD II patients, during a mean follow-up time of three years.  
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Figure 1  |  Schematic representation of intracellular pathways involved in cladribine 
cytotoxicity. (Adapted with permission from Borak, 2006).
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MATERIAlS AnD METHODS
This cohort-study includes reports of extended follow-up of 14 out of the 17 RCD II patients 
included into the open-label prospective phase-I study performed by Al-Toma et al.16 with 18 
new patients added. Three patients out of the previous study were not included in this study 
as they are followed over time outside our hospital. Between January 2000 and April 2010, 
2-CdA was prescribed to 32 RCD II patients at the VU University Medical Centre, Amsterdam, 
The Netherlands. 
Inclusion criteria
Patients diagnosed as having RCD II and treated with one or two courses of 2-CdA at the VU 
University Medical Centre were included. Cladribine was intravenously given in a dose of 
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0.1 mg/kg per day for five consecutive days. The diagnosis of RCD II was based on persisting 
or recurring clinical symptoms and small intestinal villous atrophy after a former good 
response to a strict GFD, despite strict adherence to the diet for more than 12 months. 
Furthermore, the clinically validated cut-off value of more than 20% aberrant IELs detected 
by flow cytometric analysis was used to distinguish RCD type I and type II.5 Although a 
clonal TCR-gamma rearrangement determined by PCR is still a widely accepted method 
to define RCD II, Verbeek et al.5 showed that the percentage of aberrant IELs detected by 
flow cytometric analysis is a more accurate way to define RCD II. The presence of EATL was 
excluded by using selected investigations17-20 and its diagnosis was confirmed according to 
the WHO classification of tumours of haematopoietic and lymphoid tissues.21 Furthermore, 
pre-treatment with immunomodulatory drugs within six months or any experimental drug 
within 30 days of the study entry was not allowed.
Follow-up and criteria of response
Before and during follow-up after 2-CdA treatment a clinical assessment was carried out 
noting in particular signs and symptoms of malabsorption, body mass index (BMI), albumin, 
and haemoglobin (Hb). A nutritional screening was performed by a dietitian specialised in CD 
in almost all patients prior to treatment and nutritional support was given when indicated. 
Clinical response was defined as improvement of the diarrhoea, abdominal discomfort and/
or signs of malabsorption, combined with at least two out of the following parameters of 
intestinal integrity within the normal range or an improvement of ≥1 point: 1) Hb, 2) BMI 
and 3) albumin. Multiple duodenal biopsies were taken by upper gastro-intestinal endoscopy 
in order to detect histopathological abnormalities and to perform immunophenotyping of 
IELs by flow cytometric analysis at different time points (planned at 3, 6 and 12 months, and 
then every year during follow-up). Isolation of small intestinal T-lymphocytes and staining 
for immunophenotyping were performed as previously described.5 Complete histological 
response has been defined as a normalisation of the architecture of the duodenum, classified 
as a Marsh 0 or I lesion according to the modified Marsh classification.22 A decline of 20% 
or more in the percentage of aberrant IELs was considered a significant immunological 
response. In addition, survival rate and EATL occurrence were evaluated during follow-up. 
Furthermore, following on Verbeek et al.10 who hypothesised that pre-treatment with 
common immunosuppressive drugs, including azathioprine and prednisone might influence 
the response to 2-CdA treatment, this study compared RCD II patients pre-treated with 
immunosuppressive agents before 2-CdA was prescribed (group I) to those treated with 
upfront 2-CdA (group II). 
Ethical approval and informed consent 
Approval for this open label study protocol was obtained from the local ethics committee in 
2000 and all patients gave their informed consent. 
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Statistical analysis
Quantitative data were expressed as medians and means. Kaplan-Meier survival curves were 
constructed using SPSS software (SPSS Inc., Chicago, Illinois, USA). In addition, the log 
rank test was used to assess the statistical significance. A p-value of less than 0.05 was 
considered statistically significant.
RESulTS
In total, 32 RCD II patients who were treated with 2-CdA were included with a median follow-
up time of 31 months (range 4-120). Patient characteristics (Table 1) show a median age of 
>50 years, with a male predominance. Prior to the start of 2-CdA therapy, ten patients failed 
to respond clinically and histologically to conventional immunosuppressive drugs (defined as 
group I), including high dose prednisone in two and azathioprine or 6-tioguanine added to 
prednisone in eight patients. The remaining 22 patients (defined as group II) were initially 
treated with 2-CdA following diagnosis of RCD. 
Disease status
In agreement with our previous study, 2-CdA was feasible and well tolerated without serious 
adverse events.10 Overall, 18 (56%) of the RCD II patients were responsive to one or two 
courses of 2-CdA based on the clinical, and complete histological and/or immunological 
response (Figure 2). Seven showed a clinical and histological response, four a clinical 
and immunological response, and seven a clinical, histological as well as immunological 
response. Out of the remaining 14 patients unresponsive to 2-CdA, two were admitted for a 
second course of 2-CdA in the last six months and in anticipation of evaluation of response. 
Six non-responsive patients were evaluated for high dose of chemotherapy followed by 
autologous hematopoietic stem-cell transplantation (au-SCT). In two of them stem cells 
could not be harvested, therefore four patients were actually transplanted.23 Another six 
patients had an expectative follow-up, two of them had an exacerbation after an initial 
response to 2-CdA for almost 2 and 3.5 years.
Table 2 shows the clinical, histological and immunological 1- and 2-year response rates to 
2-CdA treatment. In total, clinical response was observed in 26 (81%), complete histological 
response in 15 (47%) and immunological response in 13 (41%) of the RCD II patients. The 
median levels of BMI, Hb and albumin increased from 20.9 kg/m2, 7.8 mmol/L and 36 g/L 
at baseline to 23 kg/m2, 7.9 mmol/L and 39g/L at the end of follow-up, respectively. In 
addition to the fifteen patients in whom complete histological response, defined as Marsh 
0 or I, was observed, two patients had a partial histological response from Marsh IIIB and 
IIIC lesions at baseline to Marsh II and IIIA at the end of follow-up respectively. The median 
percentage of intestinal aberrant IELs before 2-CdA treatment was 61% and declined to 56% 
after 2-CdA treatment. The time to a 50% response rate was three years. Approximately 
33% of the patients lacked a clonal TCR-γ gene rearrangement, although all patients had 
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
Cladribine in RCD II  |  149
an aberrant IELs of more than 20%. A statistical significance between the percentage of 
aberrant IELs and the clonality status was not found. 
Analysis of the overall response in patients pre-treated with immunosuppressive drugs 
prior to 2-CdA (group I) and those with up-front 2-CdA treatment showed no statistical 
significance (log rank, p=0.856). Immunological (log rank, p=0.030) response, however, was 
significantly higher in group II. In addition, a trend towards a higher clinical response in 
group II (log rank, p=0.058) was found. Yet, for the histological response rate a statistical 
significance was not observed (Table 2). Cox-regression analysis showed that the following 
parameters have no predictive value for response to 2-CdA: age at 2-CdA infusion (p=0.06), 
gender (p=0.60), TCR-γ clonality (p=0.604), and percentage of aberrant IELs (p=0.646), 
degree of small intestinal villous atrophy (p=0.610), BMI (p=0.095), albumin (p=0.936) and 
Hb (p=0.953) before treatment.  
Table 1  |  Patient characteristics.
Gender        
  Male  18
  Female  14
Median age of CD diagnosis (yr), range  58.5 (38-74)
Median age of RCD II diagnosis (yr), range           64 (42-78)
Median age at the start of 2-CdA treatment (yr), range    64 (45-78)
Treatment prior to 2-CdA
  None  22
  Immunosuppressive drug  10
Median follow-up time (months), range  31 (4-120)
HlA-DQ status
  DQ2 heterozygous    17
  DQ2  homozygous    12
  DQ2 and DQ8             2
  Unknown  1
TCR-γ gene rearrangement
  Monoclonal  18
  Polyclonal  9
  Unknown  5
Marsh grade before 2-CdA
  Marsh IIIA  13
  Marsh IIIB  11
  Marsh IIIC  8
Median intestinal aberrant IEls before 2-CdA (%), range  61 (21-96)
Median BMI before 2-CdA (kg/m2), range         21 (16-27)
Median albumin level before 2-CdA (g/l), range
 36   (23-47)
(Reference value 35–52 g/L)
Median Hb level before 2-CdA (mmol/l), range  7.8   (6.0-9.8)
Abbreviations: CD, coeliac disease; RCD, refractory coeliac disease; 2-CdA, cladribine; 
BMI, body mass index; Hb, haemoglobin.
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Figure 2  |   Flowchart of the response to cladribine treatment. 
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Abbreviations: RCD, refractory coeliac disease; 2-CdA, 2-chlorodeoxyadenosine; au-SCT, autologous 
hematopoietic stem-cell transplantation; EATL, enteropathy associated T-cell lymphoma.
Table 2  |  The 1-year and 2-years response rates and the median time to response in the 
pre-treated (I) and the up-front cladribine (II) group. 
Treatment           (n) Response (%) Time to a 50%
1 yr 2 yr response rate (mo) 
Histological Group I  10 13 25   36
Response Group II 22 20 58   24
Overall   32 10 48   36 (3-96)
Immunological1 Group I  10 11 11 >60
Response Group II 22 52 58   12
Overall   32 39 44   41 (2-96)
Clinical2 Group I  10 67 67   6
response Group II 22 95 95   3
Overall   32 81 81   3  (2-72)
Overall Group I  10 22 38   36
Response Group II 22 28 43   30
Overall   32 25 41   36
1P=0.030 and 2P=0.058 between group I and II.  
Survival 
The overall median survival is almost 4.5 years. In total, 37% (12/32) of the included 
patients died, due to an EATL in 42% (5/12). All patients diagnosed with EATL (15%) died 
subsequently, having a median survival of only 4.4 months (range 0-12) after diagnosis.
The survival curve (Figure 3A) shows a statistically significant difference (p=0.037) 
between responders and non-responders to 2-CdA treatment. The 3- and 5-years survival 
is 83% in the responding group and 63% and 22% in the non-responding group, respectively. 
One-sixth (3/18) of the responders died, one due to refractory disease status and two were 
diagnosed with EATL within three and nine months after the last infusion of 2-CdA. 
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Approximately 65% (9/14) of the non-responders died, three as a consequence of developing 
an EATL within 8, 12 and 44 months after 2-CdA treatment (Figure 2). The exceptionally 
delayed progression into EATL in the latter patient might be explained by treatment with 
high dose of chemotherapy followed by au-SCT eight months after 2-CdA treatment. The 
remaining six unresponsive patients deceased as a result of refractory disease status; 
one treated with chemotherapy and au-SCT died after one year of follow-up and five 
with expectative follow-up despite lack of response to 2-CdA after a median follow-up of 
18 months (range 4.5–60). The patient in the latter group who died five years after 2-CdA 
treatment, had an exacerbation after an initial remission to 2-CdA for 3.5 years and then 
refused further treatment. 
In addition, there was no statistical significance (p=0.23) between the overall survival 
in the pre-treatment group (I) and the upfront 2-CdA treatment group (II) as depicted in 
Figure 3B. 
Figure 3  |  Kaplan-Meier survival curves. 
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A: Survival rate of responders and non-responders to cladribine treatment (Log Rank: p=0.037).
 * Three patients died in the 1st and 5th year; $ one patient died in the 2nd, 3rd and 4th year of 
    follow-up, respectively.
B: Survival rate of the pre-treatment (I) and the upfront cladribine (II) group (Log Rank: p=0.23).
 * Four patients died in the 1st year; $ one patient died in the 1st, 3rd and 4th year of follow-up, 
   respectively; # two patients died in the 2nd year of follow-up. 
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DISCuSSIOn
Approximately half of the RCD II patients have an unfavourable clinical course as a 
consequence of non or partial response to current available therapies and subsequently the 
progression into EATL7, 8 For that reason clinicians have become increasingly interested in 
treating this condition alternatively and more effectively. However, there is no standardised 
approach reported so far. In this study a large cohort of RCD II patients treated with 2-CdA 
has been analysed. 
In agreement with Al-Toma et al16, this report describing almost twice as many patients 
with extended follow-up, showed that 2-CdA is indeed feasible and well tolerated without 
serious adverse events after short and long-term follow-up. Our data show that RCD II 
patients responsive to 2-CdA treatment have a statistically significant increased survival 
compared to those who are unresponsive. Although the median follow-up time was only 
30 months, after 1.5 year of follow-up none of the responders died compared to four non-
responders, indicating a clear difference in survival rate. The overall 5-year survival of RCD II 
patients in this analysis is 46% so far, which is in line with other single-centre studies11, 12, 
and is expected to improve after extended follow-up. Previous reports included RCD II 
patients treated with diverse steroid-like drugs11, 12, whereas in this study ten RCD II 
patients unresponsive to such immunosuppressive drugs were included as well. However, 
unexpectedly the overall survival did not significantly differ between patients pre-treated 
with conventional immunosuppressive drugs (group I) compared to those with upfront 
2-CdA treatment (group II). Nevertheless, a clearly increased median survival rate in 
group II was observed. The lack of statistical significance might be due to the small cohort 
included in group I. In addition, some of the RCD II patients, treated with conventional 
immunosuppressive drugs, died before 2-CdA treatment could be initiated as previously 
reported by our group24 and were therefore not included in the current analysis. Apart from 
favouring clinical course and increasing survival, preventing EATL represents the ultimate 
goal of treating RCD II. Although treatment with 2-CdA could not prevent progression 
into EATL, compared to previous reports showing EATL in 33–52% of the RCD II patients 
within five years7, 11, our results showed a much lower rate of lymphomagenesis (17%), yet 
approximately 50% has a 5-year follow-up.   
Furthermore, our open-label and observational data showed that 2-CdA is an effective 
treatment in obtaining clinical and immunohistological response in more than half of the 
RCD II patients. Previous studies reported a good clinical response after treatment, but 
histological response rates up to only 30% were found depending on the type of treatment.11, 12 
Consistent with these findings, a clinical response rate of 80% was found. The potential 
advantage of 2-CdA, however, seems to be a good histological response. In fact, histologic 
healing (Marsh 0 or I) was observed in almost half of the cases and a partial response of 
at least two Marsh scores in another three cases. Although not statistically significant, the 
2-year histological response rate in up-front 2-CdA group (II) was twice that of the pre-
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treatment group (I), possibly indicating a beneficial effect of upfront 2-CdA treatment. 
Furthermore, Malamut et al.11 recently described a 74% steroid-dependency in a large cohort 
of RCD II patients treated with corticosteroids. Since there is no need for corticosteroids 
when 2-CdA therapy is prescribed, steroid-dependency and its complications will not occur.
In this cohort, the proportion of RCD II patients lacking a clonal TCR-γ gene rearrangement 
was relatively high (33%) compared with that reported in other studies4, 11, 12, although all 
patients had more than 20% aberrant IELs determined by flow cytometric analysis. This 
discrepancy might be the result of some technical aspects of the DNA analysis, for instance 
a reduced DNA quality due to formalin fixation of the biopsies and a limited sensitivity of the 
PCR in case of a low percentage of aberrant IELs. Therefore, the tested polyclonal status 
in this cohort is most likely overestimated. However, we have previously shown5 that flow 
cytometry of aberrant IELs is superior to clonality analysis for risk stratification in RCD II.
Approximately 40% of the RCD II patients showed an immunological response after 
2-CdA treatment, defined as a decrease of more than 20% of the aberrant intestinal IELs 
determined by flow cytometric analysis. However, the majority still showed more than 30% 
aberrant IELs during follow-up. Expansion of these aberrant T-lymphocytes, which reside 
in the intraepithelial as well as lamina propria layer of the small intestine25, is generally 
accepted as the culprit factor in the progression into EATL. Conversely, in our series the 
persisting high percentage of aberrant mucosal T-lymphocytes did not correlate with the 
relatively low EATL occurrence found during the time of follow-up so far. Unfortunately, 
reports from other centres on the immunological response determined by flow cytometric 
analysis after treatment are lacking. Whereas the percentage of aberrant IELs is established 
to be important in the diagnostic work-up for distinguishing RCD type I and II5, apparently it is 
questionable whether this percentage is a predictive marker for progression into EATL during 
monitoring of the therapeutic response. Further research is mandatory to further elucidate 
EATL risk stratification. Immunophenotyping of the aberrant T-cells by flow cytometric 
analysis of small intestinal biopsies and probably also genotyping seem to be appropriate 
methods to search for predictive markers. In addition, future studies on quantifying the 
mass of aberrant IELs using immuno-PET techniques, instead of the currently determined 
percentage of aberrant IELs, given the relatively equal depletion of normal and aberrant 
IELs upon 2-CdA treatment, have to be conducted.
In the current analysis approximately half of the RCD II patients was unresponsive 
to 2-CdA, for yet unknown reasons. A significant association with the degree of mucosal 
villous atrophy, the percentage of aberrant IELs, and levels of BMI, Hb and albumin before 
2-CdA treatment, clonal TCR-γ gene rearrangement and HLA-DQ status was not revealed. 
Although dose-finding studies with 2-CdA infusion in RCD are not conducted, clinical dose-
finding studies in lymphoproliferative diseases showed good response rates with an identical 
treatment schedule.13, 26 In addition, compared to intravenous infusions and subcutaneous 
injections which provide identical plasma 2-CdA levels, oral administration has a much lower 
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bioavailability (approximately 40%) due to degradation through acid in the stomach and 
intestinal bacteria.14 A higher dose and/or a prolonged treatment schedule might result in 
a higher response rate, yet the maximum tolerated dose established in lymphoproliferative 
diseases without serious adverse events was 0.1mg/kg/per day for 7 days.13 A recent 
clinical trial of oral cladribine for relapsing multiple sclerosis showed that short-course and 
high dose (3.5mg/kg) therapy is effective, yet lymphocytopenia is frequently reported.15 
Furthermore, the high sensitivity of hairy cell leukaemia (HCL) for treatment with 2-CdA, 
showing low resistance levels, is hypothesised to be the result of p53-dependent pathways 
required for killing resting cells and its inhibitory effect on the cholesterol metabolism 
which is highly active in HCL cells.14 Physiological conditions such as increased repair of 
DNA, increased anti-apoptotic effects and decreased activation of deoxycytidine kinase, an 
enzyme required for the cytotoxicity of 2-CdA, might be contributing factors to resistance 
as well.27 Whether the same results regarding administration route, treatment schedule and 
resistance pattern of 2-CdA also correlate with such good response rates in RCD II, remains 
to be further elucidated. The registration of oral 2-CdA for multiple sclerosis in Europe, 
might be a further step forward towards the application of this drug in RCD as well as some 
other gastro-enterological diseases refractory to currently available therapies, including 
Crohn’s disease, ulcerative colitis and autoimmune hepatitis.
In conclusion, 2-CdA appears to be a promising treatment in RCD II. This analysis showed 
excellent clinical and histological response rates after 2-CdA treatment. Furthermore, 2-CdA 
therapy does not necessitate the additional use of corticosteroids and subsequently prevents 
steroid-dependency and its complications. Although EATL could not be fully prevented, its 
incidence was restricted to 17%. Multicentre, randomised clinical trials with 2-CdA and/
or other new treatment options are mandatory to standardise the treatment strategy for 
RCD II, in order to further decrease morbidity and mortality in this patient group. 
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ABSTRACT 
Objectives: Autologous haematopoietic stem-cell transplantation (au-SCT) has been an 
effective therapy for refractory disease, in both malignancies and severe autoimmune 
diseases. It seems feasible and safe for refractory coeliac disease (RCD) type II, although 
long-term results have not been evaluated yet. With current therapies, progression into 
enteropathy associated T-cell lymphoma (EATL) occurs in 60-80%, having a high mortality 
rate. Therefore, it is important to evaluate new treatment strategies. 
Methods: Between March 2004 and February 2010, 18 RCD II patients were evaluated for 
au-SCT preceded by conditioning with fludarabine and melphalan, as a consequence of 
unresponsiveness to cladribine therapy. Adverse events, survival rate, EATL development, 
and change in clinical, histological and immunological course were monitored. 
Results: Thirteen patients were transplanted successfully and followed for >2 years; 
the 4-year survival rate was 66%. Only one patient died because of transplant-related 
complications. The majority of patients showed an impressive clinical improvement and five 
a complete histological response. In five patients, au-SCT could not be performed; they all 
died with a median survival of 5.5 months. EATL was observed in one transplanted patient, 
only after four years of follow-up. 
Conclusion: Au-SCT after conditioning with high dose chemotherapy in RCD II patients 
unresponsive to cladribine therapy, is feasible, and seems promising.
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InTRODuCTIOn
Coeliac disease (CD) is a major health care issue world wide, with a prevalence of around 
1%, affecting people of all ages.1 A permanent state of intolerance to gluten-containing 
food leads to chronic inflammation of the small intestine. Hallmarks of CD are lymphocytic 
infiltration of the lamina propria, expansion of the intraepithelial lymphocyte (IEL) 
population, hyperplasia of the crypts, and atrophy of the villi. CD occurs in genetically 
susceptible individuals who almost always carry the HLA-DQ 2/8 alleles.2, 3 
Although improvement is usually seen upon life-long withdrawal of dietary gluten, a 
small percentage (2-5) of the adult-onset CD patients, especially those diagnosed above 
the age of 50 years, lacks clinical and histological response despite strict adherence to 
such a gluten-free diet (GFD) for more than 12 months. Patients are classified as having 
refractory coeliac disease (RCD) if dietary consumption of gluten and other causes of 
malabsorption with villous atrophy are ruled out.4, 5 On the basis of immunophenotyping 
of the IELs, RCD can be subdivided into two groups: type I with phenotypically normal and 
type II with phenotypically aberrant IELs, aberrance being defined as lack of the surface 
markers CD3, CD4 and CD8, but with expression of cytoplasmic CD3. Clonal expansion of 
these aberrant IELs is thought to be responsible for progression to enteropathy associated 
T-cell lymphoma (EATL).4, 6, 7 The genesis and expansion of these monoclonal T-cells involve 
both inappropriate immune responses to gluten and acquisition of genetic abnormalities. 
RCD II is in most patients resistant to most studied therapies, including corticosteroids, 
budesonide, infliximab, cyclosporine, IL-10 and azathioprine/prednisone8 and has a high 
risk of progressing to EATL (60-80% within 5 years).9, 10 This peripheral T-cell lymphoma has a 
very poor prognosis with a 2-year survival of only 15%, mainly because of failure to respond 
to chemotherapy.9, 10 Therefore, it is of utmost importance to evaluate new treatment 
strategies for RCD II patients, and in particular for those unresponsive to conventional 
immunosuppressive drugs to improve the clinical course and prevent or delay development 
of EATL. 
Until 2005 in our tertiary referral centre for RCD, type II patients were initially treated 
with conventional immunosuppressive drugs, mainly azathioprine or prednisone or both, 
cladribine was prescribed if they were clinically and histologically unresponsive. Cladribine 
is a synthetic purine nucleoside homologue with cytotoxic activity. Since 2005 a modified 
treatment strategy has been initiated with cladribine being drug of first choice, based on a 
study showing that azathioprine combined with prednisone is not effective in most RCD II 
patients.11 For patients not responding, an alternative was sought. High dose chemo/
radiotherapy followed by autologous haematopoietic stem-cell transplantation (au-SCT) has 
been effective therapy for refractory disease not only in haematological malignancies, but 
also in severe autoimmune disease.12-14 In autoimmune disease, au-SCT is supposed to induce 
immunoablation with subsequent regeneration of naïf T-lymphocytes derived from reinfused 
haematopoietic progenitor cells.13-15 Analysis of our first seven RCD II patients treated with 
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au-SCT showed this treatment approach is feasible and well tolerated in coeliac patients. 
Survival at that time seemed promising, but follow-up was short.16
This analysis evaluates the follow-up of 18 RCD II patients, including seven patients 
of our pilot study, who were selected for au-SCT as a consequence of unresponsiveness to 
conventional immunosuppressive and/or cladribine therapy. Fifteen patients were treated 
in Amsterdam, one in each Italy, Portugal and Germany.
MATERIAlS AnD METHODS
This study reports extended follow-up of the open-label prospective phase I study performed 
by Al-Toma et al.16 with six new transplanted patients added, who were referred after 
inclusion of the latter study was finished. Between March 2004 and February 2010, 18 
cladribine unresponsive RCD II patients were evaluated for au-SCT.
Inclusion and exclusion criteria
Patients aged <70 years and diagnosed with RCD II were included when they showed no 
response to one or two courses of cladribine, administered intravenously in a dose of 
0.1mg/kg per day for 5 consecutive days. Response was defined as clinical (improvement 
of signs and symptoms of malabsorption and weight gain) and histological (Marsh criteria 
0/I) and/or immunological (>20% decrease of aberrant IELs) response. The diagnosis of 
RCD II was based on persisting or recurring symptoms and small intestinal villous atrophy 
after a former good response despite strict adherence to a GFD for at least 1 year.5, 17 
Furthermore, the clinically validated cut-off value of >20% aberrant IELs detected by flow 
cytometric analysis was used to distinguish RCD type I and type II.7 A lower percentage of 
aberrant T-cells was allowed in the presence of ulcerative jejunitis. T-cell receptor (TCR)-γ 
gene rearrangement was performed as previously described.7 Although this clonal TCR- γ 
rearrangement is still a widely accepted additional method to define RCD II, Verbeek et 
al.7 showed that the percentage of aberrant IELs detected by flow cytometric analysis is 
more accurate to define RCD II. EATL was excluded by several investigations after CT-scan18, 
whole body PET-scan19, MRI-enteroclysis20, upper gastro-intestinal endoscopy, video capsule 
endoscopy21 and/or double-balloon enteroscopy22. This diagnosis was confirmed according 
to the WHO classification of tumours of haematopoietic and lymphoid tissues.23 WHO 
performance status24 had to be ≤2, and no severe concomitant cardiac, pulmonary, renal 
or hepatic disease was to be present. Active uncontrolled infection and HIV positivity were 
also exclusion criteria. 
Peripheral blood stem cells mobilisation, conditioning and au-SCT
Mobilisation of haematopoietic progenitor cells from the bone marrow into the peripheral 
blood was achieved using granulocyte colony-stimulating factor (G-CSF) 2x10 µg/kg by 
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s.c. injection daily for at least four days without preceding chemotherapy. The minimum 
amount of CD34+ cells collected was 2x106 per kg. The conditioning regimen consisted of 
fludarabine administered orally for five days (40 mg/m2 per day) and an intermediate dose 
melphalan (administered i.v., 2 days, 70 mg/m2 per day), as shown in Figure 1. At day 0 stem 
cells were reinfused. The purpose of this conditioning regimen was both intensive T-cell 
depletion and myeloablation by a purine analog added to melphalan (total dose 140 mg/m2). 
All patients received standard antibacterial and antifungal prophylaxis during neutropenia 
and trimethoprim-sulfamethoxazole gluten-free syrup 480-960 mg daily until six months 
after transplantation. Total parenteral nutrition and blood and platelet transfusions were 
given if indicated.
Follow-up and criteria of response
Before, during and after au-SCT, a clinical assessment was carried out noting in particular 
signs and symptoms of malabsorption. Body mass index (BMI), WHO performance status, and 
the need for transfusions, for additional nutritional support and for additional antimicrobial 
treatment were documented. Clinical response is defined as improvement of diarrhoea 
and constant or improved WHO performance status, combined with at least two out of 
the following clinical parameters within the normal range or an improvement of ≥1 point: 
1) BMI, 2) albumin and 3) Hb. Multiple duodenal biopsies were taken by upper gastro-
intestinal endoscopy to detect histopathological abnormalities and to perform IELs 
immunophenotyping by flowcytometry analysis7, 25, 26 at different time points (3, 12 and 24 
months) after au-SCT. Isolation of small intestinal IELs and staining for immuno-phenotyping 
were performed as previously described.7 Complete histological response is defined as a 
normalisation of the architecture of the small intestinal mucosa, classified as Marsh 0 or 
I lesion according to the modified Marsh criteria.27 A decline of >20% in the percentage 
of aberrant IELs was considered a significant immunological response. In addition, overall 
survival and the EATL occurrence were evaluated during follow-up.
Statistical analysis
Quantitative data were expressed as medians. Kaplan-Meier survival curves were constructed 
using SPSS software (SPSS Inc. Chicago, Illinois, USA). 
Ethics approval and informed consent 
Approval of the medical ethics committee was obtained, and all treated patients signed an 
informed consent in accordance with the Declaration of Helsinki.
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Figure 1  |  Conditioning regimen before au-SCT.
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RESulTS
In total, 18 RCD II patients (Table 1) who were refractory to cladribine therapy were eligible 
for au-SCT. The median time between cladribine treatment and au-SCT was 6.25 months. 
All patients entered the treatment protocol, however five patients did not make it to au-
SCT (Table 2): two due to unsuccessful leukapheresis and in three patients progression into 
EATL occurred before stem cells could be collected, as depicted in Figure 2. The patients 
reaching actual transplant (n=13) had a median follow-up time of >2 years, ranging from 10 
up to 67 months.
 
Survival and disease status
Out of the 18 patients unresponsive to cladribine, eight patients died (44%), five of them due 
to EATL (28%). If au-SCT was not reached for any reason, mortality in the non-transplanted 
cohort was high; all patients died within a median follow-up of 5.5 months (range 1-12.5). In 
the transplanted group, however, 23% (3/13) of the patients died. There was one transplant-
related death due to septicaemia with subsequent meningitis. The other two patients died of 
chronic encephalitis and EATL, complications associated with CD rather than transplantation. 
Interestingly, in the latter patient EATL occurred four years after transplantation (Figure 2). 
All five patients in whom EATL occurred, died, with a mean survival of 2 months (range 
0-8) after diagnosis. The overall 3- and 4-year survival after undergoing au-SCT in case of 
unresponsiveness to cladribine therapy is 80% and 66% respectively (Figure 3).  
Overall clinical, histological and immunological outcome is depicted in Table 3. All 
transplanted patients reached follow-up of almost one year to assess remission status. 
Within one year after au-SCT, the majority of patients (11/13) showed impressive clinical 
improvement with normalisation of stool frequency, disappearance of gastro-intestinal 
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symptoms, and normal levels of or improvement of ≥1 point in BMI, albumin and/or Hb. 
All patients had a WHO performance status of 0 at the end of follow-up. In addition, 
improvement of BMI was documented from a median level of 20,1 kg/m2 at baseline to 22.5 
kg/m2 after au-SCT. The median serum albumin level increased from 36 to 42g/L (Table 3). 
In total, 38% (5/13) had a complete histological response, defined as Marsh 0 or I. 
Two of them achieved this response within three months, two within six months and one 
after two years. One patient had a partial response from a Marsh IIIB to Marsh II lesion 
and two patients already had a Marsh 0 and I lesion before au-SCT. The remaining two 
patients showed stable and progressive histological abnormalities after au-SCT. The median 
percentage of immunophenotypically aberrant IELs was 45% before transplantation and 54% 
at the end of follow-up. Only one patient showed a decrease in the percentage of aberrant 
T-lymphocytes to within the normal value. The patient showed a clinical and complete 
histological response as well. 
Figure 2  |  Flow chart of cladribine-resistant RCD II patients.
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Table 1  |  Patient characteristics.
Transplanted
n=1
not transplanted 
n=5
Gender
  Male  7  3
  Female  6  2
Median age at CD diagnosis (yr), range  50 (37-68)  63 (45-66)
Median age at RCD II diagnosis (yr), range  58 (42-68)  64 (47-70)
Median age at (intention to) au-SCT (yr), range  59 (43-68)  65 (52-70)
Treatment prior to au-SCT
  Cladribine  13  5
  Azathioprine / Prednisone  3  2
Median time between cladribine and au-SCT (mo), range 1   6.25 ( 3-30)
Median follow-up time (mo), range  26 (10-67)  5.5 (1-12.5)
HlA-DQ status
  DQ2 heterozygous    4  2
  DQ2 homozygous    8  2
  DQ2 and DQ8            1  1
TCR-γ rearrangement
  Monoclonal  8  4
  Polyclonal  5  1
Abbreviations: CD, coeliac disease; RCD, refractory coeliac disease.
1 Due to change in treatment strategy two patients were transplanted two years after cladribine therapy.
Table 2  |  Transplant characteristics. 
Patients Duration 
admission 
(days)
Re-infusion 
CD34+ cells 
(x106/kg)
Time to 
neutrophil 
recovery1 
(days)
Time to 
platelet 
recovery 2 
(days)
TPn Platelet 
transfusion
Red blood cells 
transfusion
  1 19 2.09 12 11 Yes 1x 3x
  2 17 2.21 12 11 Yes 2x 6x
  3 14 2.06 12 12 Yes 1x No
  4 24 2.00 17 27 No No No
  5 16 2.26 7 7 No 1x 6x
  6 29 2.21 18 17 Yes No 3x
  7 23 2.47 19 17 Yes No 1x
  8 24 2.17 13 14 No 1x 6x
  9 19 2.96 16 15 No No No
10 25 2.40 20 22 No 1x 2x
11 30 3.60 13 8 Yes No 2x
12 28 3.26 12 9 Yes No No
13 19 2.27 14 12 No 1x No
Median 
(range)
23
(14-30)
2.26
(2-3.6)
13
(7-20)
12
(7-27)
Abbreviation: TPN, total parenteral nutrition.
1 Neutrophil recovery: time to achieve a neutrophil count above 0.5x109/L.
2 Platelet recovery: time to platelet count above 20x109.
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Figure 3  |  Survival curve of RCD II patients unresponsive 
to cladribine therapy who were treated with high dose 
chemotherapy followed by au-SCT.
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DISCuSSIOn
Till now there is no standardised treatment strategy for RCD II.8 The high risk of subsequent 
progression to EATL with dismal prognosis highlights the need for new treatment strategies. 
Although treatment with conventional immunosuppressive drugs, including azathioprine 
and prednisone, may lead to clinical response in several RCD II patients11, 28, 29, most of 
them do not have complete histological improvement, do not have a beneficial survival 
due to progression into EATL11, 30 and/or become steroid-dependent.28 Therefore, in our 
medical centre cladribine rather than azathioprine is prescribed, showing similar clinical 
improvement, but with better histological response rates without any steroid dependency 
and need for long-term medication.31 However, approximately half of the patients is still 
clinically and histologically unresponsive to this therapy. In our analysis this specific group 
of RCD II patients refractory to cladribine therapy was scheduled for treatment with high 
dose chemotherapy followed by au-SCT.
In agreement with our pilot study16, we report in this larger cohort of RCD II patients 
that the treatment approach we described is feasible and no serious transplant-related 
short-term adverse events were noted. Moreover, during extended follow-up no secondary 
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malignancies and myelodysplastic disorders were observed so far. Treatment-related 
mortality was not increased compared to other indications for au-SCT.
The 5-year survival reported for RCD II, irrespective of treatment is currently 44-58%.9, 28, 29 
In these series, patients were initially treated with different types of medication, mainly 
conventional immunosuppressive drugs. In our analysis however, only RCD II patients 
unresponsive to these treatment options were scheduled for au-SCT, having a 4-year survival 
of 66% if they manage to proceed transplantation. This survival rate seems promising so 
far, as this specific group of unresponsive patients has a worse prognosis. In addition, 
this is supported by the high mortality of the five refractory patients who could not be 
transplanted.  
Four patients were already diagnosed as having overt EATL before first leukapheresis 
attempt, reflecting the quick development of this condition. The EATL rate observed in 
the transplanted group (1/13) is much better than that reported in published RCD II series 
(60-80%)32, however, in a small series. Even if we include the non-transplanted patients 
who developed EATL, the EATL rate is less than reported (30%). As one transplanted patient 
developed an overt EATL only after four years of follow-up, chemotherapy followed by 
au-SCT might possibly delay the development of this type of lymphoma. Whether progression 
into EATL is prevented or delayed must be elucidated by more prolonged follow-up.
In addition, in two patients transplantation could not be performed because of failure of 
stem cell collection, most likely as a consequence of previous administration of cladribine 
therapy. Both cladribine and fludarabine are purine nucleoside analogues. Although 
fludarabine-containing regimens are well known for impairing stem cell mobilisation, less is 
known about the influence of cladribine on mobilisation efficacy.33 However, it seems from 
our data that cladribine might indeed influence stem cell collection. A solution might be 
mobilisation after single-dose cyclophosphamide together with G-CSF and/or implementing 
plerixafor.34 This new approach should be evaluated in this patient group.
Our results showed an impressive clinical improvement and enhanced quality of life 
in almost all patients after transplantation. Approximately half of the patients had a 
significant recovery of the architectural abnormalities of the small intestinal mucosa. It is 
intriguing that a high percentage of aberrant IELs persists after au-SCT, particularly in view 
of the improved Marsh score. These aberrant T-cells reside in the intraepithelial as well 
as the laminia propria layer.35 Although this percentage is crucial in the diagnostic work-
up for distinguishing RCD types I and II,7 our data suggest that the percentage of aberrant 
IELs is not suitable for monitoring therapy and predicting prognosis, at least in this cohort 
and time of follow-up. In fact, the percentage of aberrant T-cells is not the same as the 
overall depletion of T-cells after au-SCT. Whether the absolute aberrant T-cell load, which 
might be quantified by flow cytometric analysis or by quantitative PET scanning, instead of 
the percentage of aberrant T-cells is more suitable to predict prognosis is not clear yet. If 
histopathology or another undefined parameter should be used to quantify mass needs to 
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be investigated as well. Furthermore, clonal expansion of these aberrant IELs is considered 
to be responsible for progression into an EATL, however in our series the persisting high 
percentage of aberrant IELs after au-SCT was not reflected in increased EATL development. 
In addition, the TCR-γ rearrangement performed after au-SCT could not detect a clonal peak 
with current available technology (data not shown). So far, it is still generally accepted that 
aberrant T-cells are the factor responsible in EATL development. Thus, further reduction 
of T-cells or T-cell mass by intensifying conditioning pre-au-SCT might improve outcome. 
This could be achieved by a higher dose of fludarabine/cladribine combined with anti-CD52 
(alemtuzumab), anti-thymocyte globulin or new specific anti-T-cell agents. 
Randomised clinical trials comparing conservative follow-up to au-SCT, if unresponsive 
to cladribine therapy, are not available so far. In the future, multicentre randomised trials 
or trials with historical control groups will be needed to explore these new treatment 
strategies. 
In conclusion, high dose chemotherapy followed by au-SCT in RCD II patients unresponsive 
to cladribine therapy is well tolerated and no clinically relevant long-term complications 
were found so far. Moreover, if the patients manage to proceed au-SCT, an impressive clinical 
and histological improvement is obtained, and survival rates so far are promising probably 
because of less progression to EATL. 
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Enteropathy associated T-cell lymphoma (EATL) is associated with refractory coeliac 
disease (RCD).1, 2 Approximately 50% of patients with coeliac disease (CD) is diagnosed 
at adulthood, of them 2-5% develops RCD. RCD patients comprise two groups: one with 
immunophenotypically aberrant intraepithelial lymphocytes (RCD II) and one without these 
cells (RCD I), the cut-off being 20%.2 Aberrant IELs are characterised by lack of surface 
expression of CD3, CD4 and CD8. 60-80% of RCD II patients develops EATL within five years.3 
EATL is almost inevitable lethal, although high-dose chemotherapy followed by autologous 
stem-cell transplantation (au-SCT) might improve survival.3 Experience with myeloablative 
or reduced-intensity conditioned (RIC) allogeneic stem-cell transplantation (allo-SCT) in 
T-cell non-Hodgkin’s lymphoma is limited, but promising.4 We report the first two coeliac 
patients with EATL in whom we performed allo-RIC-SCT with a HLA-identical sibling donor.
CASE I
A 66 year old man, recently diagnosed with CD, presented with weight loss and night 
sweats. Abdominal CT-scan showed increased wall thickness of the jejunum and mesenterial 
lymphadenopathy, suggestive of EATL.5 Double balloon enteroscopy revealed ulcerative 
jejunitis and stenosis due to multiple masses. A diagnosis of EATL was confirmed by biopsies. 
Bone marrow investigation revealed 15% aberrant T-cells (CD3+, CD7-).2 He underwent a 
resection of the involved small bowel segment, with primary anastomosis. After surgery there 
were no signs of a short-bowel syndrome and a strict gluten-free diet (GFD) was started. 
Post-surgical FDG-PET evaluation showed multiple lymph nodes suspicious of residual EATL. 
Treatment with six cycles of CHOP chemotherapy was initiated and subsequent FDG-PET 
showed complete response afterwards. 
HLA-typing identified two siblings as fully matched donors. One of them was diagnosed 
with CD during pre-transplant screening. The other sibling, with a negative coeliac 
serotype, was therefore selected. At six weeks after the last chemotherapy, allo-RIC-SCT 
was performed following conditioning with fludarabine (25 mg/m2) and cyclophosphamide 
(500 mg/m2; flu-cy) for five consecutive days. A total of 4.8x106 CD34+ cells/kg were 
infused after conditioning. Donorchimerisms after one and two months were 83% and 90%, 
respectively. 
At two months after allo-SCT the patient developed a relapse of EATL. Rapid deterioration 
of his clinical condition precluded further treatment and the patient died three months 
after allo-SCT.
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CASE II
A 61 year old man was admitted with perforation of the jejunum. He underwent partial 
surgical resection of the jejunum. Pathological examination revealed perforation due to 
EATL (Marsh IIIA). Bone marrow investigation revealed 0.01% aberrant T-cells. 
After surgery there were no signs of a short-bowel syndrome and a strict GFD was 
initiated. Post-surgical FDG-PET evaluation showed intense uptake in the left upper part of 
the abdomen. There were no other signs of EATL. After six cycles of CHOP chemotherapy 
FDG-PET showed clinical remission. 
The patient was subsequently transplanted with a HLA compatible matched sibling two 
months after finishing chemotherapy. A total of 8.3 x 106 CD34+ cells/kg were infused after 
conditioning. At one month after transplantation, donorchimerisms were 23% in peripheral 
blood and 19% in bone marrow.  
At six weeks after transplantation the patient developed non-specific abdominal 
complaints and a rise of the lactate dehydrogenase. As relapse was suspected, 
immunosuppressive medication was discontinued. After two weeks, relapse of EATL was 
confirmed. His condition deteriorated quickly and nine weeks after allo-SCT the patient 
died.
DISCuSSIOn 
To date, treatment of EATL is rather disappointing. Recently, several studies with high-dose 
chemotherapy and au-SCT have been published. These regimens showed improving results, 
but only in selected patients. Bishton and Haynes3 illustrated the beneficial effect of high-
dose chemotherapy in six patients. In total, four patients are still alive after two till four 
years follow-up. Other reports, however, showed less favourable results.6-8 New strategies 
are therefore urgently needed. 
Theoretically, allo-SCT might be a treatment option for patients diagnosed with EATL. 
In a prospective, multicentre phase II trial, a total of 170 elderly (≥45 years) patients with 
relapsed or refractory lymphomas of all types (including 14% aggressive T-cell non-Hodgkin’s 
lymphoma) received allo-RIC-SCT from HLA-identical sibling donors. This procedure was 
found to be feasible and effective. A trend towards a higher relapse rate was observed in 
patients with aggressive lymphoma in partial response or with refractory disease before 
transplantation. Withdrawal of cyclosporine contributed to a clinical response. Median time 
to progression was six months.9 In an earlier study a poor outcome of allo-RIC-SCT in patients 
with chemoresistant and high-grade lymphomas (including T-cell non-Hodgkin’s lymphoma) 
was reported.10 Although this retrospective study failed to show an effect of intensity 
of conditioning, it was hypothesised that these patients benefited less from allo-SCT, 
as the beneficial effect of graft versus lymphoma (GvL) takes a few months to develop. 
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Donor lymphocyte infusion was successful, illustrating a GvL effect.10 
We decided to offer allo-RIC-SCT to chemosensitive patients in clinical response using 
our flu-cy conditioning scheme. As HLA-DQ2 and DQ8 are associated with CD, the donor 
search needed special consideration to exclude donors with CD by serological screening. 
The two cases presented are the first EATL patients treated with allo-RIC-SCT. The 
experimental setting led to the selection of HLA-identical siblings only. Although both 
patients were chemosensitive and in clinical response before transplantation, they 
developed relapse of EATL within a few weeks after transplantation. As a GvL effect could 
not have occurred, the conditioning probably was not sufficiently potent to buy time. 
Possibly more intensive consolidation, for instance the Bishton schedule, is necessary 
to improve current results in this highly aggressive lymphoma.3 Moreover, it may be that 
introducing GvL in an earlier stage, established by more rapid exclusion of immunosuppressive 
medication, might improve results.
In conclusion, this report of allo-RIC-SCT in patients with EATL and CD illustrates its 
feasibility, but also disappointing results in two patients in clinical response in excellent 
condition pre-transplant. It is possible that more intensive consolidation is needed to 
improve results.
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TOEKOMSTPERSPECTIEF
Een beeld schetsen 
van de wereld om je heen 
kan niet zonder  
(gebruik te maken van) 
perspectief. 
Dat leidt tot (denk)beelden 
die naast elkaar blijven bestaan 
zonder kans op convergeren.
In toekomstperspectief gezien, 
kan dit tot niets anders leiden 
dan zonder inzicht te (ver)dwalen.
Pas na divergeren 
is er weer (uit)zicht. 
Een beter en breder 
toekomstperspectief! 
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GEnERAl DISCuSSIOn
Growing insight into the clinical presentation of coeliac disease (CD) has resulted in novel 
diagnostic, prognostic and therapeutic dilemmas. Chapter one provides an overview of the 
latest trends in epidemiology, clinical presentation, diagnosis, complications and treatment 
with respect to the spectrum of CD. Since the recognition of its broad clinical spectrum, 
especially adult-onset CD and complications of CD are a matter of debate, in particular 
refractory coeliac disease (RCD) and enteropathy associated T-cell lymphoma (EATL), which 
are recognised as relevant clinical entities since more than two decades. As a subset of 
these patients has a poor prognosis, it is of utmost importance to accurately differentiate 
between uncomplicated and complicated forms of CD in order to enable early intervention. 
Despite increased understanding during recent years, the underlying pathophysiology is not 
completely understood, some aspects of the diagnostic work-up are still under debate, a 
standardised treatment protocol is lacking and parameters for predicting and monitoring 
these complicated stages of CD are not yet available. This thesis provides novel insight in 
the diagnostic aspects and therapeutic options in CD and its complicated stages.
PART I: DIAGnOSTIC ASPECTS
Serum parameters beyond standard antibody testing 
To date, small intestinal biopsies obtained by gastro-duodenal endoscopy are still required 
in the diagnostic work-up and follow-up of uncomplicated as well as complicated CD. The 
histopathological observation of villous atrophy in florid CD is well appreciated. To date, 
small intestinal biopsies obtained by gastro-duodenal endoscopy are still required in the 
diagnostic work-up and follow-up of uncomplicated as well as complicated CD in adults. 
The recently published revised ESPGHAN (European Society for Paediatric Gastroenterology 
Hepatology and Nutrition) guidelines for the diagnosis of coeliac disease in children mention 
the option for omitting duodenal biopsies and histology if certain conditions are fulfilled.1 
But, the guidelines for adult patients have not been revised yet. The histopathological 
observation of villous atrophy in florid CD is well appreciated. However, the behaviour of 
the enterocyte itself in adult-onset CD has not yet been investigated. As mucosal villous 
atrophy is the hallmark of both active CD and refractory CD, histopathological classification 
according to the modified Marsh criteria2 is of no use to distinguish between these stages of 
CD. Although CD associated antibodies are valuable for diagnosing active CD and monitoring 
response to a gluten-free diet (GFD), these antibodies are within their reference range in 
complicated CD and therefore of no use in predicting as well as monitoring RCD and EATL. 
Chapter two shows that enterocyte destruction determined by serum intestinal fatty-
acid binding protein (I-FABP) levels is evidently increased in adult CD patients at time of 
diagnosis as compared to healthy controls. I-FABP levels correlate with both villous atrophy 
and IgA-tTG titres and decline after initiation of a GFD. In contrast to serum I-FABP levels in 
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childhood CD that rapidly decrease after initiation of a GFD3, low grade enterocyte damage, 
detected by serum I-FABP levels, persists in adults upon long-term adherence to a GFD, 
despite the lack of villous atrophy and detectable IgA-tTGA levels in the majority of cases. 
These findings are in keeping with the slow and incomplete mucosal recovery observed in 
a substantial number of adult-onset CD patients upon a GFD with subsequent normalised 
serology and disappearance of symptoms.4-6 Moreover, serum I-FABP levels correlate 
clearly with the degree of villous atrophy observed in patients adhering to a GFD. So far, 
however, it is unknown whether the observed persisting enterocyte damage in adults may 
indicate non-compliance or unintentional gluten intake, despite evaluation by a specialised 
dietitian, or a manifestation of the autoimmune disease itself. Taken together, our findings 
support the currently changing opinion towards the clinical aspects of adult CD. Although 
the diagnosis of CD in adult patients proceeds along the same lines as that of younger 
patients, it appears to be more complex due to its initial presentation with less prominent 
symptoms of impaired intestinal absorption, with signs of micronutrient deficiencies, other 
autoimmune diseases or even with malignancies.7 Furthermore, as mucosal recovery may be 
slow in adult patients diagnosed with CD, closely monitoring clinical response and possible 
complications, including implications of long-lasting malabsorption, development of 
autoimmune diseases, refractory CD and (intestinal) malignancies, appears to be important. 
I-FABP clearly represents a potential marker for monitoring a GFD to detect ongoing mucosal 
abnormalities without the need to perform a gastro-duodenal endoscopy. However, larger 
prospective studies are mandatory to elucidate the specific value of serum I-FABP in 
diagnosis and follow-up. Currently, serum I-FABP levels in the complicated forms of CD are 
under investigation. Preliminary data show no differences in the severity of enterocyte 
damage between active CD and RCD I, II as well as EATL. In addition, it might be of interest 
to investigate the presence of IgA-tTG deposits in the small intestine and other (serum) 
markers indicating intestinal integrity in complicated CD. 
Chapter three provides further insight in the ability of several immunological and 
biochemical markers in the peripheral blood to distinguish the various CD subsets at time 
of diagnosis. The gluten-induced inflammation in active CD and the gluten-independent 
inflammation in RCD I/II show resemblance based on the serum levels of IL-8, IL-17, IL-22 
and sCD25 as well as the biochemical inflammatory parameters CRP, ESR and leukocyte 
count. RCD II differentiates itself by elevated serum IL-6 and granzyme-B concentrations. 
Furthermore, the clearly elevated levels of IL-8 and sCD25 found in both RCD subsets over the 
GFD group, suggest that these parameters might be helpful in monitoring the inflammatory 
disease status and in differentiating between these groups in ongoing research and daily 
clinical practice. In addition, serum IL-6 and albumin levels might be potentially useful to 
identify patients with complicated CD, as elevated IL-6 levels are a distinctive feature of 
both RCD II and EATL, and lower levels of albumin were observed in RCD I/II and EATL. 
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Whether RCD type I and II are two related disease entities or two independent conditions is 
still under debate. Our results show that both types share similar inflammatory characteristics 
and T-cell activation status. In addition, progression of RCD I into both RCD II8 and EATL9 has 
been observed, although only sporadically. However, a substantial aberrant IEL population10 
displaying a cytotoxic profile is the specific hallmark of RCD II. Increased serum levels of 
soluble granzyme-B and the high expression of intracellular granzyme-B in aberrant IELs 
(chapter four) were observed. Although group-wise trends can be appreciated, at least 
at the single patient level, so far no serum parameter appears sufficiently sensitive and 
specific for differentiating RCD type I and II or predicting transition into EATL, including 
those analysed in the present thesis. Hence, it follows that this is an area that needs further 
study. 
Origin and immunophenotype of aberrant IEls in RCD II 
The aberrant IEL population observed in RCD II lacks expression of the T-cell lineage-specific 
surface CD3-TCR-complex, but expresses the cytoplasmatic CD3 antigens and displays 
T-cell receptor rearrangements10, 11 indicative of T-cell lineage commitment. These cells 
are considered a premalignant cell population from which aggressive EATL evolves in half 
of the cases.11, 12 However, currently the cellular origin of these cells is unclear and there 
are no histopathological or immunophenotypic features identified that have a prognostic 
value in the evolution of aberrant IELs into an EATL. It has been hypothesised that they 
derive from mature TCR+ IELs, in particular gamma-delta T-lymphocytes11, 13, 14, or from 
CD3-CD7+ NK/T-cell precursor cells found in the small intestine of healthy individuals 
possibly in consequence of the ongoing extrathymic maturation of T-cells in the intestinal 
mucosa throughout life.15, 16 Following this, chapter four reveals a heterogeneous TCR-
gene rearrangement pattern and a lack of expression of the early T-cell development-
associated markers TdT, CD1alpha and CD34 in RCD II duodenal biopsies. This strongly 
suggests that the aberrant IEL population originates from a monoclonal expansion of partly 
matured T-cells that have deranged in their development before reaching full maturity. In 
contrast, Schmitz et al.17 showed that three RCD II cell lines expressed several activation 
receptors and NK-associated genes, including KIRs, granzyme-H and NKG2D. Interestingly, 
in our study only those patients harbouring the most mature aberrant IEL population, 
based on an almost completed TCR rearrangement, developed an EATL. It is tempting to 
speculate that the presence of aberrant IEL populations with different levels of maturity 
is, at least in part, an explanation for the clinical observation that only half of the RCD II 
patients eventually develops an EATL. The observed decreased PCNA expression in aberrant 
IELs might indicate an impaired DNA-mismatch repair system18, 19 and may consequently 
facilitate further transformation of these aberrant cells. Further research addressing the 
cause and consequences of this abnormal IEL development is definitely warranted.
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As some RCD II patients display polyclonal TCR-gamma, yet clonal TCR-beta or TCR-delta 
rearrangements, we suggest TCR-beta gene rearrangement analysis as the most valuable of 
available rearrangement analyses in the diagnostic work-up of RCD. This recommendation is 
supported by a recent publication by Perfetti et al.20 In addition, these results confirmed our 
previous findings that clonality analysis of only the TCR-gamma gene rearrangement misses 
monoclonal populations at risk for EATL. In contrast to immunophenotypical identification 
of aberrant populations.10 Furthermore, as aberrant IELs are not strictly confined to the 
small intestine but are also observed in other, extra-intestinal organs21, it is of interest to 
clarify their dissemination pattern in order to find a lead for novel therapeutic options. 
Phenotypic and genomic characteristics of EATl
Currently, the immunophenotype of EATL determined by immunohistochemistry plays a 
pivotal role in its diagnostic work-up, showing expression of CD3, CD7 and CD103, but lack 
of expression of CD4, CD5 and CD8 in the majority of cases. Furthermore, type 1 EATL 
usually exhibits a cytotoxic immunophenotype, characterised by expression of CD30, TIA-1, 
perforin and granzyme-B.22-24 Chapter five reports on an in-depth flow cytometric analysis of 
the immunophenotype and analysis of genomic alterations of EATL cells primarily presenting 
as leukemic ascites. The immunophenotype of this EATL is substantially different from the 
corresponding aberrant T-lymphocytes found in RCD II. First, the absence of the T-cell lineage 
associated markers CD2, CD7, CD52 and CD103, indicating further transformation. Second, 
the lack of CD103 and LFA-1 expression that may have contributed to migration of these 
cells outside the gastro-intestinal tract. Importantly, lack of CD7 and CD103 expression on 
EATL has not been reported so far and is not included in the current WHO classification of 
haematological malignancies.24 Third, compared to aberrant IELs in RCDII (chapter four) an 
extensive proliferative activity indicated by high expression levels of Ki-67 and PCNA was 
found. Furthermore, the observed expression of CD25 on the EATL cells was in agreement 
with previous work indicating that sCD25 is a sensitive marker for tumour burden in some 
lymphomas.25 However this could not be confirmed by the previously described study in 
chapter three (the serum levels of sCD25 did not significantly differ between EATL and RCD). 
Moreover, in keeping with the evidently increased serum levels of IL-6 in EATL as compared 
RCD I/II (chapter three), IL-6 was clearly detected in the leukemic ascites, illustrative for 
the local pro-inflammatory environment.
In agreement with limited studies on the karyotype of aberrant IELs in RCD, we observed 
a gain in chromosome 9q and trisomy of chromosome 1, previously suggested as an early and 
late event of EATL transformation, respectively.26 The current WHO classification postulates 
a 9q gain or a 16q loss responsible for inducing transition from RCD into EATL, and gains 
of 1q/5q and 8q distinguishing between most cases of type 1 and 2 EATL, respectively.24 
In contrast, we found both 1q and 8q gains, suggesting an increased level of chromosomal 
instability. Further insight into the mechanisms responsible for the development of EATL 
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may open new doors for early recognition and treatment of EATL. Extended genetic analysis 
including karyotyping and array CGH as well as functional and expression profiling of small 
intestinal aberrant IELs as compared to their normal counter parts, could be supportive in 
the search for new, more sensitive markers to predict the occurrence of EATL in an early 
stage. 
PART II: THERAPEuTIC OPTIOnS 
Coeliac disease: An-PEP
The only currently available treatment for CD consists of life-long dietary exclusion of 
gluten27, perceived as a substantial burden particularly due to high costs, dietary restriction, 
reduced social activity, and increased health worries.28 Alternative treatment modalities 
that reduce the need of dieting focus on modification of dietary components, enzymatic 
degradation of gluten, inhibition of intestinal permeability and modulation of the immune 
response.29 In line with this, chapter six of this thesis describes a randomised double-blind 
placebo-controlled pilot-study to the gluten-degrading Aspergillus niger-derived prolyl 
endoprotease (AN-PEP) in CD. Although AN-PEP appears to be well tolerated in the majority 
of coeliac patients, a two week gluten challenge (with placebo) seems to be insufficient 
to induce a clear clinical response, based on Marsh grade and CD associated antibodies. 
Consequently, no treatment effects of AN-PEP could be detected. Therefore, further studies 
with modified study design including a high dose of gluten consumption for an extended 
period of time with many more patients are warranted to support the potential of AN-PEP 
in degrading gluten. It might also be interesting to perform a study designed the other way 
round: small amounts of gluten with AN-PEP or placebo for a much longer period of time. 
Moreover, in addition to a dietitian inquiry and the CD associated antibodies IgA-tTG, IgA-
EMA, and IgA/G-DGA, it might be of interest to search for more sensitive makers to evaluate 
diet compliance and/or unintentional gluten intake. Recently, Biagi et al30 presented a 
simple and rapid questionnaire that verifies compliance to a GFD, however, education by an 
experienced dietitian remains very important. As suggested previously (chapter two), serum 
I-FABP levels and IgA-tTG deposits in the small intestine might be of potential use. 
RCD I: Tioguanine
Although the prognosis of RCD I is much more favourable than that of RCD II, as reflected 
in 5-year survival rates of around 90% and 44-58%, respectively9, 12, 31, treatment is believed 
to be important in preventing complications of longstanding malabsorption. Apart from 
a GFD and nutritional support, corticosteroids are the mainstay of treatment in RCD I. 
Unfortunately there are also snags attached to this therapy, including systemic side 
effects and corticosteroid dependency in the majority of cases.9 To reduce corticosteroid 
dependency and in case of corticosteroid refractoriness, azathioprine has been advocated 
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with good clinical response rates.32 Currently, treatment is largely empiric based on small 
series, showing good clinical response rates, yet histological response is lagging behind. 
Chapter seven reports on the non-conventional thiopurine derivative tioguanine in RCD I 
showing a good safety profile and clinical and histological response in the majority of cases. 
Therefore, tioguanine might be a suitable alternative treatment option for RCD I, either 
as first-line treatment, second-line treatment in patients unresponsive to corticosteroids 
and/or azathioprine, or as a steroid-sparing drug. In addition, further research is also 
warranted to establish the optimal treatment duration of tioguanine. In consequence of 
its rare incidence large multicentre international randomised trials including azathioprine, 
tioguanine, budesonide and placebo should be performed to establish the validity of each 
and any treatment option in RCD I. 
RCD II: Cladribine and au-SCT 
In the past decade several conventional and more experimental therapies have been 
evaluated in small series of RCD II9, 31-39, yet, a validated standard treatment of RCD II is 
lacking. The high risk of progression to EATL with dismal prognosis highlights the need for 
new treatment strategies. Since 2005 cladribine is the drug of first choice in our medical 
centre, but patients not responding to cladribine receive high dose chemotherapy with 
subsequent autologous haematopoietic stem-cell transplantation (au-SCT). Chapter 
eight and nine show that our suggested treatment protocol seems to hold promise. Both 
cladribine therapy and high dose chemotherapy followed by au-SCT were well tolerated. 
Approximately half of the patients responded well to cladribine, having a significantly 
higher survival rate compared to those who were unresponsive. The observed 80% clinical 
response rate was consistent with previous studies9, 31, hence, the potential advantage of 
cladribine seemed to be a better histological response, besides its steroid-sparing effect. 
The median overall survival and 2-year histological response rate of patients treated with 
up-front cladribine appeared to be superior to patients unresponsive to thiopurines and/or 
prednisone and subsequently treated with cladribine. Unfortunately progression into EATL 
could not be fully prevented, but, compared to previous reports showing EATL in 33–52% 
within 5 years9, 12, cladribine therapy appeared to result in a lower rate of lymphomagenesis 
(17%), yet approximately half of the patients had a 5-year follow-up. 
Although the overall clinical response rate of cladribine was actually good, with 
regard to our response criteria (defined as clinical, and complete histological and/or 
immunological response), for unknown reasons half of RCD II patients were unresponsive. 
Possibly a higher dose and/or a prolonged treatment schedule might result in a higher 
response rate. Therefore dose-finding studies need to be conducted. This specific group 
of unresponsive patients has a worse prognosis. If they manage to proceed high dose 
chemotherapy followed by au-SCT the observed 4-year survival of 66% seems promising. This 
is supported by an impressive clinical improvement and enhanced quality of life in almost 
all patients after transplantation. Approximately half of them showed a significant recovery 
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of the architectural abnormalities of the small intestinal mucosa. As EATL was observed only 
after four years of follow-up in one transplanted patient, chemotherapy followed by au-SCT 
might possibly delay the development of this type of lymphoma. Whether progression into 
EATL is prevented or delayed must be elucidated by more prolonged follow-up.
Overall, multicentre randomised trials comparing thiopurines and cladribine, and if 
unresponsive followed by au-SCT, to further explore these treatment strategies is warranted. 
Ongoing efforts to investigate other new treatment options such as IL-15 blocking antibodies 
(as IL-15 has a key role in the pathogenesis of RCD) are recommended in order to further 
decrease morbidity and mortality in this patient group. 
EATl: Allo-SCT
EATL is a virtually lethal condition with an overall 5-year survival of less than 20%.12, 40 To 
date, treatment of EATL is rather disappointing with a 2-year survival of 28% upon the 
classic CHOP (cyclophosphamide, doxorubine, vincristine and prednisone) protocol41 and 
an estimated median survival of 7.5 months upon CHOP-like or other new chemotherapy 
regimens.40, 42, 43 Approximately half of the cases is eligible for chemotherapy due to an 
advantaged stage at initial presentation, a poor performance status, multifocal involvement 
of the small intestine and/or complications. In addition, only half of them completes their 
scheduled chemotherapy.41, 44 In small series dealing with au-SCT preceded by different 
induction and conditioning chemotherapy regimens, variable results were reported.44-47 
Patients with an early stage of disease and use of a more aggressive conditioning regimen 
seemed to benefit most. Following a prospective study of 14 patients, a single course of 
CHOP with subsequent aggressive regimen IVE/MTX (ifosfamide, etoposide, epirubicin/
methotrexate) followed by au-SCT seemed promising, with a 5-year survival of 60%.44 An 
alternative treatment option evaluated in case-reports is Alemtuzumab (anti-CD52) plus 
chemotherapy, however, so far relapse could not be prevented48, 49. We are awaiting the 
results of a randomised phase III study in The Netherlands to evaluate the effectiveness of 
Alemtuzumab with 2-weekly CHOP versus 2-weekly CHOP alone and consolidated by au-SCT 
in patients <60 years of age (www.hovon.nl). As previous reports indicated lower relapse 
rates in allogenic haematopoietic stem-cell transplantation (allo-SCT) as compared to 
au-SCT in patients with indolent and high-grade non-Hodgkin lymphomas50, 51, chapter ten 
reports the first two patients with a type 1 EATL in whom allo-RIC-SCT with a HLA-identical 
sibling donor was performed. Although both patients were chemosensitive and in clinical 
remission before transplantation, a relapse of EATL occurred within a few weeks after 
transplantation. As a graft versus lymphoma effect could not have occurred, the conditioning 
(fludarabine, cyclophosphamide) probably was not sufficiently potent to buy time. Possibly 
more intensive consolidation is necessary to improve current results in this highly aggressive 
lymphoma. Introducing graft versus lymphoma in an earlier stage, established by more rapid 
exclusion of immunosuppressive medication, might improve results. 
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FuTuRE PERSPECTIVES 
This thesis “On the work-up of (refractory) coeliac disease” reveals novel insight into 
clinical aspects and treatment of the spectrum of CD, yet many areas require further study. 
First, the majority of coeliac patients respond well to a GFD, however it still has to 
be unravelled for what reason some, in particular adult patients, are refractory to a 
GFD ensuing RCD and/or EATL. In addition, the controversial role of strict adherence to 
a GFD in the development of RCD and EATL52-54 has to be further addressed in ongoing 
research. Following this, further identification of novel serological, immunophenotypic, 
genetic and/or molecular prognostic parameters for these complicated forms of CD is of 
utmost importance to decrease morbidity and mortality. To differentiate between RCD II 
patients who will develop an EATL and those who will not, is the ultimate target. Apart 
from serum I-FABP levels, other parameters representing intestinal permeability, such as 
antibodies against food antigens and zonulin levels are included in current investigation. In 
addition to IL-6, IL-8 and granzyme-B levels (chapter three), cytokine production profiles 
in the peripheral blood or by intestinal aberrant IELs may be topic of further research. 
Ongoing immunophenotypic analysis of aberrant IELs as compared to their normal counter 
parts (chapter four and five) involving additional markers representing the NK- or T-cell 
lineage, dendritic cells, DNA mitotic cell cycle profile, homing receptors and apoptosis are 
recommended. At the molecular level, TCR-beta gene rearrangement analysis is strongly 
suggested as an additional marker in the current diagnostic work-up of RCD (chapter four), 
hence larger series are mandatory to validate these data. Investigation of TCR-alpha chain 
rearrangements may provide further information on the origin of aberrant IELs. Furthermore, 
it is likely that in addition to MYO9B55, HLA-DQ2 homozygosity56 and chromosomal gains of 
1q, 9q and 5q26 (chapter 5) or deletion in 16q24, which are not routinely detected in the 
diagnostic work-up, other genes are associated with the development of RCD and EATL. 
International genome-wide association studies, and functional and expression profiling of 
small intestinal aberrant IELs in complicated CD may shed new lights on this matter.
Second, RCD II is a commonly accepted clinical disease entity with specific characteristics, 
whereas the role of RCD I within the spectrum of CD sill remains under debate. Do RCD I 
and II refer to a sliding scale within the CD spectrum, or does RCD I resemble florid CD 
in consequence of long-term unintentional gluten intake which could not be detected by 
currently available methods? Or does it represent an independent disease entity showing 
great similarity to CD? 
Third, as aberrant IEls are not strictly confined to the small intestine21 and can even be 
found outside the gastro-intestinal tract at initial presentation (chapter five), analysis of 
homing receptors and genetic profiling will largely contribute to our understanding of their 
dissemination pattern and may provide a lead for novel therapeutic options. In addition, it 
might be interesting to investigate aberrant IELs in the stomach and colon as well. 
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Fourth, a GFD remains the only effective treatment for CD despite alternative treatment 
modalities, including enzymatic degradation of gluten by AN-PEP (chapter six), therefore 
new clinical trials are warranted. Several therapeutic options for RCD and EATL have been 
investigated. However treatment remains challenging due to the fact that EATL development 
could not be fully prevented in RCD II (chapter eight and nine) and EATL itself still has a 
dismal prognosis despite treatment (chapter ten). In addition to novel treatment options 
such as blocking IL-15 or CD30 based on their involvement in the pathogenesis of RCD and 
EATL, respectively, evaluation of the most commonly used therapies in these complicated 
forms of CD in large randomised trials is mandatory (i.e. azathioprine, budesonide and 
tioguanine in RCD I; azathioprine and cladribine in RCD II; CHOP with alemtuzumab in 
EATL). As the low incidence of RCD and EATL hampers the development of such trials, 
improvement of therapeutic strategies requires international collaboration with consensus 
about diagnostic criteria, and clinical and histologic response definition during follow-up.    
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TOEWERKEn nAAR DOElTREFFEnDER DIAGnOSE En BEHAnDElInG 
VAn (REFRACTAIRE) COElIAKIE 
In hoofdstuk 1 van dit proefschrift wordt een algemene beschrijving van coeliakie gegeven, 
inclusief epidemiologie, diagnose, behandeling en complicaties.
COElIAKIE
Coeliakie is een chronische darmaandoening gekenmerkt door glutenintolerantie bij mensen 
met een bepaalde genetische aanleg. Gluten is een eiwit dat in tarwe, rogge en gerst 
voorkomt. De aandoening wordt veroorzaakt door een reactie van het afweersysteem 
met vorming van antistoffen tegen gluten waardoor de darm ontstoken raakt en de 
slijmlaagcellen (enterocyten) afsterven (vlokatrofie) met als gevolg een verminderde 
absorptie van voedingsstoffen. Naar schatting treft deze auto-immuun ziekte een op de 
honderd mensen in de westerse wereld, de meesten zonder diagnose. Van oudsher is coeliakie 
een kinderziekte met klassieke maag-darmklachten: diarree, vette plakkerige ontlasting en 
gewichtsverlies. De laatste twee decennia wordt coeliakie in toenemende mate vastgesteld 
bij adolescenten en volwassenen met een uiterst divers klachtenpatroon, variërend van 
bovengenoemde symptomen tot atypische verschijnselen zoals bloedarmoede, botontkalking, 
blaasjesvormende huidaandoening (dermatitis herpetiformis) en gedragsveranderingen. 
Voor het stellen van de diagnose is een maag-darm onderzoek met afname van weefsel 
uit de dunne darm tot op heden de gouden standaard. Het aantonen van antistoffen in het 
bloed ondersteunt de diagnose.
Alhoewel er steeds meer bekend wordt over de ontstaanswijze van coeliakie, is er 
nog weinig onderzoek verricht naar schade van de enterocyten zelf in het ziekteverloop. 
In hoofdstuk 2 van dit proefschrift wordt dit bij volwassenen met coeliakie onderzocht 
met behulp van I-FABP (intestinal fatty-acid binding protein) concentraties in het bloed. 
Zoals verwacht worden er bij het stellen van de diagnose coeliakie hogere I-FABP waarden 
gevonden dan in het bloed van mensen zonder deze diagnose. Van grotere betekenis is de 
correlatie tussen de gemeten I-FABP waarden enerzijds en de antistof concentraties in het 
bloed en de mate van vlokatrofie in weefsel uit de dunne darm anderzijds. Na behandeling 
met een glutenvrij dieet dalen de I-FABP waarden sterk. Opvallend genoeg niet tot de 
waarden bij niet-coeliaken, ondanks normalisatie van antistoffen en het verdwijnen van 
vlokatrofie bij de meerderheid van de patiënten. Ook tijdens langdurige follow-up lijken 
de I-FABP waarden te correleren met de mate van vlokatrofie. Het is onduidelijk of deze 
persisterende enterocytschade het gevolg is van ‘therapieontrouw’, onbedoelde gluten-
inname of de ziekte coeliakie zelf. Mogelijk kan I-FABP in de toekomst gebruikt worden voor 
de evaluatie van een glutenvrij dieet. Grote prospectieve studies zijn nodig om dit vast te 
stellen. 
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De enige doeltreffende behandeling van coeliakie is het verwijderen van gluten uit de voeding, 
maar een dergelijk dieet is lastig vol te houden door hoge kosten, gluten contaminatie van 
voedingsmiddelen, sociaal-culturele aspecten en beperkte beschikbaarheid van alternatieve 
glutenvrije producten. Wetenschappelijk onderzoek richt zich derhalve op alternatieven 
voor een glutenvrij dieet, zoals vaccinatie, neutraliseren van gluten in producten door 
middel van genetisch gemodificeerde tarwe en orale enzymen die gluten afbreken voordat 
deze de dunne darm bereiken. In hoofdstuk 6 wordt een eerste placebo-gecontroleerde 
studie beschreven naar een dergelijk enzym, namelijk Aspergillus niger-derived prolyl 
endoprotease (AN-PEP). Volwassen coeliaken werd gevraagd gedurende twee weken gluten 
bevattende crackers met AN-PEP gelei als ontbijt in te nemen, gevolgd door een normaal 
glutenvrij dieet gedurende de daarop volgende twee weken. In de aansluitende twee weken 
werden patiënten gerandomiseerd voor inname van gluten bevattende crackers, met een 
gelei van ANPEP of placebo. AN-PEP werd goed verdragen door de meerderheid van de 
patiënten. Echter, een periode van twee weken blijkt te kort om symptomen en darmschade 
(bloedonderzoek en darmbiopten) bij patiënten uit de placebogroep aan te tonen. Derhalve 
kunnen er geen conclusies over de werking van AN-PEP worden getrokken. Vervolgstudies 
zijn gewenst, met een langere periode van gluten inname en met patiënten die recent met 
een glutenvrij dieet zijn gestart.
Bij de meeste jonge patiënten herstelt de darmschade en verdwijnen de klachten met 
als gevolg een betere kwaliteit van leven. Daarentegen is bij een aanzienlijk percentage 
van de nieuw gediagnosticeerde volwassen coeliaken het herstel van het darmepitheel traag 
en onvolledig, ondanks normalisatie van de antistoffen en het verdwijnen van de klachten.
RCD En EATl 
Het op volwassen leeftijd stellen van de diagnose coeliakie, met name boven het 50e 
levensjaar, is sterk geassocieerd met het ontwikkelen van de complicaties refractaire 
coeliakie (RCD) en enteropathie geassocieerd T-cel lymfoom (EATL). In tegenstelling tot de 
groep patiënten met een traag herstel van het darmepitheel, wordt RCD gekenmerkt door 
persisterende of recidiverende symptomen en voor coeliakie karakteristieke darmschade, 
ondanks een streng glutenvrij dieet gedurende 12 maanden en normalisatie van de 
antistoffen. Refractaire coeliakie wordt onderverdeeld in twee typen; op basis van het 
aankleuren van verschillende ‘celoppervlakte eiwitten’ op specifieke cellen in de dunne 
darm. Type I met minder dan 20% en type II met meer dan 20% afwijkende cellen. Deze 
zogenaamde aberrante cellen worden beschouwd als voorstadium van EATL, kanker met 
een slechte prognose. Bij ongeveer de helft van de RCD type II patiënten ontstaat een EATL. 
Alhoewel bepaalde genetische kenmerken zijn geassocieerd met RCD en EATL, zijn 
er tot nu toe geen testen die de ontwikkeling van deze gecompliceerde vormen van 
coeliakie kunnen voorspellen. In hoofdstuk 3 van dit proefschrift worden daarom nieuwe 
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(immunologische en/of biochemische) parameters in het bloed onderzocht, die kunnen 
differentiëren tussen de ongecompliceerde en gecompliceerde vormen van coeliakie 
op het moment van diagnose. Uit dit onderzoek blijkt dat de gluten-geïnduceerde 
ontsteking in actieve coeliakie veel overeenkomsten heeft met de gluten-onafhankelijke 
ontstekingsreactie in RCD I/II. Anderzijds onderscheiden RCD II en EATL zich door verhoogde 
waarden van de ontstekingsparameter IL-6 en worden bij RCD II patiënten hogere waarden 
van de cytoxische parameter granzyme-B gevonden. Verder worden bij de gecompliceerde 
vormen van coeliakie evident lagere albumine waarden gevonden ten opzichte van de 
ongecompliceerde vormen van coeliakie. Er worden geen parameters gevonden die RCD I 
en RCD II kunnen differentiëren. Vooralsnog blijft voor dit onderscheid het percentage 
aberrante cellen in dunne darmweefsel van essentieel belang. 
Naast nieuwe serologische parameters, kan meer inzicht in de oorspong en 
karakteristieken van deze aberrante cellen mogelijk richting geven aan het opstellen van 
een risicoprofiel voor de ontwikkeling van een EATL. In hoofdstuk 4 wordt in een grote groep 
RCD II patiënten, middels DNA afkomstig uit dunne darmweefsel en oppervlakte kenmerken 
van aberrante cellen, de origine van dergelijke cellen onderzocht. Deze aberrante cellen 
zijn zeer waarschijnlijk door oorsprong T-cellen (cellen betrokken bij de afweer) die ergens 
in hun ontwikkeling stagneren. Echter, er wordt een grote diversiteit in de mate van rijping 
van deze cellen tussen de verschillende patiënten waargenomen. Opvallend is dat juist 
de patiënten met de meest rijpe aberrante populatie een EATL hebben ontwikkeld. Op 
basis van onze resultaten is het aannemelijk om het standaard (moleculair) onderzoek, 
tegenwoordig gebruikt in de diagnostiek van RCD, uit te breiden. Op dit moment wordt in 
de diagnostiek naar RCD alleen de zogenaamde T-cel receptor-gamma bepaald, terwijl ons 
onderzoek aangeeft dat er ook bij een normale TCR-gamma (niet clonaal) toch een verhoogd 
risico op een EATL lijkt te bestaan. Deze uitbreiding (TCR-beta) kan er voor zorgen dat een 
geselecteerde patiëntengroep met een verhoogd risico op een EATL niet wordt gemist.
Ondanks de goede 5-jaars overleving van RCD I (ongeveer 90%), is behandeling uitermate 
belangrijk om de lange termijn gevolgen van absorptiestoornissen van nutriënten in de 
darm te voorkomen. Naast een glutenvrij dieet zijn middelen die de ontstekingsreactie 
in de darm onderdrukken (corticosteroïden, azathioprine) een belangrijk onderdeel in de 
behandeling. Corticosteroïden hebben bij langdurig gebruik bijwerkingen en de meerderheid 
van de patiënten blijft afhankelijk van deze medicijnen. Behandeling met azathioprine 
heeft een goede klinische respons maar volledig herstel van het darmepitheel is er slechts 
bij een minderheid van de patiënten. Hoofdstuk 7 evalueert een eerste onderzoek naar de 
behandeling van tioguanine (ontstekingsremmer) bij 12 RCD I patiënten. Tioguanine werd 
goed verdragen zonder ernstige bijwerkingen. Bijna alle patiënten vertoonden een klinische 
respons en bij meer dan de helft herstel van het darmepitheel. Mogelijk is dit medicijn een 
alternatief voor de behandeling van RCD I 
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In tegenstelling tot RCD I, is de 5-jaars overleving van RCD II slechts 44% tot 58%. Op 
dit moment is er geen eenduidige behandeling voor RCD II. In de afgelopen jaren zijn 
verscheidene behandelingen geëvalueerd, echter een EATL kan (nog) niet worden voorkomen. 
Anders dan bij RCD I, is behandeling met azathioprine en corticosteroïden niet effectief 
gebleken voor RCD II. De korte termijn resultaten van cladribine en chemotherapie gevolgd 
door autologe stamcel transplantatie waren veelbelovend bij kleine aantallen patiënten. 
Hoofdstuk 8 en 9 beschrijven de lange termijn resultaten van het vaste behandelschema 
van RCD II dat sinds 2005 in het VU medisch centrum te Amsterdam wordt gehanteerd: eerst 
cladribine en bij onvoldoende of het ontbreken van een respons chemotherapie en autologe 
stamcel transplantatie. Net als in de eerder gepubliceerde korte termijn studies met een 
beperkt aantal patiënten lijkt deze behandelstrategie veilig. In totaal werden 32 patiënten 
behandeld met cladribine. Een klinische respons van 80% is vergelijkbaar met eerdere studies 
waarin verschillende medicamenten werden geëvalueerd. Echter onze resultaten laten 
een beter herstel van het darmepitheel (ongeveer 50% van de patiënten) zien. Patiënten 
met een goede respons hadden een significant betere overlevingskans ten opzichte van 
de patiënten zonder respons. Tevens zijn er aanwijzingen dat patiënten die na diagnose 
direct met cladribine zijn behandeld een betere overleving hebben dan patienten die niet 
respondeerden op azathioprine en vervolgens met cladribine zijn behandeld. Alhoewel 
ongeveer de helft van de patiënten een follow-up duur van 5 jaar heeft, lijkt cladribine 
behandeling de ontwikkeling van een EATL te voorkomen dan wel uit te stellen. EATL werd 
gediagnosticeerd bij slechts 17% van de patiënten in vergelijking met 30-50% beschreven 
in eerdere studies. Achttien patiënten met onvoldoende herstel na cladribine behandeling 
kwamen in aanmerking voor hoge doses chemotherapie gevolgd door transplantatie. Vijf 
patiënten konden niet worden getransplanteerd en hadden een mediane overleving van 
slechts 5.5 maand. De overige dertien getransplanteerde patiënten met een follow-up van 
ruim twee jaar hadden een 4-jaars overleving van 66%. Klinische respons met verbetering 
van de kwaliteit van leven werd gezien bij de meerderheid van de patiënten en herstel 
van het darmepitheel bij iets minder dan de helft van de patiënten. Slechts één patiënt 
ontwikkelde een EATL, en wel vier jaar na transplantatie. Gezien het ontbreken van grote 
gerandomiseerde onderzoeken, mede door de kleine aantallen patiënten met RCD, zijn 
internationale studies wenselijk om de verschillende bestaande behandelopties onderling 
te vergelijken. 
Tot op heden is er geen doeltreffende behandeling voor EATL, waarbij de 5-jaar 
overlevingskans minder dan 20% is. Meer inzicht in de mechanismen die ten grondslag 
liggen aan de ontwikkeling van een EATL zal waarschijnlijk leiden tot vroege herkenning van 
deze aandoening en mogelijk tot de ontwikkeling van nieuwe behandelopties. Hoofdstuk 5 
beschrijft een bijzondere presentatie van een patiënt met een EATL, waarbij de tumorcellen 
in het buikvocht uitgebreid geanalyseerd zijn voor wat betreft oppervlakte kenmerken 
en genetische veranderingen. De oppervlakte kenmerken van deze EATL verschillen van 
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aberrante cellen bij RCD II patienten. De gevonden chromosomale veranderingen komen 
grotendeels overeen met de huidige classificatie van dit type kanker, aangevuld met enkele 
tot dusver onbekende veranderingen. Verder onderzoek naar de functionele betekenis van 
deze en andere genetische veranderingen is noodzakelijk. 
Wetenschappelijk onderzoek richt zich verder op nieuwe behandelopties van EATL. 
Hoofdstuk 10 beschrijft twee EATL patiënten behandeld met chemotherapie gevolgd 
door allogene stamcel transplantatie. Hoewel beide patiënten een goede respons op de 
chemotherapie lieten zien, werd een recidief EATL binnen een paar weken na transplantatie 
waargenomen. Mogelijk dat intensievere behandeling met chemotherapie en/of 
immunotherapie voorafgaand aan transplantatie tot betere resultaten zal leiden. Vooralsnog 
is er geen doelmatige behandeling voor EATL en lijkt het vroegtijdig onderkennen van 
RCD II van essentieel belang. Daarnaast zal voortschrijdend inzicht in de ontstaanswijze 
van RCD en EATL in de toekomst aanleiding kunnen zijn tot het ontwikkelen van nieuwe 
alternatieve behandelopties. 
TOEKOMST PERSPECTIEF
Hoewel in dit proefschrift nieuwe aspecten met betrekking tot de diagnostiek en 
behandeling van het spectrum van coeliakie zijn weergegeven, blijft verder onderzoek 
noodzakelijk. Het is vooralsnog onduidelijk waarom slechts een deel van de coeliakie 
patiënten RCD en/of een EATL ontwikkelt. Bovendien is de rol van een strikt glutenvrij 
dieet hierin controversieel. Nieuwe parameters die een voorspellende waarde hebben bij 
het identificeren van deze gecompliceerde vormen van coeliakie resulteren mogelijk in 
afname van morbiditeit en mortaliteit. In tegenstelling tot RCD type II dat een erkend 
ziektebeeld met specifieke kenmerken is, staat RCD type I binnen het spectrum van 
coeliakie ter discussie. Een beperkt aantal RCD I patiënten ontwikkelt een RCD type II, dat 
een nauwe relatie met het spectrum van coeliakie doet vermoeden. Aan de andere kant 
wordt in de literatuur gesuggereerd dat vanwege de overeenkomsten met actieve coeliakie, 
RCD I het gevolg is van langdurig onbewust gluten inname, hoewel dit met de huidige testen 
niet aan te tonen is. Het percentage aberrante cellen heeft een belangrijke plaats in de 
huidige diagnostiek van RCD II, echter vervolgonderzoek naar de karakteristieken van deze 
cellen is essentieel voor het verkrijgen van meer inzicht in de ontstaanswijze van RCD II en 
EATL. Aangezien deze aberrante cellen ook buiten de dunne darm kunnen voorkomen, kan 
verder onderzoek naar kenmerken van een dergelijke verspreiding een aanzet zijn tot het 
ontwikkelen van nieuwe behandelopties. Helaas zijn er nog te weinig grote internationale 
studies die het onderlinge effect van de verschillende behandelopties van RCD I en RCD II 
vergelijken en bovenal is er een grote vraag naar alternatieve middelen die de ontwikkeling 
van RCD II naar EATL (kunnen) voorkomen. Vooralsnog blijft een glutenvrij dieet de enige 
bewezen doeltreffende behandeling van ongecompliceerde coeliakie, maar veelbelovende 
alternatieve behandelingen zijn in ontwikkeling. 
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DAnKWOORD
‘It syl heve!’ … ‘It giet oan!’
Ruim vier jaar geleden begon ik vol goede moed aan een wetenschappelijke reis in de 
wereld van de coeliakie. Zo’n eeuwenoude ziekte, in het jaar 100 door een Griekse arts 
voor het eerst beschreven, wat valt daar nog aan te ontdekken? Van coeliakie wist ik wel 
iets, maar van refractaire coeliakie en de associatie met T-cel lymfomen had ik nog nooit 
gehoord! Maar zoals A. Einstein ooit zei: “Als we wisten wat we deden, heette het geen 
onderzoek”. Het ‘boekje’ is gedrukt en het doel van deze reis is na hard werken bijna 
bereikt. Het vormgeven van dit proefschrift was een reis vol hoogtepunten, maar er waren 
zeker ook spannende en moeilijke momenten. Een reis die ik zonder alle ‘reisgenoten’ die 
ik gaandeweg heb ontmoet niet had kunnen volbrengen. Allen bedankt! In het bijzonder wil 
ik de volgende mensen bedanken:
Allereerst mijn promotor, prof.dr. C.J.J. Mulder die het vier jaar gelden heeft aangedurfd om 
mij in het onderzoeksteam op te nemen. Beste Chris, bij jou begon mijn wetenschappelijke 
reis en die zal waarschijnlijk ook na deze dag niet eindigen, want zoals je het zelf ooit gezegd 
hebt: “het is maar een ‘proef’schrift”! Ik wil je bedanken dat je dit allemaal mogelijk hebt 
gemaakt. Dank ook voor je motiverende woorden, je steun tijdens de congressen en in het 
bijzonder je persoonlijke betrokkenheid. De gezellige etentjes tijdens congressen zal ik 
nooit vergeten; een schort is aanbevolen als je mij rode wijn schenkt!
Dr. M.W.J. Schreurs, beste Marco, en dr. B.M.E. von Blomberg, beste Mary, twee geweldige 
copromotoren die mij met enthousiasme en geduld wegwijs hebben gemaakt in de wereld 
van de wetenschap en immunologie, en mij het reilen en zeilen op het laboratorium hebben 
bijgebracht. Ik had in 2008 nooit verwacht dat ik nog eens blij zou worden van de resultaten 
van een ELISA of de kleuringen van darmbiopten! Marco, je nam altijd alle tijd. Zelfs uren na 
kantoortijd zaten we onder het genot van een glaasje wijn samen achter de computer voor 
het (her)schrijven van een artikel of in het laboratorium de laatste metingen te verrichten. 
Daarnaast waren er nog de nodige brainstorm sessies op het balkon onder het genot van 
een “bakje 3-3”. Na jouw vertrek naar Rotterdam is er weliswaar contact op afstand, maar 
nog steeds vol enthousiasme. Mary, ook jij stond altijd voor me klaar. Je welkome kritische 
blik op nieuwe onderzoekslijnen en de eerste versies van artikelen maakt je samen met je 
warme persoonlijkheid en betrokkenheid tot een fijne collega. Ik heb de samenwerking met 
jou en Marco als duo als zeer prettig ervaren. Bovenal wil ik jullie ontzettend bedanken 
voor het vertrouwen en de gezelligheid op de werkvloer en tijdens congressen. Een ritje in 
de audi-TT, afdalen en op jacht in de Franse mijnen, het vrijdagmiddag wijntje, picknicken 
in het Vondelpark … ik zal het niet snel vergeten. Ik hoop dat ik in de toekomst net zo 
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enthousiast en didactisch mijn vak aan anderen kan overbrengen als jullie dat aan mij 
hebben laten ervaren.
Dank aan de leden van de promotiecommissie, prof.dr. P.C. Huijgens, prof.dr. G.A. Meijer, 
dr. A. Al-Toma, dr. J. van Bergen, dr. G. Bouma en dr. A.C.E. Vreugdenhil voor het beoordelen 
van mijn thesis en jullie aanwezigheid vandaag. 
  
Alle medewerkers van de polikliniek maag-darm-leverziekten van het VUmc wil ik 
bedanken voor hun hulp en gezelligheid in de afgelopen jaren. Alle artsen en endoscopie 
verpleegkundigen voor het verkrijgen van de darmbiopten, Esmee voor het afnemen van 
bloed, Sylvia, Cynthia en Stella als vraagbaak en de baliemedewerkers voor het verzamelen 
van statussen. In het bijzonder wil ik dr. Ad van Bodegraven bedanken voor zijn belangrijke 
bijdrage aan de presentaties voor congressen; jouw kritische vragen zijn altijd stof tot 
nadenken. 
Alle collegae arts-onderzoekers, veel dank voor de prettige samenwerking en vooral de 
gezelligheid op en buiten de werkvloer. Met zijn allen naar Chicago, New Orleans, Londen 
en Barcelona, echt onvergetelijk! Dirk, super dat je vandaag mijn paranimf wil zijn. Na onze 
gezamelijke paper kun je vandaag vast alle vragen (voor mij) beantwoorden! Wieke, mijn 
voorganger, bedankt dat ik jouw onderzoekslijn heb kunnen voortzetten, voor je feedback 
en de fijne samenwerking. Jolanda, Laura en Roy wil ik bedanken vanwege de prettige 
samenwerking en het bespreken van werkperikelen, gedeelde smart is tenslotte halve 
smart. Hopelijk mag ik snel aanwezig zijn op jullie promotie. 
Alle medewerkers van de afdeling immunologie en pathologie van het VUmc, zonder jullie 
inzet en hulp had ik niet zoveel data kunnen verzamelen en analyseren. Ondanks mijn 
gebrek aan ervaring in het laboratorium, stonden jullie altijd open voor vragen en werd ik 
opgenomen binnen jullie team. Martine en Petra, ons bezoek aan Sint Etienne en Budapest 
waren reuze gezellig! 
De volgende mensen wil ik bedanken voor hun bijdrage aan mijn proefschrift:
In de eerste plaats natuurlijk alle co-auteurs, veel dank voor de hulp en het kritisch 
reviewen van de artikelen. In het bijzonder wil ik Frits Koning, Jeroen van Bergen en 
Jennifer Tjon uit het LUMC te Leiden apart bedanken voor de samenwerking, dat dit tot in 
de verre toekomst voorgezet mag worden. De afdeling hematologie van het VUmc, prof.dr. 
P.C. Huijgens, Otto Visser, Mariëlle van Wondergem en Josine Regelink, veel dank voor de 
fijne en vruchtbare samenwerking. Ilma Korponay-Szabo, many thanks for the opportunity 
to learn more about the analysis of mucosal deposits at your laboratory in Budapest. Maaike 
Bruins, namens DSM, veel dank voor de financiële mogelijkheid om de AN-PEP studie te 
kunnen uitvoeren en het congres in London, waar zaken en plezier elkaar ontmoetten bij 
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een glas ‘malbec’. Hopelijk kan hieraan na publicatie snel een vervolg gegeven worden. 
Marlou Adriaanse en Anita Vreugdenhil, dank voor de fijne samenwerking en de gezellige tijd 
die we hebben doorgebracht op congressen. 
Ook veel dank aan alle patiënten die deel hebben genomen aan de verschillende 
onderzoeken en aan Eric Holm voor het ontwerpen van de voorkant. 
De combinatie arts-assistent in de kliniek en in de ‘vrije’ uurtjes promoveren viel niet altijd 
mee. Daarom wil ik alle collega’s van de interne geneeskunde van het Sint Lucas Andreas 
ziekenhuis bedanken voor hun steun en begrip, en vooral voor de gezellige tijd! Bedankt 
ook aan mijn huidige collega’s van de afdeling maag-darm-leverziekten van het Kennemer 
Gasthuis te Haarlem.
Lieve vrienden, zonder jullie steun had ik mijn promotie niet kunnen afronden. Soms 
verstreken er weken zonder elkaar te zien of spreken, maar gelukkig zijn vrienden als 
sterren, je ziet ze niet altijd maar je weet dat ze er zijn. Deze dag wil ik dan ook graag 
samen met jullie delen. Ingrid, ‘bijna-zus’, wat was het heerlijk om de afgelopen jaren af 
en toe ‘aan te mogen schuiven’ (de komende maand in Amsterdam?), mijn hart te luchten 
en vooral ook gezellig samen op pad te gaan. Ik ben blij en vereerd dat jij vandaag naast me 
staat als paranimf. Dat onze vriendschap maar oneindig lang mag duren. 
Lieve pap, mam, Antje, Auke en familie, het is zo gewoon dat jullie altijd voor me klaar 
staan en toch ook zo bijzonder. Er zijn geen woorden die kunnen beschrijven hoe ontzettend 
belangrijk jullie voor mij zijn. Lieve Ruud, na vandaag niet meer ieder weekeind werken, 
geen frustraties meer over de computer en “ik moet aan mijn promotie” is niet langer een 
excuus … Engelengeduld heb je. Jij zorgde voor de nodige koffiebreaks en motiveerde me 
keer op keer als het even tegen zat. Lieve Ruud, je verdient mijn allergrootste kus!
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Figure 1  |  Morphology and immunohistochemical analysis of the ascitic fluid EATL cells.
 MGC staining CD3 CD39
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